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Abstract 
Linear covalently closed (LCC) DNA minivectors serve to be superior to conventional 
circular covalently closed (CCC) plasmid DNA (pDNA) vectors due to enhancements to both 
transfection efficiency and safety. Specifically, LCC DNA minivectors have a heightened 
safety profile as insertional mutagenesis is inhibited by covalently closed terminal ends 
conferring double-strand breaks that cause chromosomal disruption and cell death in the low 
frequency event of chromosomal integration. The development of a one-step, E. coli based in 
vivo LCC DNA minivector production system enables facile and efficient production of LCC 
DNA minivectors referred to as DNA ministrings. This novel in vivo system demonstrates 
high versatility, generating DNA ministrings catered to numerous potential applications in 
gene therapy and vaccine development.  
In the present study, numerous aspects pertaining to the generation of gene therapeutics 
with LCC DNA ministrings have been explored with relevance to both industry and clinical 
settings. Through systematic assessment of induction duration, cultivation strategy, and 
genetic/chemical modifications, the novel in vivo system was optimized to produce high 
yields of DNA ministrings at ~90% production efficiency. Purification of LCC DNA 
ministrings using anion exchange membrane chromatography demonstrated rapid, scalable 
purification of DNA vectors as well as its potential in the separation of different DNA 
isoforms. The application of a hydrogel-based strong Q-anion exchange membrane, with 
manipulations to salt gradient, constituted effective separation of parental supercoiled CCC 
precursor pDNA and LCC DNA. The resulting DNA ministrings were employed for the 
generation of 16-3-16 gemini surfactant based synthetic vectors and comparative analysis, 
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through physical characterization and in vitro transfection assays, was conducted between 
DNA ministring derived and CCC pDNA derived lipoplexes. Differences in DNA topology 
were observed to induce differences in particle size and DNA protection/encapsulation upon 
lipoplex formation. Lastly, the in vivo DNA minivector production system successfully 
generated gagV3(BCE) LCC DNA ministrings for downstream development of a HIV DNA-
VLP (Virus-like particle) vaccine, thus highlighting the capacity of such system to produce 
DNA ministrings with numerous potential applications.  
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1.1 Introduction to Gene Therapy 
Gene therapy (GT) involves the administration of nucleic acids for the purpose of treating 
diseases associated with the absence, abnormal expression, or overexpression of specific 
genes or genetic elements. Such therapies often entail the delivery of specific gene 
expression cassettes catered to the expression of a deficient protein product. Delivery of such 
expression cassettes can be achieved through recombinant viruses, referred to as viral 
vectors, or through non viral means using bacteria derived recombinant plasmid DNA 
(pDNA) vectors [1]. 
1.1.1 Current Advances in Gene Therapy 
Globally, there are over 1,800 approved GT clinical trials with viral vectors accounting 
approximately two-thirds of all trials [2]. Adenoviral vectors are the most commonly used 
viral vector due mainly to their high transfection efficiency, high expression, and infection of 
non-dividing cells [2]; each of which are features commonly shared amongst many different 
viral vectors. The prominence of such vectors is exemplified by the Chinese approval of 
Gendicine (SiBiono GeneTech Co.), a non-replicative recombinant adenoviral vector (rAd-
p53) for the treatment of head and neck squamous cell carcinoma, and Onocorine (Sunway 
Biotech Co. Ltd), a conditionally replicative recombinant adenoviral vector for the treatment 
of late stage refractory nasopharyngeal cancer, in 2003 and 2005 respectively [3]. In  2008, 
Cerepro (Ark Therapeutics Group plc) became the first and only adenoviral vector to have 
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completed a phase III clinical trial [3]. More recently, Glybera (UniQure), an adeno-
associated viral vector delivering human lipoprotein lipase gene in muscle tissue for the 
treatment of lipoprotein lipase deficiency, received approval in 2012 as the first gene 
therapeutic from the European Commission [3-5]. The successful development of such 
therapeutics highlights the effectiveness of viral vectors for gene delivery and the potential of 
gene therapy in the treatment of many different diseases.  
1.1.2 Safety Limitations of GT Viral Vectors 
Despite the high usage of viral vectors to gene delivery application, the employment of viral 
vectors poses important safety concerns due to potential induction of undesired 
immunostimulatory responses and/or insertional mutagenesis. Among the five main classes 
of viral vectors (oncoretroviruses, lentiviruses, adeno-associated viruses, adenoviruses, and 
herpes simplex viruses), adenoviral vectors are considered the most immunogenic as they 
may induce cytotoxic T-lymphocyte (CTL), neutralizing antibody, and cytokine-mediated 
inflammatory responses [6]. Inflammatory responses imparted by the adenoviral capsid have 
been shown to linearly correlate with increasing vector dose and a "threshold effect", 
whereby limited symptoms are observed before severe cellular damage occurs at dosages 
above the threshold; this effect has also been implicated in dose-escalation studies [6]. In 
conjunction with the promiscuity of viral vectors, the systemic delivery of these vectors may 
also lead to severe complications from inflammatory responses. Such complications are 
represented by the tragic death of Jesse Gelsinger, a patient in phase I gene therapy clinical 
trial for an adenoviral vector based therapeutic treating ornithine transcarbamylase (OTC) 
deficiency [6-8]. OTC is a metabolic enzyme required for the breakdown of ammonia and 
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intermediate phenotypes have been observed in males with genetic mutations contributing to 
partially defective enzyme. The genetic nature of the disease prompted a GT approach and 
the use of adenoviral vectors as a viable option. However, intra-hepatic administration of the 
vectors led to systemic inflammation, multi-organ failure, and the eventual death of the 
subject. Autopsy reports later attributed vector induced activation of innate immunity as the 
main cause of death [8].  
Safety concerns associated with insertional mutagenesis have also been documented in an 
ex vivo GT strategy to treat X-linked severe combined immunodeficiency (SCID-XI) using a 
γ-retroviral vector [2, 7, 9]. SCID-XI is caused by genetic mutations in the gene encoding 
interleukin 2 receptor-γ (IL2RG) leading to the faulty development of T cells and natural 
killer (NK) cells and subsequent complications from infections due to a lack of lymphocytes 
in the blood. From 1999 to 2009, a total of 20 patients suffering from SCID-XI were treated 
with a γ-retroviral vector to correct the genetic defect, achieving an impressive 85% success 
rate. However, a quarter of these patients were later found to have developed T-cell 
leukemia, with one patient succumbing to the cancer [9]. Development of T cell leukemia 
was attributed to the uncontrolled proliferation of T-cells due to vector integration near the 
LMO2 proto-oncogene promoter and subsequent deregulated expression of oncogenes [2]. In 
conjunction with the enhancer activity of the viral long terminal repeats, the vector was 
identified to integrate in a semi random manner, targeting promoter and gene regions of 
actively transcribed genes at higher frequencies [9]. Similarly, the development of acute T 
cell leukemia was also found in a patient enrolled in a GT clinical trial for treating Wiscott-
Aldrich syndrome using a γ-retroviral vector possessing viral long terminal repeats [2]. 
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1.2 Non-Viral Gene Delivery 
Aside from serious safety concerns, the application of viral vectors is hindered by limited  
repeat administrations due to pre-existing immunity, size of delivered gene construct, scale-
up, as well as high production costs, contamination during production, and lack of desired 
tissue selectivity [6, 10-12]. Such drawbacks continue to drive the exploration of non-viral 
means of gene delivery. Non-viral delivery systems are generally advantageous over viral 
vector systems with respect to: 1) safety (immunocompatibility); 2) production costs; 3) 
scalability; 4) the ability to transfect larger sized pDNA; and 5) adaptability for different 
delivery options (e.g. targeted delivery, time-dependent release, enhanced circulation times, 
repeat administrations) [10, 11, 13-15]. However, while preferential from a safety 
perspective, non-viral delivery systems generally suffer from low transfection efficiencies 
[16], an important obstacle that must be addressed in order for such systems to be recognized 
as effective vehicles for gene delivery. 
1.2.1 Barriers of Gene Delivery 
The low transfection efficiencies associated with non-viral delivery systems are directly 
attributed to the various barriers encountered during the process of gene delivery (Figure 
1.1). There are numerous extracellular barriers that must be bypassed prior to reaching the 
target tissue/cells. Unprotected pDNA vectors are rapidly degraded by nucleases upon 
systemic delivery. Although the packaging of DNA cargo into synthetic vectors may offer 
protection from nuclease degradation, the net positive charges of these vectors gives rise to 
several additional problems: 1) non-specific interactions with negatively charged cellular 
blood components, vessel endothelia, and serum proteins; and 2) extravasation across the 
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endothelial barrier and extracellular matrices. Interactions with negatively charged serum 
proteins results in the formation of ternary complexes and large aggregates. In severe cases, 
vessel obstruction and risks of pulmonary embolism may arise from significant aggregation 
with other blood components like erythrocytes [17, 18]. The highly charged particles may 
prompt interactions with complement components leading to opsonization and subsequent 
complement activation that results in their removal by the reticuloendothelial system [19, 
20]. The above mentioned interactions compromise systemic delivery of vectors contributing 
to rapid removal and short half-life in vivo.  
Upon reaching the target cells, the cell membrane is the next significant barrier due to 
repulsive forces between negatively charged DNA and the negatively charged membranes. 
Net positive charges of synthetic vectors promote effective electrostatic interactions with cell 
membranes, enabling cellular uptake by endocytosis. However, without appropriate 
mechanisms of endosomal escape, the endocytosed vectors are subjected to lysosomal 
degradation. Intracellular trafficking of released DNA cargo is hampered by cytoskeletal 
elements rendering passive diffusion ineffective. The limited mobility of DNA elevates the 
risk of degradation by intracellular nucleases prior to reaching the nuclear membrane. 
Finally, the nuclear membrane poses yet another barrier as passive diffusion through the 
nuclear pore complex (NPC) is restricted to small molecules (ions, metabolites, and smaller 
proteins) less than 60 kDa or 9-11 nm in diameter [1, 12]. The dissociation and 
reorganization of nuclear membrane during mitosis facilitates nuclear entry as a 50-3000 fold 
increase in gene product was previously observed in transfection of cells at G2 or G2/M 
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stages compared to cells at G1 [21]. However, nuclear entry remains problematic for gene 
delivery in non-dividing cells.    
   
 
Figure 1.1 Extracellular and intracellular barriers to gene delivery: A) Degradation of 
unprotected, naked pDNA vectors by nucleases upon systemic delivery; B) Removal of synthetic 
vectors by the reticuloendothelial system; C) Significant aggregation with blood components leading 
to vessel obstruction; D) Extravasation of naked pDNA and synthetic vectors across the endothelial 
wall and extracellular matrix; E) Repulsive forces between naked pDNA vectors and cell membrane 
inhibit effective cellular uptake and internalization; F) Lysosomal degradation of synthetic vectors 
and DNA cargo in absence of endosomal escape; G) Degradation of released DNA cargo by 
intracellular nucleases; H) Nuclear membrane obstructing nuclear entry and transgene expression.   
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1.3 Non-Viral Delivery Systems 
Non-viral gene delivery systems can be divided into three major categories: naked pDNA 
vectors, physical delivery, and chemical delivery via synthetic vectors. The basis of physical 
delivery systems stems from disruptions to cell membranes for pDNA vectors to bypass this 
barrier. Established methods such as microinjection, gene gun, and electroporation are 
examples of physical gene delivery that have been previously explored, each with its own 
inherent advantages and disadvantages. In addition, sonoporation, optical transfection, and 
magnetofection are three examples of emerging techniques, pointing to the ongoing 
exploration of suitable methods of physical gene delivery. Chemical delivery systems involve 
the packaging of pDNA into synthetic vectors. The design of these synthetic vectors involves 
a bottom-up approach where different components pertinent to transfection (DNA 
compaction and encapsulation, targeted delivery, cellular uptake and internalization, 
endosomal escape, and nuclear localization) are combined together to form a self-assembling 
nanoparticle. Each gene delivery system is described in greater detail below.  
1.3.1 Naked pDNA Vectors 
Direct injections of naked pDNA vectors have been explored in vivo with low success rates 
and they often require high doses of pDNA due to the large size and hydrophilic nature of the 
plasmid, which severely hampers the ability to bypass several physical barriers including 
blood endothelium, extracellular matrix, and cell membrane [22]. In particular, negatively 
charged DNA is subjected to repulsive forces from the negatively charge cell membrane 
which diminishes the close interactions required for successful uptake. The unprotected 
pDNA vector is also subjected to intra and extracellular nuclease degradation during the 
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delivery process, further limiting successful internalization and expression of intact 
functional pDNA vectors [22]. 
1.3.2 Physical Delivery Systems: Microinjection, Gene Gun, Electroporation 
Microinjection involves direct targeted injection of pDNA vectors into the cell nucleus for 
efficient gene delivery. Unfortunately, low throughput and the requirement of high precision 
and accuracy render this method ineffective in any practical (i.e. clinical) setting. The gene 
gun, also known as ballistic gene delivery, is a needle free method involving the discharge of 
accelerated pDNA-coated gold or tungsten particles of various sizes directly into cell 
cytoplasm. Despite efficient gene delivery, there are several disadvantages associated with 
gene gun including: low throughput; non-specific, non-uniform, and variable delivery; 
limited tissue depth; and potential for substantial inflammation/damage to the administered 
area [23]. Similarly, electroporation, which involves the application of an electrical field for 
localized transient changes in cellular membrane permeability, has documented high 
throughput gene delivery across a variety of cells and tissues in vitro and in vivo [24]. 
However, they are notorious for inducing substantial cell death leading to low cell viabilities 
[23]. Although the above mentioned methods are able to overcome some issues contributing 
to low transfection efficiencies hampering non-viral gene delivery, they have yet to become 
widely accepted systems for gene delivery as they are difficult to standardize in clinical trials 
and their application is considered to be laborious and impractical [25].  
1.3.3 Emerging Delivery Systems: Sonoporation, Optical Transfection, Magnetofection 
Sonoporation employs low intensity ultrasound to induce modifications to the endothelial 
layer, along with increases in membrane permeability and transient pore formation. The 
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process is often accompanied by the addition of microbubbles, contrast agents used in 
ultrasound imaging, to improve pore formation through controlled bubble collapse referred to 
as cavitation [26]. The application of sonoporation in gene delivery provides several 
advantages over other physical methods: 1) ultrasound is commonly applied as a non-
invasive diagnostic medical imaging technique using clinically approved microbubbles; 2) 
site specific delivery may be achieved through effective image-guided spatial and temporal 
control over ultrasound; and 3) sonoporation is highly suitable for repeat administrations [26, 
27]. In addition, sonoporation may work in tandem with chemical delivery systems by 
coupling synthetic vectors (eg. lipoplexes and polyplexes) to microbubbles for enhanced 
delivery [26, 28] or act as a release mechanism for controlled cytoplasmic release of DNA 
cargo within cells [29]. Further evaluation is required to ascertain the optimal acoustic 
parameters capable of uniform cavitation and DNA entry into different tissues.  
In optical transfection, femtosecond-pulsed lasers providing near infrared (700-1100 nm) 
multiphoton pulses have been used for single cell transfections yielding high transfection 
efficiency and low cytotoxicity. Direct single target irradiation induces photon absorption 
and free electron excitation that contributes to localized changes in membrane permeability 
including transient pore formation [30-32]. However, the high transfection efficiencies 
achieved using femtosecond pulsed lasers are overshadowed by low throughput, limited 
loading concentrations, and the requirement of expensive equipment [31]. Alternatively,  
nanosecond-pulsed lasers have been applied to generate photomechanical stress waves, 
referred to as laser-induced stress waves (LISW), that create shear forces for transient 
increase in membrane permeability and entry of exogenous pDNA vectors by passive 
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diffusion [31]. LISW in GT was previously demonstrated in NIH/3T3 murine fibroblast [33] 
in vitro as well as rat skin/muscle [34, 35] and mouse central nervous system [36] in vivo. In 
particular, the application of LISW in combination with polyethylenimine (PEI)/DNA 
synthetic vectors yielded efficient and widespread expression of the gene of interest (egfp) in 
mouse central nervous system with penetration depth of 1.5 mm and 3.5 mm into the cortex 
surface of adult and newborn mice respectively [36]. Further exploration of Q-switched 
Nd:YAG lasers for LISW mediated gene therapy may be warranted as they are commercially 
available, cost effective, easy to operate, safe, and approved for use in head and neck 
surgeries [35].  
Magnetofection refers to gene delivery mediated by the application of magnetic fields 
acting on magnetic vectors typically comprising superparamagnetic iron oxide nanoparticles 
(SPIONs). These systems are generating significant interest as GT vectors due to their 
superparamagnetic properties, high biocompatibility, low toxicity, biodegradability in vivo, 
and concurrent applications in magnetic resonance imaging [37-39]. The formation of these 
magnetic vectors involve association of magnetic nanoparticles with lipid or polymer based 
synthetic vectors predominantly through electrostatic interactions [40]. Magnetofection 
serves to enhance gene delivery through rapid sedimentation overcoming the diffusion 
barrier which limits vector accumulation and lowers vector concentrations at target tissues. 
The introduction of magnetic fields rapidly sequesters magnetic vectors to target tissues 
which contribute to improved vector delivery despite lower administered doses.  
Magnetofection offers several significant advantages: 1) rapid vector internalization, 2) high 
transfection efficiencies at lower vector doses, and 3) lower cytotoxicity [37, 41]. In addition 
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to enhancing transfection efficiency by magnetofection, the application of an external 
magnetic field allows for localized and guided targeting in regions specifically exposed to the 
magnetic field. This feature is highlighted by Song et al. [42] where moving the external 
magnetic field down the spinal cord of adult male Wistar rats changed the regional 
distribution pattern of transgene expression. Despite the advantages of magnetofection in 
vitro [37] and in vivo [43-45], it is limited by low penetration depth of the external magnetic 
field, high field strengths required to overcome hydrodynamic forces for magnetic vector 
localization, and insufficient biodistribution analysis demonstrating the effects of magnetic 
targeting [46].   
1.3.4 Chemical Delivery Systems: Synthetic Vectors 
Enhanced transfection efficiencies exhibited in the above mentioned emerging techniques 
share a common theme of using synthetic vectors in combination with physical methods of 
gene delivery. Synthetic vectors offer advantages of: 1) complexation and compaction of 
pDNA vectors into discrete particles facilitating extravasation and delivery to target cells; 2) 
improved cellular uptake by promoting effective electrostatic interactions with cell 
membrane; 3) protection against extra and intracellular nucleases upon effective DNA 
encapsulation; 4) improved cytoplasmic release; and 5) intracellular trafficking to perinuclear 
regions for optimal nuclear localization. Synthetic vectors are classified according to their 
basic composition with cationic lipids (lipoplex), cationic polymers (polyplex), and cationic 
peptides as three major variations. 
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1.3.4.1 Polymer-based Vectors 
Polymer-based vectors employ cationic polymers, containing a large number of primary, 
secondary, tertiary, and/or quaternary amine groups, for complexation and encapsulation of 
negatively charged DNA by electrostatic interactions. Strong DNA interactions with the high 
density of amine groups result in the formation of polyplexes that are typically more stable 
than cationic lipid derived lipoplexes [11]. Polyplex formation also protects the DNA cargo 
from degradation by nucleases during the delivery process. The net positive charges of these 
polyplexes prompt efficient cellular uptake through electrostatic interactions with negatively 
charged cell membranes, allowing polyplex internalization by endocytosis. Depending on the 
nature of the cationic polymer, polyplexes may also possess inherent abilities to promote 
endosomal escape, through the proton sponge effect, for cytoplasmic release and nuclear 
localization of DNA cargo. Generally, polymers of high molecular weight constitute higher 
charge density, leading to better DNA complexation and improved transfection efficiencies; 
however, this comes at a cost of greater cytotoxicity. Hence, an intricate balance between 
transfection efficiency and cytotoxicity is critical in the design of effective polymer-based 
vectors. Numerous variations of cationic polymers have been previously applied to GT, with 
poly-L-lysine (PLL), polyethylenimine (PEI), chitosan, and poly(amidoamine) (PAMAM) 
dendrimers as four commonly used polymers in synthetic vectors for gene delivery (Figure 
1.2).    
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Figure 1.2 Structures of commonly used polymers in synthetic vectors for gene delivery. 
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1.3.4.1.1 Poly-L-Lysine (PLL) 
Poly-L-Lysine (PLL)/DNA vectors consist of PLL, a synthetic repeat of the amino acid (a.a.) 
lysine with varying degrees of polymerization ranging from 90-450 residues, and such 
vectors are suitable for in vivo administrations as they are highly biodegradable [47]. The 
polymer length of PLL has significant influences over the extent of polymer-DNA 
interactions, complex stability, polyplex size, transfection efficiency, and cytotoxicity. 
Increasing polymer length contributes to greater net positive charge, tighter binding with 
DNA, and better protection from DNA degradation. PLL/DNA polyplexes with higher 
molecular weight were previously shown to exhibit prolonged circulation and reduced 
interactions with erythrocytes when compared to low molecular weight PLL/DNA 
polyplexes [47]. However, increasing the molecular weight of the polymer contributes to 
increasing cytotoxicity. By itself, PLL/DNA polyplexes elicit sub-optimal transfection 
efficiencies and require the co-application of endoosmotropic agents (eg. chloroquine) for 
raising endosomal pH to inhibit degradation by hydrolytic enzymes; or modifications with 
imidazole structures/fusogenic peptides for effective endosomal escape and improved 
delivery [17]. 
1.3.4.1.2 Polyethylenimine (PEI) 
Currently considered to be the standard of polymer based vectors, linear and branched 
polyethylenimine (PEI) ranging from 800 to 25kDa have been applied for DNA 
complexation and transfection with 25 kDa branched and 22 kDa linear PEI being commonly 
used for gene delivery [48, 49]. Transfection efficiencies of PEI/DNA polyplexes are 
dependent on molecular weight, degree of branching, zeta potential, and particle size. 
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PEI/DNA polyplexes form homogeneous nanoparticles around 100 nm and exhibit enhanced 
transfection over PLL based vectors due to high density of primary, secondary, and tertiary 
amines promoting effective complexation [17]. Concurrently, the high density of amines, 
with compatible pKa values, confers significant buffering capacities over a wide range of pH; 
thus promoting effective endosomal escape according to the “proton sponge effect” [11, 12, 
50]. Under physiological pH conditions within the early endosome, the majority of amines in 
PEI remain unprotonated. During the transition from early to late endosome, the endosome 
becomes progressively acidified through an ATPase enzyme that actively shuttles protons 
from the cytosol. A buffer effect ensues as protonation of the unprotonated amines in PEI 
causes more protons to be shuttled in order for the progressive drop in pH to occur. Increased 
proton shuttling is balanced by increasing concentrations of chloride counterions within the 
endosome, both of which contribute to raising osmotic pressure that causes osmotic swelling 
and eventual rupture of the endosome [17, 22]. Previous studies supporting the proton sponge 
effect indicated delayed endosomal acidification, enhanced chloride ion accumulation, and 
significant increases in relative endosome volume for PEI and poly(amidoamine) polyplexes, 
but not in non-buffering PLL polyplexes [51]. The removal of protonable amines by N-
quaternization was shown to result in the abrogation of buffering capacities and an 
approximately 50 fold reduction in transfection efficiency when compared to parental 
PEI/DNA polyplexes [52]. Clinical studies have been conducted using linear 22 kDa PEI due 
to high transfection with acceptable biocompatibility. Of particular interest, linear 22 kDa 
PEI modified with mannose and dextrose was previously applied for transfection of pDNA 
encoding HIV proteins into target antigen presenting cells (APC) [49]. Despite enhanced 
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transfection efficiencies exhibited by PEI/DNA polyplexes, further modifications must be 
explored to overcome the issues relating high cytotoxicity, from the highly dense positive 
charges, and non-biodegradability of the polymer.  
1.3.4.1.3 Chitosan 
Chitosan is composed of linear polysaccharide with randomly distributed D-glucosamine (2-
amino-2-deoxy-glucose) and N-acetyl-D-glucosamine (2-(acetylamino)-2-deoxy-D-glucose) 
joined by β-1,4 linkages. Chitosans are sought after as suitable synthetic vectors as they are 
biodegradable, biocompatible, and non-allergenic while possessing strong DNA affinity, 
mucoadhesive properties, and low cytotoxicity [53]. DNA complexation and encapsulation is 
influenced by both molecular weight and the degree of deacetylation as chitosan vectors with 
inherent low molecular weights and deacetylation resulted in inefficient DNA condensation 
and protection from degradation [54]. Presence of primary amines with pKa of 6.5 grants 
chitosan/DNA polyplexes buffering capacity but at a restricted pH range of 5-7 and at 
reduced capacities when compared to PEI based polyplexes [53]. Differences in buffering 
capacities between PEI and chitosan based polyplexes was illustrated through image based 
quantification [55] as DNA degradation was observed for chitosan/DNA polyplexes due to 
unpacking within the endolysosomes. In contrast, the high buffering capacity of PEI/DNA 
polyplexes led to rapid endosomal escape, allowing the polyplexes to attain comparable 
stabilities in endolysosomes and cytosol. The relatively lower transfection efficiencies for 
chitosan/DNA polyplexes was also attributed to reduced cellular uptake, due to less efficient 
DNA compaction, and limited nuclear transport of the DNA cargo [53].  
 
  17 
1.3.4.1.4 Poly(amidoamine) (PAMAM) Dendrimers 
Dendrimers are highly branched, highly symmetrical polymers with well defined 3D 
spherical structures and numerous terminal groups. They are comprised of three main 
domains: 1) a central core; 2) branches of repeating units forming a series of radially 
concentric layers referred to as generations; and 3) identical terminal functional groups for 
multiple interactions [56]. The structural nature of dendrimers constitutes features of 
monodispersity, high density of peripheral functional groups, defined globular shape, and 
multivalency. Poly(amidoamine) (PAMAM) dendrimers are composed of a central core of 
tertiary amines, an amide backbone, and primary amines as functional groups presented on 
the surface [53]. The surface primary amines (pKa ~7-9) permit effective DNA binding and 
cellular uptake while the interior tertiary amines (pKa ~3-6) provide buffering capacity 
critical to endosomal escape. Dendrimer charge ratio and dendrimer generation are two 
parameters critical to optimal transfection efficiency [57] with higher generations, G5 to 
G10, enabling better DNA complexation [17, 56, 58]. PAMAM dendrimers exhibit no 
significant cytotoxicity in vitro or in vivo, but their biocompatibility is dependent on 
size/generation, surface charge, and concentration. As dendrimers enable precise control over 
size, shape, and terminal groups, specific modifications may serve to improve transfection 
efficiency while limiting cytotoxicity. 
1.3.4.2 Cationic Peptide Vectors 
Peptide-assisted gene delivery offers improved gene delivery while attaining biodegradability 
with reduced cytotoxicity and immunogenicity. Various peptides have been incorporated into 
different synthetic vectors in overcoming numerous barriers during the delivery process: 1) 
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cell targeting peptides (eg. RGD peptide) for targeted delivery; 2) cell penetrating peptides 
(CPP) for cellular uptake; 3) endoosmolytic peptides including histidine rich and fusogenic 
peptides for endosomal escape; and 4) nuclear localization signal (NLS) peptides for nuclear 
localization. By themselves, highly positive charge peptides, like oligolysine and 
oligoarginine peptides, can act as standalone vectors as they can effectively bind and 
compact DNA. In comparison to polymers (PLL), oligolysine peptides have inherit 
advantages of specified peptide lengths, lower toxicity, and site specific modifications for 
improved delivery [47]. Oligolysine peptides of 13 or more a.a. residues were determined to 
achieve effective DNA compaction, forming complexes ranging from 53 to 231 nm [59]. A 
subsequent study reported the ability of oligolysine peptides, with 18 lysine residues, to 
protect DNA from degradation by endonuclease [60]. Similarly, oligoarginine peptides 4 to 
16 residues long with modification by N-stearylation were shown to transfect cells with a 100 
fold improvement in transfection efficiency [61]. MPG and trans-activating transcriptional 
activator (Tat) derived peptides are two variations of CPPs previously demonstrated to 
achieve successful nucleic acid/gene delivery. CPPs are short cationic or amphipathic 
peptides, 5-30 a.a. in length, with a net positive charge and improved cellular uptake through 
direct penetration and endocytosis. MPG is an amphipathic peptide comprised of a lysine rich 
SV40 nuclear localization signal (NLS) hydrophilic domain for DNA binding and a 
hydrophobic domain, derived from HIV gp41 fusion sequence, for protection from DNA 
degradation. This peptide was first to demonstrate peptide based siRNA delivery through 
non-covalent, electrostatic interactions [24]. Tat peptide, an arginine rich peptide derived 
from the 48-60 a.a. sequence of HIV trans-activating transcriptional activator (Tat) protein, 
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was shown to compact DNA and enhance transfection efficiency by six to eight fold over 
control peptides [47]. The above mentioned peptides, along with many peptide variations, 
have been applied to the delivery of pDNA, oligonucleotides, siRNA, and miRNA [62, 63]. 
However, transfection efficiencies remain insufficient as they are hindered by a lack of 
endosomal escape. Tat peptides, modified with the addition of 10 histidine residues for 
endoosmolytic capabilities, were reported to achieve a 7000 fold increase in transfection 
efficiency over the native peptide and the incorporation of 2 additional cysteine residues, for 
DNA protection, was indicated to further improve transfection [64]. Exploration of different 
peptide derivatives with similar modifications may enable effective gene delivery by cationic 
peptide vectors. 
1.3.4.3 Cationic Lipids 
Cationic lipids are composed of a cationic hydrophilic head group and a hydrophobic domain 
connected together by a linker. The hydrophilic head group commonly consists of a 
combination of phosphate and amine groups while the hydrophobic domain consists two 
types of hydrophobic moieties including aliphatic chains, cholesterol, and/or other variations 
of steroid rings [11]. The linker - commonly consisting of ether, ester, carbamate, or amide 
bonds - determines the flexibility, stability, and biodegradability of the cationic lipid [65]. 
DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), a double 
chain monovalent quaternary ammonium lipid developed by Felgner et al. [66], was the first 
generation of cationic lipids that led to the development of the first commercialized reagent, 
Lipofectin (Invitrogen), applied for lipid-based transfection or lipofection. This spawned 
further modifications for subsequent generations of cationic lipids (Figure 1.3) which are still 
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commonly used for transfection today. DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium methyl sulfate) is a DOTMA derivative comprised of ester bonds, in 
place of ether bonds, for higher biodegradability and corresponding lower cytotoxicity [17]. 
DOSPER (1,3-dioleoyloxy-2-(6-carboxyspermyl)-propyl amide), DOGS (Di-octadecyl-
amido-glycyl-spermine), and DOSPA (2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-
N,N-dimethyl-1-propanaminium trifluoroacetate) are three examples of cationic lipids with 
modified head groups derived from polyamine spermine. The increased cationic groups in 
these multivalent lipids promote stronger DNA interaction for enhanced delivery. 
Lipofectamine
TM
 2000 (Invitrogen), a commonly used commercialized transfection reagent 
composed of DOSPA and a neutral lipid, 1,2-dioleoyl-sn-glycero-3-
phosphatidylethanolamine (DOPE), at 3:1 ratios, is an example of such multivalent lipids. 
Modifications to the length of aliphatic chain was shown to influence gene delivery capacity 
of monovalent lipids, like DOTMA and DOTAP, as transfection efficiency increases with 
decreasing chain length (C14 > C16 > C18); however, such relationship was not observed with 
respect to lipospermine derivatives [12]. In place of aliphatic chains, the application of 
cholesterol derived cationic lipids, DC-Chol (3β-[N-(N',N'-dimethylaminoethyl) carbamoyl] 
cholesterol), was shown to promote better stability and reduced cytotoxicity for improved 
transfection efficiencies in vitro [12, 67]. As numerous variations can be applied to each of 
the three primary components, the high number of possible permutations contributes to over 
hundreds of different cationic lipids that have been explored and successfully applied to 
develop synthetic vectors for gene delivery.  
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Figure 1.3 Structures of commonly used cationic lipids in synthetic vectors for gene delivery.  
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1.3.4.3.1 Lipoplex Formation, Packing Structures and Influences of Helper Lipids 
The formation of lipoplexes stems from favorable electrostatic interactions between 
negatively charged DNA and positively charge cationic lipids. This is an entropy driven 
process arising from rapid lipid mixing/reorganization and subsequent release of tightly 
bound counterions from both DNA and lipid bilayers [68-72]. Distinct phases of lipoplex 




) charge ratios 




 charge ratios of <1, DNA-DNA 
repulsion predominates leading to the formation of discrete lipoplex particles with excessive 




=1) or slightly positive charge ratios, 
charge neutralization prevents effective DNA encapsulation and prompts significant 
aggregations that prevent the generation of discrete lipoplexes [50]. The addition of excess 
lipid, conferring charge ratios >1, allows for effective DNA complexation and encapsulation 
leading to the formation of discrete lipoplex particles that are separated by electrostatic 
repulsion. Increasing charge ratios favors DNA compaction into small discrete lipoplex 
particles while instilling a positive surface charge for efficient cellular uptake upon optimal 
interactions with negatively charged cell membranes. However, this comes at a cost as 
cytotoxicity increases with greater cationic lipid content and surface charge [69]. 
Depending on the lipid composition, lipoplexes adopt a variety of phase structures 
including: 1) lamellar L
C
α, 2) hexagonal HI, and 3) inverted hexagonal H
C
II (Figure 1.4). 
Lamellar structures are characterized as DNA monolayers sandwiched between cationic 
membrane bilayers. Higher ordered hexagonal structures are characterized as DNA "rods" 
intercalated between spherical micelles arranged in a hexagonal lattice whereas inverted 
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hexagonal structures are characterized as DNA "rods" coated with a lipid monolayer 
arranged in a hexagonal lattice [70, 71].  The formation of the different phase structures is 
dependent on the curvature of the lipid system. The lipid components influencing the 
spontaneous curvature of the membrane, Co = 1/Ro,  will determine the actual curvature, C = 
1/R,  where Ro is the spontaneous radius of curvature of the lipid monolayer and R is the 
actual radius of the lipid system; the actual curvature describes the dominant structure of the 
self assembled lipoplexes as follows: lamellar (C = 0), hexagonal (Co > 0), and inverted 
hexagonal (Co < 0) [69, 73]. Spontaneous curvatures and corresponding phase structures 
relate to the concept of molecular packing parameter (P) defined as         where V and l 
are the volume and length of hydrophobic tails, and a0 is the surface area of the head group 
[74]. Different packing parameters are associated with different expected aggregate shapes: P 
< 1/3 for spheres, 1/3 < P < 1/2 for cylinders, 1/2 < P < 1 for vesicles and flexible bilayers 
(lamellar), P = 1 for planar bilayers (lamellar), and P > 1 for inverted structures (inverted 
hexagonal) (Figure 1.5) [69, 74]. The packing parameter is not always constant and 
modifications to the solution conditions (eg. temperature, pH, salts) can have drastic 
influences over the resulting phase structures [74].  
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Figure 1.5 Packing parameter and expected aggregate structures. 
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The incorporation of neutral helper lipids DOPE or cholesterol (Figure 1.6) is capable of 
mediating the transition from lamellar to inverted hexagonal phase structures, a feature often 
considered critical to successful endosomal escape of lipoplexes [75]. DOPE has been 
previously demonstrated to exhibit pH dependent phase behaviors. At pH of 9 and above, 
DOPE is negatively charged and exists as spherical micelles; however, at physiological pH 
and temperatures above 10-15° C, the zwitterionic head groups of DOPE abolishes repulsion 
between head groups which leads to transitions into inverted hexagonal packing structures 
[76, 77]. The addition of pH responsive DOPE, possessing a packing parameter of P > 1, 
results in alterations to the actual curvature of the lipid system in accordance to the 
proportion of DOPE being incorporated. Greater fractions of DOPE contribute to a more 
negative actual curvature which increases the propensity for lamellar to inverted hexagonal 
phase transitions [73]. The relative ratio of DOPE to cationic lipid serves to determine the 
transition pH of DOPE from lamellar to inverted hexagonal as mixed systems of cationic 
lipid, with ethylenediamine head group, and DOPE decreased the transition pH of DOPE 
[77]. Hence, by controlling the DOPE composition within the lipid system, the overall phase 
structure of lipoplexes and pH induced phase transitions can be effectively regulated. 
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Figure 1.6 Neutral lipids in lipoplex formation. 
 
1.3.4.3.2 Overcoming barriers with cationic lipid based synthetic vectors. 
A substantial amount of research effort has been focused on the development of novel 
cationic lipids for gene delivery in part due to the ability of such synthetic vectors to bypass 
the numerous barriers described above. Effective DNA compaction and encapsulation by 
cationic lipids results in protection from nuclease mediated DNA degradation as well as the 
formation of discrete, small lipoplexes capable of cellular uptake by endocytosis (Figure 1.7). 
With the incorporation of ligands for targeted delivery, such lipoplexes are internalized by 
receptor mediated endocytosis. In absence of targeting ligands, lipoplexes undergo non-
specific electrostatic interactions with anionic cell surface heparin sulfate proteoglycans 
(HSPGs) and may be internalized by various endocytic pathways including: phagocytosis, 
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macropinocytosis, clathrin mediated endocytosis, caveolae mediated endocytosis, and non-
clathrin/non-caveolae mediated endocytosis [14, 78, 79]. These pathways differ with respect 
to vesicle size, embedded endosomal proteins, preferential uptake of specific particle sizes, 
and the ultimate fate of internalized particles [1, 79]. Due to the resulting polydispersities 
upon lipoplex formation, multiple pathways may be involved with clathrin mediated 
endocytosis being the predominant pathway due to preferential uptake of particles ≤ 200 nm. 
Particles ranging from 200-500 nm in size may undergo caveolae mediated endocytosis [80], 
while particles >500 nm may undergo phagocytosis or macropinocytosis; however, direct 
correlations between particle sizes and endocytic pathway have yet to be clearly elucidated. 
Upon clathrin mediated endocytosis, the early endosome, carrying the endocytosed vesicles, 
transitions to late endosome as they are subjected to microtubule assisted intracellular 
trafficking towards the microtubule organizing centre (MTOC) situated in the perinuclear 
region [14]. Progressive acidification during the transition from early to late endosome 
results in lysosomal degradation upon fusion with lysosomes. In caveolae mediated 
endocytosis, the endocytosed vesicles may fuse with the early endosome or caveosome, an 
endosomal compartment of neutral pH that is not subjected to lysosomal degradation [81]. 
Microtubule assisted transport of endocytosed lipoplexes towards MTOC drives rapid 
intracellular trafficking to the perinuclear region. However, suitable mechanisms of 
endosomal escape must be in place in order to prevent degradation of the DNA cargo. 
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Figure 1.7 Endocytic pathways in the cellular uptake of lipoplexes: A) Receptor mediated 
endocytosis; B) Clathrin mediated endocytosis; C) Caveolae mediated endocytosis. The incorporation 
of targeting ligands permits cellular uptake of lipoplexes by receptor mediated endocytosis. Non-
specific electrostatic interactions with anionic heparin sulfate proteoglycans (HSPGs) enable 
internalization by clathrin and caveolae mediated endocytosis. For clathrin mediated endocytosis, the 
internalized vesicle fuses with early endosomes for intracellular trafficking and transition into late 
endosomes. Endocytosed vesicles from caveolae mediated endocytosis may fuse with early endosome 
or caveosome. Subsequent endosomal escape and nuclear entry are both required for successful gene 
delivery after cellular uptake.   
 
A number of mechanisms have been proposed regarding endosomal escape of lipoplexes 
with pre-dominant lamellar phase structures (Figure 1.8) and with DOPE containing 
lipoplexes possessing pH dependent fusogenic properties (Figure 1.9). Membrane charge 
density, the average charge per unit area of membrane, has been previously determined to be 
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the universal parameter for successful endosomal escape of lamellar lipoplexes [70, 71, 76, 
82]. Lamellar lipoplexes with high membrane charge density were shown to elicit better 
endosomal escape via “flip-flop” fusion. In flip-flop fusion, lipoplexes with high membrane 
charge densities prompt close proximity interactions with anionic lipids of the endosomal 
membrane, flipping of anionic lipids from the cytoplasmic leaflet to the inner leaflet facing 
the endosomal lumen. Charge neutralization with anionic lipids induces higher ordered 
inverted hexagonal phase structures, displacing DNA upon endosomal escape [83].  
 
 
Figure 1.8 Mechanisms of endosomal escape in lamellar lipoplexes. Positively charged lipoplexes 
undergo close proximity electrostatic interactions with negatively charged anionic lipids of the 
endosomal membrane. "Flip-flop" fusion incurs as lipoplexes with high membrane charge densities 
causes anionic lipids to flip from the cytoplasmic leaflet towards to inner leaflet facing the endosomal 
lumen. This promotes charge neutralization and the induction of higher ordered structures critical to 
endosomal escape. Adapted from [73]. 
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Exponential increases in transfection efficiency have been previously observed to 
correspond with increases in charge density. However, the inherently more stable and onion-
like nature of lamellar lipoplexes render gradual endosomal escape due to slow electrostatic 
interactions between cationic lipids and anionic membrane components [82]. Lipoplexes 
from 200-400 nm with a cationic lipid to DNA charge of ≥ 2 have been observed to be most 
effective for in vitro transfections as their size stretches the limits of clathrin mediated 
endocytosis, allowing substantial membrane interactions and rapid lipid exchange [76].  
Endosomal escape by DOPE containing lipoplexes employs a mechanism that is 
independent of membrane charge density. A drop in pH, as seen during the progression from 
early endosome to late endosome, triggers lamellar to inverted hexagonal phase transitions. 
The negative curvature of inverted hexagonal lipoplexes results in an elastically frustrated 
state with the outer lipid monolayer, possessing a positive curvature, that surrounds the 
lipoplexes; this constitutes the driving force for rapid fusion with cell and endosomal 
membranes (Figure 1.9) [70, 82]. The ability of DOPE containing lipoplexes to adopt 
inverted hexagonal phase structures for rapid fusion and endosomal escape is a significant 
contributing factor to higher transfection efficiency when compared to lipoplexes with 
lamellar phase structures.  
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Figure 1.9 Mechanism of endosomal escape in fusogenic, DOPE containing lipoplexes. 
Progressive drops in pH trigger lamellar to inverted hexagonal phase transitions (A), prompting an 
elastically frustrated state that drives rapid fusion with endosomal membrane and endosomal escape 
(B). Adapted from [73]. 
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Upon successful endosomal escape, lipoplexes and free DNA vectors are required to 
translocate across the nuclear membrane for transgene expression. Previous studies had 
indicated the potential of lipoplexes to undergo fusion with nuclear membranes, as visual 
evidence suggests the extension of DNA across the nuclear membrane while in aggregate 
forms larger than the NPC [84]. However, successful nuclear delivery, in absence of cell 
mitosis, generally occurs through the NPC. Nuclear localization signals (NLS), short amino 
acid sequences functioning as tags for nuclear transport, and DNA nuclear targeting 
sequences (DTS) may be incorporated to facilitate nuclear entry. 
With considerations to in vivo administration, interactions with serum proteins and high 
clearance rate are detrimental particularly due to inverted hexagonal phase structures of 
DOPE containing lipoplexes [69]. The incorporation of polyethylene glycol (PEG) to 
lipoplexes can circumvent such issues as it masks surface charge, reduces aggregation, 
minimizes serum protein interactions, and prevents opsonin adsorption [10, 16]. 
1.3.4.4 Gemini Surfactants 
Gemini surfactants are amphiphilic molecules composed of two surfactant monomers 
(cationic, anionic, or neutral) chemically linked by a spacer (Figure 1.10). Gemini surfactants 
possess higher charge per mass ratio than cationic lipids and have a critical micelle 
concentration (CMC), the concentration of surfactants at which micelles begin to form, that is 
one to two orders of magnitude lower than their monomer counterparts [15, 85, 86]. As such, 
gemini surfactants confer advantages of reduced toxicities and cost effectiveness over 
conventional surfactants. At low concentrations, gemini surfactants self-assemble into a 
variety of higher order assemblies (spherical micelles, bilayers, and inverted micelles) 
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depending on the nature of the head group, hydrophobic tails, and spacer [87]. Gemini 
surfactant derived synthetic vectors provide numerous advantages including: 1) high positive 
charge for effective DNA complexation at low concentrations; 2) efficient DNA compaction 
generating smaller complexes than their monomeric counterparts; 3) effective endosomal 
escape alone or in combination with DOPE; and 4) suitability for long term storage, over two 
months at ambient temperatures, in lyophilized formulations without losing functionality [88, 
89]. Similar to cationic lipids, the numerous variations to the head group, hydrophobic tails, 
and spacer contribute to the high number of permutations allowing the modulation of their 
physicochemical properties and biological activity for efficient gene delivery. Different 
formulations of gemini surfactants, from traditional cationic m-s-m or N,N-
bis(dimethylalkyl)-α,ω-alkanediammonium surfactants (where m and s represent the number 
of carbon atoms in the alkyl tails and in the polymethylene spacer group) to peptide or 




Figure 1.10 Structural schematic of conventional (A) and gemini (B) surfactants. 
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1.3.4.4.1 Lipoplex formation and gene transfection using m-s-m gemini surfactants 
Similar to cationic lipids, lipoplex formation stems from electrostatic interactions between 
DNA and cationic gemini surfactants in an entropy driven process arising from the release of 
counterions from micelles and DNA [15]. Hence, gemini surfactants with a higher degree of 
micelle ionization, an indicator of counterion dissociation, are more efficient in DNA 
complexation [85]. DNA complexation is influenced by a number of contributing factors 
including the length and nature of hydrophobic tails as well as changes to the head group 
through modifications to spacer lengths and the inclusion of functional substitutions. 
Increasing alkyl tail length of m-s-m gemini surfactants serves to improve DNA compaction 
as result of greater hydrophobicity promoting stronger DNA interactions [90]. Alkyl tail 
lengths have profound effects on CMC as increasing alkyl tail lengths, with a fixed spacer, 
linearly decrease the natural log of CMC [15]. Such changes in CMC may alter DNA 
complexation and complex stability. Control of the CMC is critical as high CMC maintains a 
greater monomer concentration for DNA complexation while low CMC prompts better 
complex stability [91]. With respect to the nature of hydrophobic tails, increasing asymmetry 
between alkyl tails leads to an overall increase in hydrophobicity contributing to efficient 
DNA complexation [15]. The head group areas of m-s-m gemini surfactants are related to the 
polymethylene spacer lengths as head group areas increase with corresponding increases in 
spacer length up to a maximum at s = 10-12. Subsequent increases beyond the maximum 
results in the folding of the hydrophobic spacer causing the quaternary ammonium head 
groups to be in closer proximity [92]. As such, spacer lengths are able to modulate the degree 
of interaction between the nitrogen centres of m-s-m gemini surfactants and the phosphate 
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groups in DNA. Through manipulation to the spacer lengths of the 12-s-12 series of gemini 
surfactants, Karlsson et al. [90] have shown effective DNA complexation using gemini 
surfactants of short (s = 2-3) and long (s > 10) spacer lengths with intermediate spacer length 
being the least effective. Gemini surfactants with spacer lengths of 3 were confirmed to have 
compatible head group distances (~0.49 nm) that matched well with the spacing of phosphate 
groups (0.34 nm) in DNA [91]. Building on the findings from the impact of spacer lengths, 
amine substituted m-s-m surfactants, comprising of aza (N-CH3) or imino (N-H) 
substituent(s) two or three methylene units apart, have been developed for the generation of 
multivalent gemini surfactants (m-5N-m, m-8N-m, m-7N-m, m-7NH-m) with better DNA 
binding and complexation (Figure 1.11) [87, 93, 94]. Similar to m-3-m surfactants, the 
distances for trimethylene spacers between the nitrogen centres in 12-7N-12 and 12-7NH-12 
gemini surfactants were calculated to be ~0.51 nm [15]. 
As expected, gemini surfactants conferring improved DNA complexation were found to 
elicit enhanced transfection efficiencies. Increasing alkyl tail lengths corresponded to 
increases in transfection efficiencies with 16-3-16 and 18:1-3:18:1 gemini surfactants 
demonstrating higher transfection efficiencies over 12-3-12 gemini surfactant, with and 
without DOPE [95]. Asymmetric phytanyl-gemini surfactants (phy-3-m), possessing bulky 
hydrophobic tails, were previously demonstrated to achieve better transfection efficiencies 
over 16-3-16 gemini surfactants [85, 96]. Gemini surfactants with spacer lengths s = 3-12 
were able to compact DNA into discrete 100-200 nm positively charged particles, but 
transfection efficiencies were highest using gemini surfactants with a trimethylene spacer (s 
=3) [87]. Increasing transfection efficiencies with spacers >12 was observed in correlation 
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with improved DNA complexation upon folding of the flexible spacer [91]. With respect to 
amine substituted gemini surfactants, 12-7NH-12 exhibited significantly greater transfection 
efficiencies over 12-3-12, 12-5N-12, 12-8N-12, and 12-7N-12 (P < 0.01); the dimethylene 
spacing in 12-5N-12 and 12-8N-12 gemini surfactants were found to be too short to facilitate 
binding with adjacent phosphate groups of DNA [93].  
 
 
Figure 1.11 Chemical Structure of m-s-m gemini surfactants. 
 
Despite the evident correlations between improved DNA complexation and transfection 
efficiencies, the ability of such gemini-based lipoplexes to adopt structural polymorphisms is 
considered to be the most important factor contributing to improved gene delivery [10, 15, 
85, 91, 93, 97, 98]. Depending on the lipid to surfactant mol ratio and surfactant to DNA 





) charge ratios, the incorporation of DOPE results in the formation of numerous phase 
structures including the previously mentioned lamellar, hexagonal, inverted hexagonal 
structures as well as cubic phase structures, characterized as spherical micelles arranged on a 
cubic lattice. In the absence of DOPE, 12-3-12/DNA, 16-3-16/DNA, and 18:1-3-18:1/DNA 
gemini based lipoplexes demonstrated insignificant gene delivery capacities due to their 
inability to adopt polymorphic structures [98]. However, the abovementioned lipoplexes, 
each possessing short trimethylene spacers (s = 3), demonstrated profound structural 
polymorphism upon the incorporation of DOPE [97]. The significance of DOPE may be 
attributed to the antagonistic mixing interactions between gemini surfactants and the neutral 
lipid [99], which may be responsible for structural polymorphisms that contribute to 
endosomal escape and successful gene delivery.   
The application of imino substituted spacers, as in the m-7NH-m (m = 12, 16, 18, 18:1) 
series, demonstrated increased transfection rates, in the presence or absence of DOPE, when 
compared to unsubstituted gemini based lipoplexes. The transition from basic to acidic 
conditions, similar to that of early to late endosomes, conferred significant changes in 
aggregate size as result of the buffering capacity from the imino group and the corresponding 
pH-induced structural changes consistent with endosomal escape and increased transfection 
[93, 94]. Specifically, 12-7NH-12 gemini based lipoplexes exhibit a unique pattern with 
respect to changes in zeta potential upon changes in pH. The zeta potential curve for 12-
7NH-12 revealed an initial rise in zeta potential at basic pH until reaching a plateau at pH of 
7, before a sharp decrease around pH of 5.5; this corresponded to more prominent membrane 
fusion/collapse when compared to 12-3-12 gemini based lipoplexes [94]. As can be seen, 
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there are numerous factors at play in the rational design of gemini based synthetic vectors 
with optimal DNA complexation and high capacity for structural polymorphisms. However, 
highly efficacious gene therapeutics demand contributions from sound design of both the 
synthetic vector as well as the enclosed DNA cargo.   
1.4 Recombinant Plasmid DNA (pDNA) Vectors 
Recombinant plasmid DNA (pDNA) vectors for gene therapy typically consist of two 
essential components: i) an eukaryotic expression cassette containing genetic components 
pertinent to transgene expression in the eukaryotic host (gene of interest, promoter, intron, 
and transcription termination/polyadenylation signal), and ii) a prokaryotic backbone 
consisting of an origin of replication for plasmid amplification and an antibiotic resistance 
gene cassette for selection (Figure 1.12) [100].  
 
 
Figure 1.12 Recombinant plasmid DNA (pDNA) vectors. 
  39 
While safer than their viral counterparts, non viral delivery of such circular covalently 
closed (CCC) pDNA vectors, alone or packaged within synthetic vectors, offers a limited 
safety profile as they often result in the transfer of antibiotic resistance genes as well as other 
unwanted prokaryotic sequences with CpG motifs. The unnecessary delivery of antibiotic 
resistance genes may enable horizontal gene transfers, giving rise to antibiotic resistant 
pathogens. Unmethylated CpG dinucleotides, or CpG motifs, have the potential for eliciting 
immunostimulatory responses which reduces the efficacy of the gene therapeutic and 
potentially impose detrimental effects onto the administered host. The bacterial genomic 
DNA has a higher frequency of CpG dinucleotides, and, unlike vertebrate animals, most of 
these dinucleotides remain unmethylated [101]. CpG motifs are capable of inducing immune 
responses as they are recognized as pathogen associated molecular patterns (PAMPs) 
primarily through interactions with toll-like receptor (TLR) 9 embedded in the endosomal 
membrane of immune cells including dendritic cells, B lymphocytes, monocytes, and 
macrophages [1, 102]. CpG binding to TLR9 results in the activation of eukaryotic 
transcription factors and upregulated pro-inflammatory cytokine production [103]. As TLR9 
is situated within the endosome, the administration of synthetic vectors may heighten CpG 
mediated immunostimulatory responses. In particular, in vitro incubation of lipoplexes with 
macrophages/dendritic cells and in vivo intravenous administration of lipoplexes into mice 
both showed CpG mediated release of inflammatory cytokines at levels greater than naked 
pDNA [102]. The in vivo administration of modified pDNA vectors, with reduced CpG 
motifs, in to BALB/c mice demonstrated a 40-75% reduction in pro-inflammatory cytokine 
release [101]. The removal of additional CpG motifs, through modifications to 
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cytomegalovirus (CMV) enhancer and promoter regions, further diminished inflammatory 
responses while improving sustained transgene expression [104]. The effects of reduced 
immune responses and prolonged expression was also indicated upon the removal of CpG 
motifs in PEI/DNA polyplexes and DOTAP/DOPE/DNA lipoplexes [105]. Despite these 
improvements, Hyde et al. [106] revealed detectable inflammatory responses from the 
presence of even a single CpG motif upon intranasal delivery of lipoplexes into BALB/c 
mice. Aside from immune activation, CpG mediated TLR activation induces an antiviral state 
that inhibits gene expression and activates DNA degradation by nucleases [1]. Within the 
nucleus, the unmethylated CpG motifs may be subjected to DNA methylation which 
influences histone-DNA interactions and transgene expression. Recognition of methylated 
sites by methyl-CpG-binding domain proteins results in the repression of histone deacetylase 
which normally prevents histone hyperacetylation and the subsequent binding of 
transcriptional factors pertinent to transgene expression [102]. As such, transgene silencing 
severely hampers sustained expression upon successful delivery [107]. 
As pDNA vectors do not possess the inherent mechanisms for integration found in viral 
vectors, such vectors are significantly safer due to limited risks from insertional mutagenesis. 
However, conventional CCC pDNA vectors often possess elements or sequences, including 
viral promoters or cloned sequences, that could subject them to undesired recombination 
events [108]. Although rare, the potential risks of vector integration upon homologous 
recombination of CCC pDNA persist and this may lead to oncogenesis through the activation 
of proto-oncogenes or through the inactivation of tumor suppressor genes (see Section 1.1.2).  
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1.4.1 Novel DNA Vectors: DNA Minicircles and LCC DNA Minivectors 
As previously explained, traditional recombinant pDNA vectors are flawed by the delivery of 
unnecessary prokaryotic sequences resulting in a risk of horizontal gene transfer of antibiotic 
resistance genes, CpG mediated immunostimulatory responses, and diminished transgene 
expression. Removal of the prokaryotic backbone for the generation of DNA minicircles and 
linear covalently closed (LCC) DNA minivectors serves a dual purpose of bypassing the 
abovementioned complications while improving the delivery process through the formation 
of smaller vectors that increase extracellular and intracellular bioavailability (Figure 1.13). 
 
 
Figure 1.13 Schematic of plasmid DNA (pDNA) vectors, DNA minicircles, and Linear 
Covalently Closed (LCC) DNA minivectors. 
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1.4.1.1 DNA Minicircles 
DNA minicircles are CCC supercoiled mini expression cassettes generated from in vivo site 
specific recombination mediated by phage derived recombinases [109]. These recombinases 
typically undergo “cut-and-paste” recombination processes by acting on specific recognition 
sites generally ranging from 30-40 base pairs or longer [110]. Such processes are employed 
for the production of DNA minicircles as site specific recombination offers excellent 
specificities while attaining high activity for efficient pDNA processing in the absence of any 
additional co-factors. The generation of DNA minicircles involves recombinases acting on 
target parental pDNA substrates, carrying a eukaryotic expression cassette flanked by two 
respective recognition sites, that results in the separation of the parental pDNA into two 
distinct parts: 1) a replicative miniplasmid carrying the prokaryotic backbone, and 2) a DNA 
minicircle with the expression cassette [103].  
Depending on the catalytic amino acid residues involved in the recombination process, site 
specific recombinases are classified into: 1) the tyrosine or λ integrase family, and 2) the 
serine, or invertase/resolvase, family [110]. λ integrase, P1 Cre recombinase, and FLP 
recombinase from the tyrosine family along with ΦC31 integrase and ParA resolvase from 
the serine family have all been previously applied for the production of DNA minicircles 
(Table 1-1) [103, 109, 111-114].  
Gene delivery using DNA minicircles have previously documented 10 to 1000 fold 
increases in long term transgene expression, in vitro and in vivo, over conventional CCC 
pDNA vectors [114]. Such improvements may be attributed to the elimination of transgene 
silencing, not simply through the elimination of CpG motifs, but specifically through the 
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removal of the prokaryotic backbone. Using DNA minicircles to examine backbone induced 
effects, Chen et al. [115] demonstrated transgene silencing from backbone sequences 
covalently linked to the eukaryotic expression cassette; however, such silencing was not 
observed from the co-delivery of backbone DNA and the expression cassette as separate 
entities. Despite improved transgene expression when compared to unaltered parental pDNA, 
transgene silencing persists upon the delivery of a modified parental pDNA absent of CpG 
motifs in the prokaryotic backbone [115]. Such findings were consistent with the hypothesis 
of transgene silencing from backbone sequence induced, heterochromatin-associated histone 
modifications spreading to the adjacent eukaryotic expression cassette [107, 115].    






Tyrosine Family    
λ Integrase attB/attP Unidirectional Dimers observed 
Cre Recombinase 34 bp loxP Bidirectional Intramolecular and Intermolecular 
recombination leading to dimeric 
or trimeric species. Mutation to 
loxP to favor unidirectional 
processing.   
FLP recombinase 48 bp FRT Bidirectional Intramolecular and Intermolecular 
recombination leading to dimeric 
or trimeric species 
Serine Family    
ΦC31 integrase attB/attP Unidirectional Strictly unidirectional without 
concatemers 
ParA resolvase Res Unidirectional Strictly unidirectional without 
concatemers 
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1.4.1.2 LCC DNA Minivectors 
LCC DNA minivectors are small, dumbbell shaped vectors possessing hairpin ends enclosing 
an eukaryotic expression cassette. The hairpin loops offer vast improvements in protection 
from exonucleases conferring greater stability, an issue that drastically hinders the successful 
delivery of linear DNA. Such vectors may be generated through three distinct in vitro 
enzymatic mechanisms: 1) pDNA digestion and ligation, 2) PCR amplification and ligation, 
and 3) protelomerase, or prokaryotic telomerase, mediated processing (Figure 1.14).  
 
 
Figure 1.14 In vitro production of LCC DNA minivectors: A) Targeted pDNA digestion and 
ligation with hairpin oligonucleotides for the generation of minimalistic immunogenic defined gene 
expression vectors (MIDGE); B) PCR amplification and ligation with hairpin oligonucleotides for the 
generation of micro-linear vectors (MiLV); C) TelN protelomerase mediated pDNA processing for 
the generation of LCC DNA minivectors. Adapted from [116].  
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Minimalistic immunogenic defined gene expression vectors, or MIDGE, are the first 
generation of such vectors involving restriction endonuclease digestion of the parental pDNA 
vector, at sites flanking the eukaryotic expression cassette, followed by ligation with hairpin 
oligonucleotides for the formation of covalently closed ends [116]. The unprotected 
prokaryotic backbone sequences are subsequently removed by exonucleases, isolating the 
generated MIDGE vectors. Application of MIDGE vectors has previously shown improved 
transgene expression in colon carcinoma cells upon complexation with PEI and 
Lipofectamine [117] as well as improvements in transfection efficiencies to liver (2.5 fold), 
lungs (3.5 fold), kidneys (3.9 fold) and heart (17 fold) when compared to the parental pDNA 
vector upon in vivo hydrodynamic injection into BALB/c mice [118]. MIDGE vectors also 
have demonstrated potential to be effective DNA vaccines as the administration of such 
vectors, encoding the LACK antigen, offered protection from Leishmania infection in 
susceptible BALB/c mice at lower doses compared to conventional pDNA vectors [119].    
As an alternative to MIDGE, micro-linear vectors (MiLV) are mini linear vectors 
generated from PCR amplification of the eukaryotic expression cassette followed by 
subsequent ligation with hairpin oligonucleotides. These vectors avoid additional steps 
involved in the removal of prokaryotic sequences and can be purified using PCR clean up 
kits. MiLV vectors were previously demonstrated to resist exonuclease degradation, improve 
transfection efficiency, prolong transgene expression, and reduce immunostimulatory effects 
when compared to conventional pDNA vectors [120].    
With respect to protelomerase processing as a means of producing of LCC DNA vectors, 
certain strains of temperate bacteriophage replicate utilizing linear plasmids generated from a 
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protelomerase processing pathway. In contrast to most temperate bacteriophages, N15, PY54, 
and ϕKO2 are three prophages that do not undergo chromosomal integration and replicate 
extra-chromosomally as linear plasmids. N15 and PY54 are of particular interest as they 
share four distinct similarities: 1) both can infect Escherichia coli; 2) both exhibit structural 
features (hexagonal head and long contractile tail) that resemble lambda phages; 3) both are 
comprised of a 43.6 kb linear double stranded DNA genome that replicates as a low copy 
number plasmid; and 4) both use protelomerase, or prokaryotic telomerase, for the generation 
and replication of linear plasmids with covalently closed terminal ends [121].  
Bacteriophage N15 derived protelomerase, TelN, has previously been applied for in vitro 
protelomerase mediated processing of parental pDNA vectors into LCC DNA minivectors. 
TelN protelomerase possesses catalytic tyrosine residues for unidirectional, cleave-joining 
activity in the absence of any additional co-factors. They recognize and associate with a 310 
bp telomere occupancy site (tos) comprised of a series of inverted repeats centered on telRL, 
a 56 bp palindrome sequence [122, 123]. The 56 bp telRL, composed of a central 22 bp 
palindrome telO flanked by an inverted repeat (R3/L3), serves as the essential recognition 
sequence required for TelN binding and protelomerase mediated processing [124]. The two 
other inverted repeats (R1/L1 & R2/L2) within tos serve as additional association points 
offering better stability to the TelN-DNA complexes. TelN mediated processing begins with 
the binding of two TelN molecules, as a dimer, to telRL followed by the generation of a pair 
of staggered cuts within telO that results in 3’ phosphotyrosine DNA intermediates and 
subsequent rapid resolution into linear covalently closed (LCC) hairpin ends [123]. Heinrich 
et al. [100] generated bacterial sequence-depleted LCC DNA minivectors by inserting telRL 
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recognition sites, flanking the EGFP or IL-12 expression cassette, into the parental pDNA 
vector followed by in vitro processing using TelN protelomerase. The expression of EGFP or 
IL-12 was determined to be unaffected by the presence of hairpin ends and increased anti-
metastatic capacity was observed, in an in vivo metastatic model, for IL-12 expressing 
minivectors when compared to parental CCC pDNA vector. 
The bacteriophage PY54 derived protelomerase, Tel, shares an overall 60% similarity 
with TelN and possesses TelN-like unidirectional, cleave-joining activity in the absence of 
any additional co-factors [125]. Tel protelomerase recognizes and associates with a 140 bp 
pal site consisting of a 15 bp inverted repeat flanking a 42 bp perfect palindrome sequence 
that serves as the target site for protelomerase mediated processing. However, unlike TelN, 
the flanking inverted repeat is necessary for efficient processing under in vivo conditions 
[125]. Despite numerous similarities with TelN-telRL system, the Tel-pal system was not 
previously explored for in vitro production of LCC DNA minivectors.    
1.4.1.3 Impact of Vector Size and Topology on Gene Delivery 
DNA minicircles and LCC DNA minivectors are assumed to improve bioavailability due to 
their small sizes permitting efficient DNA packaging into synthetic vectors and rapid 
intracellular trafficking upon cytoplasmic release. Despite the fact that lipoplex size and 
structure do not vary with increasing pDNA length, the number of pDNA vectors 
incorporated into each lipoplex increases linearly with decreasing pDNA size [126]. 
Transfection activity of lipoplexes is proportional to the number of enclosed pDNA with the 
most active lipoplexes possessing the largest amounts of pDNA. The advantages of smaller 
pDNA were confirmed as smaller pDNA attained higher transfection efficiency over larger 
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pDNA when lipoplexes were restricted to possess a single coding cassette in each particle 
[126]. In a more systematic approach, Yin et al. [127] assessed the transfection efficiencies 
of varying pDNA sizes by incorporating “stuffer” DNA of different lengths. An inverse 
correlation between relative transgene expression and pDNA size was observed with most 
significant decreases occurring upon the addition of stuffer DNA ranging from 0 and 6.5 kb 
in size. Promoter activity and the effects of enhancer elements were both negatively affected 
by increasing stuffer DNA and such trends were consistent across all tested promoters and 
cell types [127]. 
With respect to DNA topology, no differences were observed in the complexation of 
linear and circular DNA with PEI, PLL, or Lipofectamine [128]. However, LCC DNA 
vectors exhibited enhanced transgene expression over CCC pDNA vectors as demonstrated 
by Kamiya et al. [129] through cytoplasmic and nuclear microinjections along with 
transfection using Lipofectamine. Microinjection of LCC vectors into the nucleus of Cos-7 
cells elicited a 5-10 fold increased transgene expression over its CCC pDNA counterpart. 
Transgene expression of LCC DNA vectors was observed to be more efficient than CCC 
pDNA for up to 14 days post-microinjection; in contrast, linear open (LO) DNA vectors 
exhibited a more rapid decrease in transgene expression when compared to CCC pDNA. 
Subsequent studies involving cytoplasmic microinjection and transfection with 
Lipofectamine also demonstrated improved transgene expression from LCC DNA vectors 
over CCC pDNA. Size dependent effects on transgene expression were observed as higher 
transgene expression was correlated with decreasing LCC vector sizes upon 
cytoplasmic/nuclear microinjection and Lipofectamine mediated transfections. In all cases, 
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the smallest tested LCC DNA minivector (2.3kb) exhibited the highest expression [129]. 
Such improvements in transgene expression from LCC DNA vectors were postulated to be 
associated with drastic improvements in stability and easier transcriptional factor loading in 
absence of DNA supercoiling.          
1.5 One-Step in vivo Linear Covalently Closed (LCC) DNA Minivector Production 
System 
LCC DNA minivectors serve to be superior to conventional CCC pDNA vectors due to 
enhancements to transfection efficiency and safety. However, the abovementioned multi-step 
enzymatic approaches hinder downstream large-scale productions due to the high costs of 
enzymes as well as the labor intensive processes associated with minivector production and 
purification. To address such drawbacks, Nafissi & Slavcev [108] developed a one-step, E. 
coli based in vivo LCC DNA minivector production system for facile and efficient 
production of LCC DNA minivectors referred to as DNA ministrings (Figure 1.15). The 
production system was constructed through the genetic engineering of W3110 RecA
+
 E. coli 
cells and the design of specific genetic constructs catered to in vivo processing of parental 
pDNA substrates by protelomerases. In brief, the construction of TelN and Tel recombinase 
expressing cells (R cells) involved the following steps: 1) PCR amplification of 
protelomerase encoding telN and tel; 2) genetic cloning of the PCR products into an 
inducible prokaryotic expression plasmid, pPL451, for CI[Ts]857 mediated thermoregulation 
of telN/tel gene expression; and 3) chromosomal integration of thermoregulated telN/tel 
expression cassette into the lacZ gene using a pBRINT-cat integrating plasmid followed by 
  50 
subsequent confirmation of integrants through blue/white screening [108]. The successful 
construction of R cells serves as the basis of the LCC DNA minivector production system.  
 
 
Figure 1.15 Schematic of the one-step in vivo LCC DNA minivector production system. The in 
vivo production system involves a recombinant E. coli for thermoregulated expression of TelN/Tel 
protelomerase. In the temperature inducible system, protelomerase expression is repressed by a 
CI[Ts]857 repressor at temperatures below 37° C. Temperature upshift to 42° C causes instability and 
dissociation of the thermolabile repressor which allows for controlled expression of protelomerase. 
Subsequent enzymatic activity of the expressed protelomerase on parental pDNA vector substrates 
results in DNA processing into LCC DNA ministrings.  
 
In order for parental pDNA vectors to become substrates for protelomerase processing, the 
vector must inherit respective protelomerase recognition sequences of telRL and pal. This 
was accomplished by the insertion of specific genetic constructs, referred to as the 
“SuperSequence”, flanking the eukaryotic expression cassette (Figure 1.16). The 
SuperSequence was comprised of the entire 142 bp pal sequence with the inclusion of Cre, 
FLP, and TelN minimal target sites (loxP, FRT, telRL) within the non-specific regions 
outside of the 42 bp perfect palindrome and the 15 bp inverted repeats [108]. In each 
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SuperSequence, the 142 bp pal was flanked by two 72 bp SV40 enhancer sequences acting as 
DNA-targeting sequences (DTS) for improved nuclear entry. The constructed vector was a 
5.6 kb pDNA that possessed a 3.2 kb prokaryotic backbone and the resulting 2.4 kb DNA 
ministring, consisting of two SuperSequences flanking the EGFP eukaryotic expression 
cassette. This system offers high versatility as the eukaryotic expression cassette can be 
interchanged to suit the expression of the desired gene of interest. 
 
 
Figure 1.16 Parental pDNA vector substrate (pNN9) for the production of LCC DNA 
ministrings. The 5.6 kb pDNA vector (pNN9) possesses two SuperSequences flanking the eukaryotic 
expression cassette for the generation of LCC DNA ministrings. Within each SuperSequence, pal and 
telRL act as protelomerase recognition sequences for the production of LCC DNA ministrings upon 
processing by Tel and TelN protelomerases. In addition, loxP and FRT act as recognition sequences 
for Cre and FLP mediated production of DNA minicircles. SV40 enhancer sequences serve as DNA-
targeting sequences (DTS) for improved nuclear entry during gene delivery. 
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1.5.1 Incorporation of Multiple DNA-targeting sequences (DTS) for Improved Nuclear 
Entry 
The SV40 enhancers within each SuperSequence act as DTS for NFκB assisted nuclear 
transport of LCC DNA ministrings through the NPC. Previously, the SV40 enhancer was 
demonstrated to bind to over 10 distinct transcriptional factors. [21, 130]. In particular, the 




M) for DTS 
and, upon binding, NFκB undergoes conformational changes that exposes the buried NLS 
peptide for shuttling of the multiprotein/DNA complex through the NPC [1, 131, 132]. 
Previous studies indicated rapid gene expression at lower dosages with SV40 DTS 
containing pDNA upon cytoplasmic microinjection; however, differences in expression were 
lost after cell division, signifying the ability of SV40 enhancers to bypass the intact nuclear 
membrane [133]. The inclusion of six DTS was demonstrated to result in rapid nuclear 
accumulation and higher number of pDNA in the nucleus, but such improvements were 
abrogated in the presence of an NFκB inhibitor [132]. Due to the small sizes of LCC DNA 
ministrings and the close proximities of the SV40 DTS to the enclosed eukaryotic expression 
cassette, the binding of NFκB could act as transcriptional enhancers that improve transgene 
expression. Hence, the incorporation of multiple SV40 DTS into DNA ministrings may serve 
a dual purpose driving rapid nuclear entry and transgene expression. 
1.5.2 DNA Ministrings: A DNA Vector with a Heightened Safety Profile 
Aside from the removal of CpG motifs deterring immunostimulatory responses, DNA 
minicircles pose potential safety concerns with regards to undesired recombination events 
leading to insertional mutagenesis. In contrast to DNA minicircles, LCC DNA ministrings 
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have a heightened safety profile as insertional mutagenesis is inhibited by covalently closed 
terminal ends conferring double-strand breaks that cause chromosomal disruption and cell 
death in the low frequency event of chromosomal integration. Such notions of heightened 
safety were demonstrated by Nafissi & Slavcev [108] as forced chromosomal integration of 
LCC DNA followed by subsequent thermoregulated expression of TelN/Tel protelomerase 
led to dramatically reduced cell viability in Tel
+
 R cells, exhibiting a 5-fold greater killing 
effect than in the TelN
+
 counterpart. Upon visualization of the E. coli integrants, induced 
protelomerase expression conferred highly contracted and irregular cell morphology when 
compared to integrants without the SuperSequence or integrants with repressed 
protelomerase expression. The surviving colonies of protelomerase expressing integrants 
were drastically lower and retained such irregular cell morphologies when grown in the 
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1.6 Summary & Thesis Objectives 
GT offers limitless potential for the treatment of numerous diseases with demonstrated 
applications in vaccine development. Despite continuing successes of viral based gene 
therapeutics achieving significant clinical outcomes, these highly efficacious vectors pose 
important safety concerns with respect to undesired immunostimulatory effects and/or 
insertional mutagenesis. Non-viral delivery systems are considered to be safer alternatives to 
viral vectors with tremendous upside in terms of versatility, scalability, and cost-
effectiveness. However, they suffer from low transfection efficiencies as they lack inherent 
mechanisms to overcome the numerous extracellular and intracellular barriers to gene 
delivery. Among the different physical and chemical systems, lipid-based synthetic vectors 
have shown the capacity to bypass such barriers and extensive understanding into the 
intrinsic mechanisms involved allow the subsequent production of highly efficacious 
synthetic vectors. Gemini surfactants possess inherent properties that make them suitable 
candidates for the generation of synthetic vectors with improved transfection efficiencies. 
Investigations into the molecular properties of gemini surfactants, their interaction with 
DNA, and the structural activity of resulting lipoplexes contributed to the rational design of 
novel gemini surfactants as synthetic vectors catered to GT. Similarly, the rational and 
intelligent design of novel DNA vectors serves to further improve therapeutic outcomes, 
allowing the generation of vectors with heightened safety profile while achieving efficacies 
that parallel their viral counterparts. Specifically, linear covalently closed (LCC) DNA 
ministrings are genetically designed to improve intracellular delivery of the DNA cargo, 
leading to enhanced transgene expression. In addition, LCC DNA ministrings offer an 
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additional level of safety as they inhibit insertional mutagenesis through covalently closed 
ends conferring double-strand breaks that cause chromosomal disruption and cell death in the 
low frequency event of chromosomal integration. The development of a one step in vivo LCC 
DNA minivector production system allows facile and rapid production of LCC DNA 
ministrings, thus addressing the limitations of scalable production as seen previously with the 
in vitro production of such minivectors.  
1.6.1 Objectives 
The overall objective of this project aims to streamline the production and purification of 
LCC DNA ministrings for the generation of novel lipid-based synthetic vectors with 
numerous potential downstream applications. Although, the in vivo LCC DNA minivector 
production system permits rapid, cost-effective, and scalable production of LCC DNA 
ministrings, the current system suffers from imperfect yields due to incomplete plasmid 
processing. Hence, the system must be optimized to improve processing of CCC pDNA 
precursors for greater yields during large scale productions. In order for the resulting DNA 
ministrings to be suitable for use in clinical settings, the minivectors are required to be 
purified towards the generation of pharmaceutical grade vectors in the absence of residual 
CCC pDNA precursors. Synthetic vectors derived from LCC DNA ministrings were 
characterized and assessed, with comparison to CCC pDNA derived vectors for their 
potential as gene therapeutics. Lastly, as a proof of concept demonstrating the versatility of 
LCC DNA ministrings in different applications, the minivector production system was used 
to generate LCC DNA ministrings catered to the downstream development of a HIV DNA 
virus-like particle (VLP) vaccine. 
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Specific objectives are listed below (Figure 1.17): 
1) Optimization of the one-step in vivo LCC DNA minivector system through the 
assessment of induction duration, cultivation strategy, and genetic/chemical 
modifications on LCC DNA ministring production efficiency.   
2) Separation and purification of LCC DNA ministrings towards the generation of 
pharmaceutical grade DNA vectors using anion exchange membrane chromatography. 
3) Characterization of DNA/16-3-16/DOPE gemini based lipoplexes for the delivery of 
LCC DNA ministrings. This includes physical characterization by particle size, zeta 
potential, and DNase sensitivity along with transfection efficiencies.  
4) Design and production of LCC DNA ministrings conferring the expression of a 
chimeric gag-V3 virus-like particle (VLP) with aims of demonstrating targeted delivery 
of the synthetic vector into dendritic cells. This serves as a proof of concept 
highlighting the versatility of DNA ministrings and act as the initial steps in the 




Figure 1.17 Flow chart of progression from production and purification to application of LCC 
DNA ministrings. 
  57 
Chapter 2 
Optimization of a One-Step Heat Inducible in vivo LCC DNA Minivector 
Production System  
 
2.1 Introduction 
The application of a one-step, E. coli based in vivo LCC DNA minivector production system 
generates minivectors through site-specific recombination on target parental pDNA substrate 
possessing an eukaryotic expression cassette flanked on each side by a multi-target site called 
SuperSequence [108]. The in vivo expression of TelN or Tel protelomerases results in the 
separation of the parental pDNA into two distinct parts: 1) a LCC mini-plasmid carrying the 
prokaryotic backbone, and 2) a LCC DNA minivector, referred to as DNA ministrings 
(Figure 2.1). LCC DNA ministrings are minimalistic expression vectors carrying the 
eukaryotic expression cassette necessary for the expression of the gene of interest. Within 
this E. coli based system, protelomerase expression, through a strong λ pL promoter, is 
regulated by temperature sensitive CI[Ts]857 repressor, whereby high level expression of the 
protelomerase occurs under temperature-induced conditions but not under repressed 
conditions. The current approach involving chromosomal integration of a single copy of the 
protelomerase gene, controlled by this temperature inducible system, corresponds to effective 
but imperfect plasmid processing efficiency that is comparable to the overall 50-90% 
recombination efficiency exhibited by DNA minicircle production employing an inducible 
system [103, 108]. 
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Figure 2.1 LCC DNA ministring production using the one-step in vivo LCC DNA minivector 
production system. Generation of LCC DNA ministrings involves TelN or Tel protelomerase acting 
on the SuperSequence multi-target site. A variety of DNA isoforms/species arises during LCC DNA 
ministring production: 1) parental LCC pDNA (5.6 kb); 2) parental supercoiled CCC pDNA (~4.0 
kb); 3) LCC plasmid backbone DNA (3.2 kb); 4) LCC DNA ministring possessing egfp as the gene of 
interest (2.4 kb). 
 
The E. coli K-12 host has often been exploited for recombinant protein expression due to 
rapid, scalable, high density growth contributing to high quantities at low production costs 
[134-136]. High recombinant protein yields are attributed to the highly characterized genetic 
profile of E. coli and the availability of numerous strong inducible promoters, vector designs, 
and mutant strains. [134, 137, 138]. Strong inducible promoters drive dedicated recombinant 
protein expression through induction of an inducer (eg. IPTG), an alteration to nutrient 
availability, or a manipulation of specific growth conditions (eg. temperature, pH) [134]. 
Temperature inducible systems enable fine control of recombinant protein expression 
through transcriptional regulation using the combination of strong major leftward (pL) / 
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rightward (pR) promoters and CI[Ts]857, a mutant thermolabile repressor derived from 
bacteriophage λ. At lower temperatures, typically around 30° C, the tight binding of 
CI[Ts]857 repressors to pL/pR operators outcompetes RNA polymerase from binding to 
overlapping pL/pR promoters which subsequently inhibit transcription.  
However, at elevated temperatures above 37° C, the thermolabile repressor becomes 
increasingly unstable and dissociates from the operator [134, 139]. Release of the repressor 
thereby enables transcription of recombinant genes downstream of the pL/pR promoter. 
Depending on the protein, bacterial strain, and culture conditions, the application of the 
pL/pR-CI[Ts]857 temperature inducible system confers yields as high as 30% of total protein 
[134], and has been shown to attain 160% of total protein synthesis in non-induced cells 
[140]. Such high yields are attributed to several inherent advantages: 1) fine repressor control 
as a single copy of cI857 gene on each multicopy plasmid is capable of eliciting 
transcriptional control over its pL/pR promoters; 2) cost effective and scalable production as 
recombinant protein is expressed in absence of any special media or expensive inducers; 3) 
high efficiency as contamination risks and additional downstream processing, including the 
removal of potentially toxic inducer by-products, are limited; and 4) high versatility as the 
expression system can be implemented into various E. coli strains [134].   
Difficulties in achieving optimal recombinant protein expression stem from various issues 
relating to low expression levels, poor protein solubility, activation of stress responses, and 
protein degradation [135]. Despite the implementation of pL/pR strong promoters, mitigating 
low expression levels, there are several interrelated factors that must be taken into 
consideration when applying temperature inducible expression systems: 1) host strain 
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selection, 2) plasmid maintenance, 3) culturing strategies, and 4) heating strategies [134, 136, 
139].  Different E. coli strains possess varying recombinant protein expression capacities and 
efficiencies. For efficient recombinant protein expression, the producer strain must attain: 
stable plasmid maintenance, protein solubility, high protein yields, and restricted proteolytic 
activity [136]. Stable maintenance of plasmids requires sufficient plasmid replication and 
partitioning for even distribution across dividing bacterial cells. However, excessive 
replication, in conjunction with recombinant protein expression, may introduce metabolic 
burden and cell exhaustion rendering growth arrest and low production [141]. Plasmid copy 
number, the average number of plasmids in host bacterial cells and an indicator of plasmid 
replication rate, must be maintained within range to allow plasmid propagation into daughter 
cells while preventing negative effects of host exhaustion. Temperature upshift and 
recombinant gene overexpression has been shown to inhibit plasmid replication while 
plasmid instability and degradation are observed upon extended incubation at high 
temperatures around 42° C [140, 142]. This demonstrates an intricate balance between 
recombinant protein expression, temperature upshift, and plasmid maintenance. Recombinant 
protein expression is favored during exponential growth phase as there is adequate cellular 
activity and metabolic resources for protein expression [141]. High levels of recombinant 
protein expression warrant high cell density cultures achieved by batch, fed-batch, and/or 
continuous cultivation [136, 143]. Fed-batch systems have often been utilized for fine control 
over growth phase and its separation from production phase, ensuring plasmid maintenance 
and low levels of metabolic stress during recombinant protein expression [134]. Similarly, 
two phase continuous systems have been implemented to achieve high cell density and 
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plasmid stability prior to the induction of recombinant protein expression, thereby ensuring 
higher productivity [144].  
An optimal heating strategy is the most important factor in successful recombinant 
expression using temperature inducible systems, as numerous stress responses become 
activated upon expression. Induced overexpression of recombinant proteins contributes to 
metabolic aberrations and stresses triggering numerous cellular responses including: general 
stress response, heat shock like response, stringent (a.a. starvation) response, and SOS (DNA 
damage) response. Such responses may elicit altered physiological states including growth 
arrest and decrease in specific growth rates [139], ribosome degradation and diminished 
protein synthesis [145], and protein misfolding/degradation [141, 146]. As overexpressed 
recombinant proteins often require folding modulators, high level expression may overload 
translational machinery resulting in protein misfolding. Hence, the potential for misfolding 
increases with the utilization of strong promoters and high levels of induction [138]. The 
accumulation of unfolded/misfolded proteins favours protein aggregation, inclusion body 
formation, and the activation of the RpoH (ϭ32) regulon triggering a heat shock-like response. 
The RpoH regulon consists of at least 120 genes conferring the expression of heat shock 
proteins (HSPs) including chaperones (ClpB, DnaK/J, GrpE GroEL/ES, ibpA, ibpB) and 
proteases (FtsH/HflB, Lon, ClpP, DegP, OmpT) that are associated with protein folding and 
degradation [134, 141, 147, 148]. Upon analysis of transcript profiles after induced 
recombinant protein expression, Gill et al. [147] linked overexpression with the upregulation 
of 11 stress related genes including most of the abovementioned chaperones and proteases. 
High level expression downregulates translational machinery and diverts resources away 
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from cell growth/division as demonstrated by a six fold increase in ATP demand upon the 
activation of recombinant overexpression and HSPs [134]. The formation of aggregates with 
varying size and complexity interferes with normal cellular metabolism [149]. These 
combined effects become significantly more prominent under the nutrient-depleted 
conditions found in high density cultures. High cell density and recombinant protein 
production constitute nutrient-limiting and slow growth conditions that introduce general 
stress response and subsequent entry into stationary phase upon activation of the RpoS 
regulon [139, 141, 150, 151].   
Simultaneously, heat induction activates the heat shock response (HSR) affecting the 
quantity and overall quality of the recombinant protein. Heat induction negatively affects 
protein folding and increases inclusion body formation [139, 143]. The activation of heat 
shock proteases results in the degradation of recombinant protein, lowering yields. 
Recombinant proteins are more susceptible to proteolytic degradation mediated by five 
ATPase-Associated with diverse cellular Activities (AAA+) heat shock proteases: Lon, 
ClpYQ/Hs1UV, ClpAP, ClpXP, and FtsH [136-138, 151]. These AAA+ proteases are 
involved in various cellular processes including DNA replication, transcription, membrane 
fusion, and proteolysis. They perform processive proteolysis through several key steps: 1) 
substrate recognition/binding; 2) unfolding; 3) translocation; and 4) proteolytic cleavage 
[152]. 
The optimization of the one-step in vivo LCC DNA minivector production system 
warranted investigation into optimal induction schedules as temperature must be finely tuned 
in order to avoid detrimental effects of deceased growth rate, cellular damage, reduced 
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viability, plasmid instability, and diminished recombinant protein expression. In this study, 
various heating conditions were explored with the intention of effective recombinant 
protelomerase expression corresponding to high DNA ministring yields upon maximal 
protelomerase mediated pDNA processing. Induction duration was optimized to circumvent 
the negative effects arising from prolonged heat stress. As scalability is one of the key 
advantages associated with temperature inducible systems, induction duration was optimized 
to accurately reflect changes to culture volume. In addition, the two stage continuous 
culturing strategy was implemented for comparison with batch cultivation, a strategy 
commonly employed in laboratory settings. Concurrent with optimization through 
manipulations to heating and culturing strategies, genetic and chemical modifications were 
also applied in an attempt to improve DNA ministring production. Since heat shock proteases 
are known to play a critical role in the degradation of recombinant proteins upon activation 
by heat stress and induced expression, protease-specific and associated gene deletions were 
introduced to promote chaperone mediated protein re-folding such that protein degradation 
by heat shock proteases would be minimized. It was hypothesized that the introduction of 
these deletions would extend Tel protelomerase turnover, thereby enhancing Tel-mediated 
LCC DNA processing and DNA ministring production. The introduction of dnaB helicase 
mutations and the antibiotic ciprofloxacin, to transiently curb pDNA replication during 
induced protelomerase expression, were also investigated as alternative strategies to promote 
the complete processing of all substrates. 
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2.2 Materials and Methods 
2.2.1 Strains and Plasmids 
The pNN9 vector [108] was used as the parental pDNA substrate for the production of LCC 
DNA ministrings (see Figure 1.16). E. coli K-12 strains were use to generate all recombinant 
cell constructs and JM109 was employed as hosts for plasmid amplification. A list of 
bacterial strains used in this study is shown in Table 2-1. 
2.2.2 Assessing Effects of Volume and Culturing Conditions on DNA Ministring 
Production 
For batch cultivation, a single colony of TelN
+
 W2NN [pNN9] or Tel
+
 W3NN [pNN9] was 
grown overnight in 5 ml LB + Ap (100 µg/ml) under repressed conditions at 30° C with 
aeration. Fresh cells were grown from the overnight culture at 1:100 dilution of various 
culture volumes (10, 20, 50, 500 ml) in a 250 ml or 2 L Erlenmeyer flask at 30° C with 
aeration to late log phase A600 = 0.8. Protelomerase expression was induced upon 
temperature upshift and incubation at 42° C for various timed durations (15, 30, 60, 120 
min). After induction, the cultures were subjected to post-induction temperatures 37° C for 
30 min prior to overnight incubation at 30° C. Cells were harvested and plasmid extracted 
with E.Z.N.A. Plasmid Mini/Maxi-Prep Kit (Omega, VWR). DNA ministring production 
efficiency was assessed by AGE and densitometry (AlphaImager, Alpha Innotech). 
Production efficiencies were calculated as a percentage of the total amount of the two LCC 
DNA product species over the total amount of monomeric DNA comprising of LCC DNA 
and all isoforms of the parental pDNA.  
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For representative two-stage continuous cultivation, a single colony of Tel
+
 W3NN 
[pNN9] was grown overnight in 5 ml LB + Ap (100 µg/ml) under repressed conditions at 30° 
C with aeration. Two batches of fresh cells were grown from the overnight culture at 1:100 
dilution of 50 ml LB + Ap in 250 ml Erlenmeyer flasks at 30° C with aeration to late log 
phase A600 = 0.8. Cells were then collected, centrifuged at 4K RPM for 10 min, and re-
suspended in 1 ml of LB + Ap. The re-suspensions were added into a preheated 2L 
Erlenmeyer flask containing 500 ml of LB + Ap (100 µg/ml) for incubation at 42° C until 
A600 = 1.0 (Two Stage Continuous A). An alternative heating condition was assessed where 
temperature upshift was extended for an additional 60 minutes after A600 = 1.0 (Two Stage 
Continuous B). Cultures were subjected to gradual temperature downshift and grown at 30° 
C overnight. Cells were harvested and plasmid extracted with E.Z.N.A. Plasmid Maxi-Prep 
Kit (Omega, VWR). DNA ministring production efficiency was assessed by AGE and 
densitometry (AlphaImager, Alpha Innotech). Calculations for the approximate amount of 
DNA ministring in each extraction was accomplished through densitometry comparisons 
between the 2.4 kb band and the 3 kb band of the DNA ladder, a known standard containing 
125 ng of DNA for every 10 µl of DNA ladder, along with subsequent extrapolations 
accounting for the amount of sample loaded and the total eluted volume from each respective 
extraction. The estimated bacterial cell concentration in the extracted culture was calculated 
according to optical density readings from A600. 
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2.2.3 Assessing the Introduction of Protease-specific and Associated Gene Deletions to 
Enhance LCC DNA Processing 
Temperature inducible protelomerase expression cassettes (lacZ::Cm-cI857-telN and 
lacZ::Cm-cI857-tel) from the previously established LCC DNA minivector production 
systems (W2NN/W3NN) [108] were introduced into four different strains, conferring four 
protease and protease associated single gene knockouts (ΔclpP, Δlon, Δhflx, Δhflk) [153], 
and their parental strain (BW25113) by P1 bacteriophage-mediated transduction. 
W2NN/W3NN cells were grown overnight in 5 ml LB + Cm (25 µg/ml) at 30° C. Phage 
generation from the donor strain was accomplished by the addition of 1:10 dilutions of 
P1rev6, prepared in 1 ml of TN buffer (0.01 M Tris-HCl and 0.1M NaCl, pH 7.8; Fisher 
Scientific, USA), into 300 µl of bacterial cells before adding 3 ml of top agar (Bacto 
Tryptone and Bacto Agar from Difco Laboratories, Sparks, MD). The solution was poured 
onto LB plates and incubated for 24 h at 37° C prior to lysate preparation. Approximately 5 
ml of TN buffer was added to the surface of the plate and incubated for an additional 8 h at 
4° C. TN buffer and the underlying top agar were collected into a sterile conical tube and 
centrifuged at 12K RPM (Avanti J-E Centrifuge, Beckman Coulter, Mississauga, Canada) at 
4° C for 20 min. Lysate was poured into a new pre-chilled conical tube and briefly vortexed 
upon the addition of 50 µl of CHCl3 (Fisher Scientific, USA). The five recipient strains were 
grown overnight in 5 ml LB or 5 ml LB + Kan (50 µg/ml) at 30° C prior to transduction. 1 ml 
of each of the overnight cultures was centrifuged at 6000 RPM for 5 min. The supernatant 
was discarded and the pellet was re-suspended with 1ml of 10 mM MgSO4 + 10 mM CaCl2 
salt solution. 100 µl of the cell re-suspension was mixed with 100 µl LB and 100-1000 µl of 
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phage lysate depending on phage titre. The cell mixture was incubated at 37° C for 20 min to 
allow phage adsorption and infection. Subsequently, 200 µl of 1M sodium citrate and 1 ml of 
LB were added prior to 1.5-2 h incubation at 30° C. Cells were centrifuged at 6K RPM for 5 
min and re-suspended in 10 µl of 1M sodium citrate and 90 µl of LB. The complete cell re-
suspension was plated on LB + Cm (25 µg/ml) using the spread plate technique. Plates were 
incubated at 30° C for 24-48 h and colonies were re-plated on new LB + Cm (25 µg/ml) 
plates supplemented with sodium citrate. Transfer of the pNN9 vector was accomplished 
using standard transformation techniques described by [154]. Transformation of the pNN9 
vector in the respective single gene knockouts, in absence of protelomerase expression, was 
confirmed to yield supercoiled CCC pDNA without LCC products (Figure 2.2). Heat 
induction using batch cultivation was performed as previously described.  
2.2.4 Assessing Effects of Ciprofloxacin on Plasmid Replication and DNA Ministring 
Production 
A single colony of W3NN [pNN9] and JW0429-Tel (Δlon) [pNN9] was grown overnight in 
5 ml LB + Ap (100 µg/ml) under repressed conditions at 30° C with aeration. Fresh cells 
were grown from the overnight culture at 1:100 dilution of 50 ml LB + Ap (100 µg/ml) in a 
250 ml Erlenmeyer flask at 30° C with aeration until late log phase A600 = 0.8. Protelomerase 
expression was induced upon temperature upshift and incubation 42° C for 60 min. After 
induction, the 50 ml cultures were divided into four 10 ml batches followed by the addition 
of ciprofloxacin at different concentrations (0, 1, 10, 100 µg/ml). The different batches were 
then incubated at 37° and 30° C for 30 and 60 min respectively prior to plasmid extraction by 
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E.Z.N.A. Plasmid Mini-Prep Kit (Omega, VWR). DNA ministring production efficiency was 
assessed by AGE and densitometry (AlphaImager, Alpha Innotech).  
 
 
Figure 2.2 Protease mutants cannot generate DNA ministrings in absence of tel/telN expression. 
Representative gel image confirming the absence of LCC DNA products without protelomerase 
expression after transformation of the parental pDNA vector, pNN9, into each respective single gene 
knockout and parental strain: DNA ladder (lane 1); ΔclpP (lane 2); Δlon (lane 3); ΔhflX (lane 4); 
ΔhflK (lane 5); BW25113 wild type (lane 6); JM109 (lane 7, 8). 
 
2.2.5 Assessing the Introduction of DnaB Helicase Mutations on DNA Ministring 
Production 
The temperature inducible protelomerase expression cassettes (lacZ::cat-cI857-tel and 
lacZ::cat-cI857-telN (Cm
R
)) were introduced into two different mutant strains, conferring 
two respective DnaB helicase mutations (dnaB8 (fast stop) & dnaB252 (slow stop)) [155], 
and their parental strain (N99) by P1 bacteriophage-mediated transduction. Transfer of the 
pNN9 vector and subsequent heat induction, using batch cultivation, were performed as 
previously described. 
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2.2.6 Statistical Analysis 
ANOVA and Welch's T-test was used as statistical analysis to compare production 
efficiencies of tested samples with controls. Production efficiencies for all tested samples and 
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JM109 F', ∆(gpt-lac)0, glnV44(AS), λ-, rfbC1, gyrA96(NalR), recA1, 





F-, λ-, IN(rrnD-rrnE)1, rph-1 lacZ::Cm-cI857-telN [108] 
W3110-Tel 
(W3NN) 
F-, λ-, IN(rrnD-rrnE)1, rph-1 lacZ::Cm-cI857-tel [108] 
JW0427 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), ΔclpP723::kan, λ-, 
rph-1, Δ(rhaD-rhaB)568, hsdR514 
E. coli Genetic 
Stock Center 
(CGSC)#8590 
JW0429 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), Δlon-725::kan, λ-, 
rph-1, Δ(rhaD-rhaB)568, hsdR514 
CGSC#8592 
JW4131 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-1, Δ(rhaD-
rhaB)568, ΔhflX723::kan, hsdR514 
CGSC#10974 
JW4132 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-1, Δ(rhaD-
rhaB)568, ΔhflK724::kan, hsdR514 
CGSC#10975 





F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), ΔclpP723::kan, λ-, 




F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), ΔclpP723::kan, λ-, 




F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), ΔclpP723::kan, λ-, 




F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), ΔclpP723::kan, λ-, 




F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), ΔclpP723::kan, λ-, 




F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), ΔclpP723::kan, λ-, 




F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), ΔclpP723::kan, λ-, 




F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), ΔclpP723::kan, λ-, 
rph-1, Δ(rhaD-rhaB)568, hsdR514, ΔhflK, lacZ::Cm-cI857-telN 
This Study 
BW25113-Tel F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514, lacZ::Cm-cI857-tel 
This Study 
BW25113-TelN F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-1, Δ(rhaD-
rhaB)568, hsdR514, lacZ::Cm-cI857-telN 
This Study 
N99 galK [155] 
BF843  galK lacI::tet dnaB8 miniTn10kan  [155] 
BF865  galK dnaB252 zjb504::Tn10 [155] 
N99-Tel galK, lacZ::Cm-cI857-tel This Study 
N99-TelN galK, lacZ::Cm-cI857-telN This Study 
BF843-Tel galK lacI::tet dnaB8 miniTn10kan, lacZ::Cm-cI857-tel  This Study 
BF843-TelN galK lacI::tet dnaB8 miniTn10kan, lacZ::Cm-cI857-telN  This Study 
BF865-Tel galK dnaB252 zjb504::Tn10, lacZ::Cm-cI857-tel This Study 
BF85-TelN galK dnaB252 zjb504::Tn10, lacZ::Cm-cI857-telN This Study 
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2.3 Results 
2.3.1 Comparative Analysis of DNA Ministring Production between Tel and TelN 
Tel protelomerase-mediated processing was previously demonstrated to achieve improved 
efficiencies over TelN protelomerase [108], however, the significance of such improvements 
was not quantitatively determined. In an attempt to quantify differences in pDNA processing 
by each respective protelomerase, LCC DNA ministring production efficiency was estimated 
by densitometry. Through direct comparisons using two different culture volumes and 
heating conditions, Tel mediated processing was confirmed to yield higher, but not 
statistically significant, ministring production efficiencies (Figure 2.3). Tel mediated 
processing attained production efficiencies of 53.6% and 65.5% for culture volumes of 20 ml 
and 50 ml respectively. This was higher than the 52.5% and 60.7% production efficiencies 
attained from TelN mediated processing. Although both protelomerases achieved similar 
ministring production efficiencies, Tel mediated processing was more consistent as 
evidenced by smaller standard deviations. Hence, Tel mediated processing was applied for 
subsequent investigations into optimal heating/culturing conditions for scalable DNA 
ministring production.       
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Figure 2.3 Comparative analysis of TelN and Tel protelomerase-mediated processing. LCC 
DNA ministring production efficiencies for TelN
+
 (W2NN) and Tel
+
 (W3NN) cells for heat induced 
batch cultivations across different culture volumes (20 & 50 ml) and heating conditions (30 & 60 
min). Production efficiencies between TelN and Tel mediated processing were not statistically 
different but greater standard deviations were observed for TelN. All heat induced cultures had 
production efficiencies significantly greater than non-induced samples (P << 0.01). 
 
2.3.2 A Two Stage Continuous Cultivation Improved LCC DNA Ministring Production 
Efficiency and Scalability 
Various tel-induction schedules were explored with the intention of maximizing 
protelomerase expression for high DNA ministring production upon protelomerase 
processing of parental pDNA. Induction duration was optimized in order to avoid the 
detrimental effects associated with prolonged heat shock. LCC DNA ministring production 
from 10, 20, 50, and 500 ml batch cultivations required a corresponding increase in induction 
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trends were made obvious by the significant differences in production efficiency between 30 
min (38.0%) and 60 min (65.5%) heat induction in 50 ml cultures (P << 0.01). 
 
 
Figure 2.4 Effects of culturing technique and volume on DNA ministring production. LCC DNA 
ministring production efficiencies of Tel+ (W3NN) cells for: 1) heat induced batch cultivations across 
different culture volumes (10, 20, 50 ml) and heat induction duration (15, 30, 60 min); 2) heat 
induced two stage continuous cultivations (A & B); 3) 500 ml batch cultivation; and 4) non-induced 
controls. For 50 ml cultures, heat induction for 60 min led to production efficiencies significantly 
greater than heat induction for 30 min * (P << 0.01). Production efficiencies for two stage continuous 
(B) was significantly greater than two step continuous (A) ** (P << 0.01) and 500 ml batch 
cultivation ** (P < 0.05). All heat induced cultures had production efficiencies significantly greater 
than non-induced samples *** (P << 0.01). 
 
 
Batch cultivations of 500 ml demanded increases in induction duration, where the 120 
minute duration resulted in DNA ministring production (75.1%) while the 60 minute 
induction did not (Figure 2.4 & 2.5). In both cases, the lower production efficiencies were 
  74 
denoted by greater residual parental pDNA substrate, signifying insufficient protelomerase 
expression and pDNA processing.  
 
 
Figure 2.5 Gel analysis of LCC DNA ministring production between batch and two stage 
continuous cultivations. Representative gel image of LCC DNA ministring production in 500 ml 
batch and two step continuous cultivations: ladder (lane 1); W3NN Batch 1 h (500 ml, 60 min) (lanes 
2-3); W3NN Batch 2 h (500ml, 120 min) (lanes 4-5); W3NN Two Step Continuous (A) (lanes 6-7); 
and W3NN Two Step Continuous (B) (lanes 8-9). The four DNA bands corresponded to the different 
species attained from Tel mediated processing: LCC DNA ministrings (2.4 kb), LCC backbone DNA 
(3.2 kb), parental CCC supercoiled pDNA (~4 kb), and parental LCC pDNA (5.6 kb). Under similar 
culture volumes and induction durations, two step continuous cultivations demonstrated greater 
ministring yields over batch cultivation. Specifically, two step continuous (A) demonstrated 
observable ministring production whereas batch cultivation 1 h (500 ml, 60 min) did not. Two step 
continuous (B) exhibited greater reduction in parental pDNA substrate over batch cultivation 2 h (500 
ml, 120 min). 
 
Between batch and two stage continuous cultivation, ministring production with two stage 
continuous culture (A) resulted in efficiency of 64.2% while batch cultivation, using 
equivalent 500 ml culture volumes and similar induction duration of ~60 minutes, did not 
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yield any observable LCC DNA ministrings (Figure 2.5). Two stage continuous cultures with 
additional 60 minutes of heat induction (B) resulted in a significant increase in ministring 
production efficiency (89.7%) when compared to two stage continuous (A) (P << 0.01) and 
batch cultivation with 120 min of heat induction (P < 0.05). Once again, the differences in 
efficiency was attributed to protelomerase processing as the amount of parental pDNA 
substrate was observably less for two stage continuous cultivation (B). In absolute terms per 
extraction, DNA ministring yields were approximated to be 27.5 µg, 87 µg, and 150 µg for 
two stage continuous (A), 500 ml batch cultivation, and two stage continuous (B) 
respectively. This corresponded to an estimated 3.2 pg, 12.1 pg, and 20.5 pg of DNA 
ministrings produced per bacterial cell for each of the three above listed variations. 
 
2.3.3 LCC DNA Ministring Production was Enhanced in a ΔhflX Host Mutation 
Background 
Induced overproduction of recombinant proteins contributes to metabolic aberrations and 
stresses and may result in numerous cellular responses including general stress, heat shock, 
stringent, and SOS responses. Such responses may elicit altered physiological states 
including growth arrest and decrease in specific growth rates. Hence, it was hypothesized 
that protelomerase turnover time may be compromised at elevated temperatures due to 
protease-mediated degradation, thereby reducing the processing of parental pDNA. To test 
the effects of proteases and associated gene products on DNA ministring production 
efficiency, pDNA processing outcomes were assessed in a variety of protease and protease-
associated isogenic mutants for Tel (Figure 2.6) and TelN (Figure 2.7).   
 
  76 
 
Figure 2.6 Effects of protease-specific and associated deletions on Tel-mediated DNA ministring 
production. LCC DNA ministring production efficiencies were assessed at various culture volumes 
and heat induction durations for strains possessing various protease and associated gene deletions 
(ΔclpP, Δlon, Δhflx, Δhflk) and isogenic Tel+ strain (BW25113, wild type). Across all conditions, the 
introduction of hflX gene deletion conferred significant increases in ministring production efficiencies 
over the original Tel
+
 wild type cells (W3NN) * (P ≤ 0.01) and isogenic Tel+ cells (BW25113) ** (P 
< 0.05). 
 
Similar trends across all strains were observed as DNA ministring production efficiencies 
were significantly lower (P < 0.05) in non induced samples when compared to induced 
samples at all culture volumes. In correlation with results from Tel+ wild type W3NN 
[pNN9], DNA ministring production from 10, 20, and 50 ml batch cultivations required 
similar increases in induction duration (15, 30, and 60 min) for high production efficiency by 
Tel and TelN protelomerases.  
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Figure 2.7 Effects of protease-specific and associated deletions on TelN-mediated DNA 
ministring production. LCC DNA ministring production efficiencies were assessed at various 
culture volumes and heat induction durations for strains possessing various protease and associated 
gene deletions (ΔclpP, Δlon, Δhflx, Δhflk) and isogenic TelN+ strain (BW25113, wild type). The 
introduction of hflX gene deletion conferred significant increases in ministring production efficiencies 
over the original TelN
+
 wild type at culture volumes of 20 ml (P < 0.05), however, such increase was 
lost at larger volumes of 50 ml due to inconsistent TelN mediated processing. 
 
Across all conditions, the introduction of an hflX gene deletion conferred a significant 
increase in Tel mediated production efficiencies compared to the wild type W3NN (P ≤ 0.01) 
and isogenic wild type BW25113 (P < 0.05) counterparts, with ideal production seen in 10 
ml cultures after 15 min tel  heat induction (84.7%) (Figure 2.6). The introduction of an hflX 
gene deletion conferred a significant increase in TelN mediated production efficiencies 
compared to wild type W2NN (P < 0.05) for culture volumes of 20 ml (Figure 2.7), however, 
such significant increase was lost at larger volumes of 50 ml due to inconsistent production 
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with TelN, as evidenced by an approximate 5 fold increase in standard deviation from the 
Tel
+
 (ΔhflX) counterpart. For both culture volumes of 20 ml and 50 ml, TelN mediated 
processing was most efficient in the ΔhflX derivative, resulting in 59.2% and 75.2% 
production efficiencies respectively.    
 
2.3.4 Ciprofloxacin Enhanced DNA Ministring Production 
Ciprofloxacin was administered in an attempt to synchronize plasmid replication rates with 
protelomerase expression to enhance LCC DNA ministring production efficiency in the in 
vivo system. It was hypothesized that transient inhibition by the fluoroquinolone antibiotic 
would elicit diminished plasmid replication, thereby enhancing plasmid processing. The Δlon 
derivative was of particular interest as it was expected to curb the metabolic burden 
associated with SOS response triggered by ciprofloxacin. The application of ciprofloxacin to 
Tel
+
 cells led to a gradual increase in pDNA processing, conferring improvements to 
production efficiency from about half to 76.6% (Figure 2.8). 
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Figure 2.8 LCC DNA ministring production efficiency upon the introduction of ciprofloxacin at 
various concentrations. Application of 0, 1, 10, and 100 µg/ml of ciprofloxacin to wild type Tel
+
 
cells (W3NN) and Δlon derivative harboring the parental pNN9 plasmid. Addition of 10 and 100 
µg/ml of ciprofloxacin to Tel
+
 cells conferred a 19.8% and 20.0% increase in DNA ministring 
production efficiency compared to the untreated induced control. Improvements to DNA ministring 
production efficiency was not observed for the Δlon derivative. 
 
Ciprofloxacin marginally increased production efficiency (~20%) at 10 µg/ml (P < 0.1), 
and little impact on efficiency was observed when ciprofloxacin concentration was increased 
10-fold to 100 µg/ml. In contrast, the application of ciprofloxacin to the Δlon derivative did 
not confer any improvement in processing efficiency. Differences in the influence of 
ciprofloxacin on wild type and the Δlon derivative were attributed to hypersensitivity of the 
Δlon derivative to ciprofloxacin as indicated by the progressive decrease in total pDNA with 
increasing concentrations of the antibiotic (Figure 2.9). In addition, the introduction of 
ciprofloxacin to the Δlon derivative contributed to incomplete Tel processing as sustained 
production of parental LCC pDNA (5.6 kb) and decreases in LCC DNA ministring (2.4 kb), 
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were observed. Thus, there was a greater preference for Tel processing at a single recognition 
site in contrast to both respective sites required for DNA ministring production. 
 
 
Figure 2.9 LCC DNA ministring production after the introduction of ciprofloxacin: DNA ladder 
(lane 1); W3NN wild type R-cell with 0, 1, 10, and 100 µg/ml of ciprofloxacin (lanes 2-5); JW0429-
Tel (Δlon) with 0, 1, 10, 100 µg/ml (lanes 6-9). A progressive disappearance of parental supercoiled 
pDNA (3.5-4 kb) was observed at increasing concentrations of ciprofloxacin. Gradual decrease in 
LCC DNA ministrings (2.4 kb) and LCC backbone DNA (3.2 kb) along with sustained production of 
the parental LCC pDNA (5.6 kb) were observed for the Δlon derivative at increasing concentrations 
of ciprofloxacin.   
 
2.3.5 Effects of DnaB Helicase Mutations on DNA Ministring Production 
Similar to ciprofloxacin, temperature sensitive dnaB[Ts] helicase mutants serve to induce 
transient interruptions in plasmid replication for improved protelomerase processing and 
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production efficiencies. The dnaB gene encodes a 470 a.a. polypeptide that assembles into a 
homohexamer [155] and is a major replicative DNA helicase critical to chromosomal 
replication of E. coli and plasmids containing the ColE1 origin of replication (OriC) [156, 
157]. DnaB is a multifunctional essential enzyme with ATP and single-stranded DNA 
binding activity, DNA dependent ATPase activity, DNA helicase activity, and priming 
activity with primase [158]. Temperature sensitive dnaB helicase mutants exhibit greatest 
phenotypic effects at non-permissive temperatures (42° C) and such effects may vary 
depending on the mutation. The dnaB8 mutation, referred to as a fast stop mutant, exhibits 
negligible primer RNA synthesis, ATPase activity, and helicase activity at non-permissive 
temperatures, resulting in immediate cessation of DNA synthesis. In contrast, the dnaB252 
mutation, referred to as a slow stop mutation, attains the abovementioned functions lacking 
in dnaB8, but exhibits interferences to interactions with DnaC, a helicase loading factor. As 
such, the mutation confers a delayed cessation of DNA synthesis and rather prevents re-
initiation of replication events [155, 158]. Hence, induced protelomerase expression and 
inhibition of plasmid replication simultaneously occurs upon temperature upshift to 42° C, 
potentially improving precursor plasmid processing efficiency. 
DNA ministring production efficiency in slow stop mutants (dnaB252) was significantly 
higher than that observed in wild type W3NN Tel
+
 cells, for culture volumes of 20 ml (P < 
0.01) and 50 ml (P < 0.05) respectively, but not compared to the isogenic wild type N99  Tel
+
 
cells (Figure 2.10 A). The application of the in vivo system into dnaB fast stop mutants 
(dnaB8) resulted in lower production efficiencies. Similar trends were observed with respect 
to TelN-mediated processing in the two respective dnaB[Ts] mutants. However, no 
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significant increase in production efficiencies, over wild type Tel
+
 W2NN wild type cells, 




Figure 2.10 Tel and TelN-mediated DNA ministring production efficiency in dnaB[Ts] mutants. 
For Tel processing (A), slow stop mutants exhibited significantly higher production efficiencies over 
wild type W3NN at culture volumes of 20 ml (68.7%; P < 0.01) and 50 ml (65.7%; P < 0.05). 
However, such increases were not evident with respect to TelN processing (B) as the isogenic wild 
type N99 was shown to elicit the highest production efficiencies at culture volumes of 20 ml (63.5%) 
and 50 ml (66.9%); both of which were comparable to production efficiencies attained in DnaB slow 
stop mutants (62.7%, 20ml & 64.7%, 50 ml). * Data not available. 
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The isogenic N99 wild type strain demonstrated slight increases in production efficiency 
over other wild type (W2NN/W3NN) cells and this may partially account for the significant 
increases observed in dnaB slow stop mutants. Interestingly, gel analysis of ministring 
production in slow stop mutants denoted reduced amounts of LCC backbone DNA, the 
component comprising the prokaryotic backbone sequences with OriC; this was in 
conjunction to greater amounts of resulting LCC DNA ministring (Figure 2.11). However, 
the amount of residual parental supercoiled CCC pDNA was observably higher in slow stop 
mutants over the fast stop mutants and the two tested wild type strains.   
 
 
Figure 2.11 LCC DNA ministring production in dnaB[Ts] mutants: DNA ladder (lane 1); Tel
+
 
W3NN (lane 2); TelN
+
 W2NN (lane 3); Tel
+
 slow stop mutant (lane 4); Tel
+
 fast stop mutant (lane 5); 
TelN
+
 fast stop mutant (lane 6); Tel
+
 isogenic wild type N99 (lane 7); TelN
+
 isogenic wild type N99 
(lane 8). Tel
+
 slow stop mutant exhibited a different gel profile with reduced amounts of LCC 
backbone DNA (~3.2 kb) and greater amounts of LCC DNA ministring (2.4 kb). 
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2.4 Discussion 
The one-step heat inducible in vivo LCC DNA minivector production system was specifically 
designed with the chromosomal integration of a single copy of protelomerase gene (telN or 
tel) in an attempt to overcome certain drawbacks associated with the overproduction and 
episomal expression of protelomerase that contribute to metabolic imbalances, activation of 
stress responses, improper protein folding, and inclusion body formation [159]. 
Chromosomal integration of the protelomerase expression cassette, in combination with 
thermoregulated control via  CI[Ts]857 repressor, permitted greater constraints on 
protelomerase expression that is unattainable in an episomal pDNA expression system. 
Complications associated with sustained plasmid partitioning and stable plasmid inheritance 
during temperature upshift can also be resolved. Simultaneously, issues relating to plasmid 
maintenance of protelomerase expression and substrate pDNA, prior to induction, can be 
avoided. Despite such improvements, maintenance and replication of the pDNA substrate 
consumes additional cellular resources and such metabolic burden was exacerbated by 
subsequent induced expression of the protelomerase. The interplay of these numerous factors 
constituted imperfect plasmid processing and reduced DNA ministring production from the 
current system. As such, careful considerations were made to culture conditions and 
induction scheduling in order to improve the overall production of DNA ministring in the in 
vivo system.  
In all instances of induction, a gradual temperature increase from 30° to 42° C was applied 
as previous findings indicated an observed improvement in recombinant protein expression 
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with slowest heating rates when compared to more rapid rates. Rapid heating rates resulted in 
decreased recombinant protein expression, likely due to the high ATP demand associated 
with rapid recombinant protein production and expression of heat shock proteins. 
Transcriptional analysis by Caspeta et al. [160] indicated a dramatic increase in mRNA levels 
for heat shock genes and such increases were most significant at rapid heating rates that 
contributed to high ATP demands from cellular responses mediating heat stress. The high 
ATP demand caused an imbalance between glycolytic and TCA cycles, shifting ATP 
production via cellular respiration to glycolysis, and led to increases in substrate level 
phosphorylation along with the generation of acetate byproduct [160]. Correlations between 
rapid heating rates and rapid onset of heat stress are likely supported due to the 
corresponding increase in rpoH mRNA levels imparted by more rapid heating rates [160]. In 
contrast, slower heating rates allow cells to better accommodate for heat induction and 
dampen the negative effects associated with rapid heat shock. These findings bode well for 
large scale production of DNA ministrings since slow heating rates are generally attained in 
large scale fermenters. In addition, Caspeta et al. [161] demonstrated higher maximum 
recombinant protein concentrations with 2.3-4.0 fold increases in biomass concentration and 
48-62% decrease in organic acid by-products after the implementation of temperature 
oscillations in conjunction with post-induction nutrient feeding strategies [161]. Such 
oscillations allowed the cells to better accommodate heat stress leading to improved cell 
growth, higher recombinant protein yields, and reduced by-product accumulation. Future 
studies involving temperature oscillations may prove to further improve DNA ministring 
production. 
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Comparisons between DNA ministring production upon TelN and Tel protelomerase 
mediated processing indicated greater inconsistencies in TelN processing across wild type 
(W2NN), genetically modified strains, and isogenic background controls despite comparable 
production efficiencies. Inconsistencies arising from TelN mediated processing were 
attributed to the influences of the recognition site, in the SuperSequence, on DNA binding 
and the overall stability of the protelomerase/DNA complex. Previously, Deneke et al. [124] 
noted a near 5-fold decrease in stability for TelN-telRL complexes compared to TelN-tos 
complexes. The TelN recognition site, telRL, was the minimal recognition site required for 
TelN processing and the absence of the accessory inverted repeats, found in tos, may have 
caused reduced binding or instability in the resulting target site. More consistent results were 
observed using Tel, likely because the SuperSequence encodes the complete 142 bp pal 
target sequence. 
For small volume batch cultivations of 10, 20, and 50 ml, there was an approximately 
linear increase in induction duration with progressive increases to culture volume. However, 
deviations from this linear trend were observed for 500 ml batch and two step continuous 
cultivations as optimal production efficiencies and overall DNA ministring yields were 
observed with shorter induction durations. Since the expressed Tel protelomerase was 
capable of acting on multiple copies of the target plasmid, high DNA ministring production 
efficiencies can be attained with relatively moderate protelomerase expression. This attribute 
contributed to reducing the duration of heat induction required for protelomerase expression 
and optimal DNA ministring production. Previous studies have shown diminished cell 
growth upon 1-2 hours of heat induction, at 42° C, due to metabolic burden associated with 
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recombinant protein production, the expression of heat shock proteins and reduced 
translation activities. This treatment also resulted in slight decrease in biomass concentration 
and reduced accumulation of recombinant proteins beyond two hours following heat 
induction [160]. It was interesting to note that the high production efficiencies achieved by 
batch and two stage continuous (B) were accomplished approximately two hours following 
initial shift to 42
o
 C. In relation to the experimental findings, optimal DNA ministring 
production was speculated to be achieved through heat induction at durations with high 
recombinant protelomerase expression, prior to cessation of cell growth and other negative 
effects associated with prolonged heat shock. With respect to batch and two step continuous 
cultivations, more effective expression and DNA processing was observed for two step 
continuous cultivations as evidenced by DNA ministring yields 60 min after heat induction. 
Such improvements were attributed to high cell density in co-ordination with continuous 
nutritional supplementation for ample Tel expression during the production phase. This 
contributed to the greater DNA ministring yields in two step continuous cultivations when 
subjected to similar induction durations.    
In this study, the introduction of protease-specific and associated gene deletions was 
hypothesized to prevent protease-mediated protelomerase degradation, thereby extending 
protein turnover of functional protelomerases. Contrary to the initial hypothesis, gene 
deletions of clpP, lon, and hflK did not result in any significant improvements to Tel or TelN 
protelomerase-mediated processing and DNA ministring production. Lack of observed 
differences in production efficiency may be attributed to the fine control of protelomerase 
expression and the minimal heat induction necessary for optimal protelomerase mediated 
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DNA ministring production. Short induction durations applied in this study did not result in 
high levels of recombinant protein that would overburden the activity of folding chaperones, 
a common observation seen in traditional recombinant protein production systems. As such, 
the activities and impact of heat shock proteases became less prominent in affecting DNA 
ministring production since folding chaperones likely re-folded the majority of misfolded 
proteins effectively and prevented the formation of non-functional proteins or inclusion 
bodies. Nevertheless, slight improvements in production efficiencies were observed upon the 
deletion of lon and hflK gene across all culturing and heating conditions for both Tel and 
TelN. Improvements to ministring production for Δlon derivatives were speculated to be 
attributed to diminished degradation of small heat shock proteins, IbpA and IbpB, by Lon 
protease [162]. IbpA and IbpB are holding chaperones that intercalate into protein aggregates 
and stabilize folding intermediates for folding chaperones [138, 143, 148]. The Δlon 
derivative should impart reduced IbpA and IbpB degradation and improved protein re-
folding. HflKC, a heterodimer consisting of HflK and HflC, has been shown to modulate the 
proteolytic activity of FtsH (HflB) protease. It was previously demonstrated that the deletion 
of hflKC genes resulted in reduced degradation of cytosolic  CII (lysogeny decision) protein 
and enhanced the degradation of membrane bound SecY (membrane secretion) protein [163-
166]. Hence, the deletion of hflK gene was expected to confer decreased degradation of 
cytosolic recombinant protelomerase leading to the slight improvement in LCC DNA 
processing efficiency.     
There was an observably greater variability in DNA ministring production efficiencies for 
ΔclpP derivatives, particularly with Tel-mediated processing in culture volumes of 10 ml and 
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50 ml that were subjected to 15 min and 60 min of heat induction, respectively. This may be 
explained by previous work of Schweder et al. [167] who reported a suppression of general 
stress response, mediated by RpoS (ϭ38), during strong overexpression of recombinant 
proteins. Deletion of the clpP gene, expressing the ClpP protease that specifically cleaves 
RpoS, was shown to negatively impact recombinant protein production due to greater sigma 
factor competition as a result of higher RpoS stability [167]. For temperature inducible 
systems, higher stability of RpoS may outcompete RpoH for RNA polymerase and 
negatively affect the accumulation of heat shock proteins necessary to effectively respond 
against heat stress [160]. Influences of higher RpoS stability in ΔclpP cells under dual stress 
of heat shock and high levels of recombinant protelomerase expression may contribute to 
highly variable efficiencies in LCC DNA processing.  
A statistically significant improvement in LCC DNA processing was observed in the 
ΔhflX derivative, potentially due to the interactions between HflX and ribosomal subunits. 
HflX is one of eight universally conserved GTPases found in prokaryotes and eukaryotes 
[168, 169]. HflX is a monomeric GTPase and ATPase previously shown to interact with 16S 
and 23S rRNA, the 30S and 50S ribosomal subunit, and the 70S ribosome;  their expression 
becomes upregulated under heat stress similar to HSPs [168-171]. Activities of HflX likely 
serve to regulate and control protein translation rates in co-ordination with the down-
regulation of translation related genes and reduced concentrations of ribosomal components 
upon heat stress and recombinant protein production [160, 167, 172]. As such, deletion of the 
hflX gene may prompt higher rates of protein translation and protelomerase expression, 
improving ministring production efficiency. 
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The addition of ciprofloxacin after induced protelomerase expression served to inhibit 
plasmid replication and bacterial cell division in order to enhance DNA ministring 
production by maximizing processing from parental pDNA. Ciprofloxacin is a broad 
spectrum fluoroquinolone antibiotic that inhibits the activity of DNA gyrase and 
topoisomerase IV, both of which are essential in the regulation of DNA topological states 
during replication and transcription in E. coli [173, 174]. The inhibitory effects of 
ciprofloxacin results in DNA damage and activation of the SOS response, causing cell cycle 
arrest and DNA repair mediated by the upregulation of RecA along with corresponding 
inactivation or degradation of LexA repressor. The upregulation of RecA following SOS 
activation can contribute to the formation of aggregates with various denatured and 
misfolded proteins. Such events result in the activation of heat shock regulon as genes 
associated with both SOS and HSR would be up-regulated following treatment with 
ciprofloxacin [173, 174]. In particular, the Lon protease is a critical component in both SOS 
and HSR. LexA and SulA, SOS response proteins that inhibit cell division through its 
binding to FtsZ, are direct targets of Lon-mediated proteolysis. Hence, the inactivation of 
Lon leads to diminished SOS response and DNA repair contributing to hypersensitivity to 
ciprofloxacin [173, 174].  
It was hypothesized that transient inhibition by ciprofloxacin on Δlon derivatives may 
elicit additional improvements to protelomerase expression by temporarily limiting the 
metabolic burden associated with SOS response, while averting cell death associated with 
prolonged exposure to ciprofloxacin. While ciprofloxacin did impact and improve LCC DNA 
processing efficiency in wild type W3NN cells, no impact was observed in the Δlon 
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derivative, thereby disproving our hypothesis. This finding may potentially be due to 
ciprofloxacin-mediated hypersensitivity, despite limited exposures to the antibiotic. 
Significant cell death and cellular aberrations would lead to down-regulation of 
protelomerase expression and could induce expression of non-functional protelomerase. 
Effects of hypersensitivity were confirmed as DNA ministring yields, upon qualitative 
observations from AGE, were far greater for wild type W3NN than the Δlon derivative. A 
lower concentration of ciprofloxacin in conjunction with shorter exposure time may 
effectively promote improved DNA ministring production in Δlon derivatives.  
With respect to DNA ministring production in dnaB[Ts] helicase mutants, significant 
increases to production efficiencies observed in dnaB252 slow stop mutants was partially 
attributed to strain variations as the isogenic control yielded an overall minor increase over 
wild type W3NN cells. However, interestingly, gel analysis denoted a disparity between LCC 
backbone DNA and DNA ministring with greater amounts of DNA ministrings being 
observed. This was in conjunction to the appearance of structural intermediates and 
topoisomers of parental supercoiled CCC pDNA with varying degrees of supercoiling. This 
is likely due to inefficient helicase loading, due to inhibited interactions with DnaC that may 
result in DnaA-oriC intermediates leading to the degradation of the DnaA-oriC bearing 
backbone DNA upon interference with replication initiation. The extent of DNA degradation 
was exacerbated in dnaB8 fast stop mutants that possess a mutation in the helicase enzymatic 
domain. The dnaB8 mutation yielded significant overall reductions in pDNA yields and 
negligible DNA ministring upon 60 minutes of heat induction. These cells are sick even at 
the permissive 30
o
 C temperature and would experience significant cell death after 60 min 
  92 
possessing trapped replication intermediates. As such, the observed findings were attributed 
to cell death and SOS-independent filamentation upon temperature upshift to the non-
permissive temperature. Previously, replication arrest upon dnaB8 inactivation was shown to 
result in cessation of growth and degradation of over half of nascent DNA upon a 
temperature upshift of 60 minutes [175]. Diminished plasmid propagation and reduced 
viabilities, upon DnaB[Ts] inactivation and the introduction of multiple stressors, may have 
severely compromised DNA ministring production.    
With considerations to the production efficiencies attained in all of the abovementioned 
modifications, two step continuous cultivation in a genetically modified ΔhflX strain 
possessing dnaB[Ts] slow stop mutation may potentially serve to attain complete pDNA 
processing with dramatically high yields of LCC DNA ministrings. Future studies assessing 
ministring production efficiencies from the proposed genetically modified LCC DNA 
minivector production system will be warranted.     
2.5 Conclusion 
The results of this study served as an optimal protocol to significantly improve LCC DNA 
ministring production using the novel in vivo system. In particular, two step continuous 
cultivation with 120 minutes of heat induction constituted a ~90% DNA ministring 
production efficiency resulting in approximately 150 µg of DNA ministring per extraction. 
The versatility of this novel technology invites numerous potential applications in gene 
transfer-mediated therapeutics. As such, downstream purification of LCC DNA ministring 
will be warranted for future clinical applications using these new generation DNA vectors.    
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Chapter 3 
Separation and Purification of Linear Covalently Closed (LCC) DNA by 
Q-Anion Exchange Membrane Chromatography 
 
3.1 Introduction 
The development of any successful gene therapeutic demands effective and efficient gene 
delivery with careful considerations to the safety profile of the therapeutic. Although viral 
vectors enable effective delivery of the DNA cargo with high efficiency, such vectors prompt 
significant safety concerns with regards to potential undesired immune responses to viral 
capsid proteins, regeneration of virulent viruses, and insertional mutagenesis [108]. As such, 
non-viral gene delivery strategies are generally safer. However, while safer, the use of 
conventional circular covalently closed (CCC) plasmid DNA (pDNA) vectors may still 
potentiate DNA vector integration into the host chromosome. The application of linear 
covalently closed (LCC) DNA vectors addresses the above limitations by promoting a 
heightened safety profile [108]. Previously, the one-step heat inducible in vivo DNA 
minivector production system was optimized for rapid and scalable processing of precursor 
CCC pDNA into LCC DNA vectors. This production system involves temperature inducible 
expression of the PY54 bacteriophage-derived recombinant Tel protelomerase followed by 
subsequent protelomerase mediated enzymatic reactions. The protelomerase acts on 
genetically engineered multi-target sites called "SuperSequences", converting conventional 
CCC pDNA into LCC DNA derivatives [108]. 
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In most plasmid extractions, the plasmid DNA (pDNA) population consists of various 
monomeric topological isoforms: supercoiled CCC, open circular (OC), and linear open 
(LO). Generally, supercoiled CCC pDNA exists as the predominant form with varying levels 
of OC and LO pDNA derivatives that arise from single and double strand breaks. Application 
of our processing system, based on the exploitation of TelN and Tel protelomerase, toward 
the production of LCC DNA vectors added an additional level of complexity with respect to 
the many different isoforms arising from the extracted plasmid population (see Figure 2.1). 
As such, additional purification was necessary to ensure that LCC DNA vectors could be 
recovered at purities suitable for clinical testing. High resolution achieved by column 
chromatography constituted high pDNA purity, making it an essential component in 
downstream purification processes [176-178]. Various chromatography techniques have been 
applied for plasmid purification including: 1) size exclusion chromatography (SEC), 2) 
reversed-phase chromatography, 3) hydrophobic interaction chromatography (HIC), and 4) 
anion exchange chromatography (AEC) [176, 178-181].  
AEC is commonly employed for pDNA capture and purification, offering several 
advantages: rapid separation; lack of required solvents; and sanitation of chromatography 
columns by sodium hydroxide [182, 183]. AEC functions through the interactions between 
negatively charged pDNA and non-specific positively charged ligands on the stationary 
phase, where the strength of this interaction is dependent on both net charge and local charge 
density. The introduction of a salt gradient displaces such interactions and pDNA elutes in 
order of increasing charge density, influenced by chain length, conformation, and topology 
[182, 184-187]. Although the different DNA isoforms possess the same chain length, charge 
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and molecular weight, separation can be achieved through differences in charge density and 
physicochemical properties between the isoforms. A high degree of compaction in 
supercoiled pDNA confers greater local charge density in comparison to OC pDNA; 
contributing to stronger interactions that cause supercoiled pDNA to elute at a later point 
than OC pDNA [186, 187]. Linear pDNA, characterized as superhelical rods with random 
coils, inherently possess greater degrees of elasticity and may be subject to stretching by 
shear forces; such a distinct property thereby contributes to the separation of linear pDNA 
from the other two isoforms [187, 188]. Using a TSKgel DNA-NPR weak anion exchange 
column, Smith et al. [187] found size and gradient change-rate dependent variations in the 
elution order between supercoiled and LO pDNA. Although separation between the different 
isoforms was observed, complete separation was unattainable under experimental conditions. 
In a subsequent study using a quinine-carbamate based weak anion exchanger, Mahut et al. 
[185] reported that the elution order of isoforms was indifferent to changes in mobile phase, 
gradient change-rate, or plasmid size, but varied depending on changes in temperature. At 
temperatures above 35° C, they noted a higher retention of supercoiled pDNA, as it eluted 
after LO pDNA. However, at temperatures below 25° C, supercoiled pDNA eluted at points 
between that of OC and LO pDNA, and co-elution of supercoiled and LO pDNA was 
observed at 30° C. [185]. 
The generally large size of pDNAs poses significant limitations on commercial 
purification processes by column chromatography, primarily due to the inability of large 
biomolecules to pass through the porous beads (<0.2 µm) of the stationary phase, resulting in 
pDNA to be adsorbed predominantly on the surface, thereby limiting capacity [177, 181-183, 
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186, 189]. Previous studies reported that substantive amounts of resin beads were required 
for pDNA purification as fractional amounts of pDNA (~ 0.2–2 g) were loaded per liter of 
resin, in contrast to the 10-100 g achieved for protein purification [181]. Time consuming 
and labour-intensive processes involved in column packing, cleaning, and regeneration, 
along with reported low recovery and irreversible pDNA binding, pose further limitations on 
conventional column chromatography [177]. Anion exchange membrane chromatography 
may overcome such limitations as anion exchange membranes possess large convective pores 
(2 µm), enabling rapid transport of pDNA to membrane surface while attaining binding 
capacities an order of magnitude higher than their resin counterparts [176-178, 184, 189]. 
High throughput is attainable as pDNA purification efficiencies are achieved even at elevated 
flow rates [176, 178]. Commercial pDNA purification can be achieved as purification is 
scaled up linearly using the disposable, ready-to-use membranes [177, 189]. 
Zhong et al. [177] previously showed that using a hydrogel-based strong anion exchange 
(Q) membrane yielded high binding capacity (12.4 mg/ml) and ~90% plasmid recovery upon 
pDNA purification. This membrane was composed of a polypropylene membrane support 
completely encased by a functionalized hydrophilic hydrogel upon swelling. The inherent 
property of high adsorption and desorption associated with hydrogel-based membranes 
prompts further exploration of their potential in separating different pDNA sizes and 
isoforms for purification of LCC DNA. 
In this study, anion exchange membrane chromatography was applied toward the 
separation and purification of LCC DNA isogenic derivatives from CCC pDNA parent 
precursor after passage through the one step in vivo LCC DNA vector production system.  As 
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such, anion exchange membrane chromatography was assessed for its utility as a scalable 
system for the purification of human grade therapeutic LCC DNA minivectors. 
3.2 Material and Methods 
3.2.1 Production of LCC DNA products 
A single colony of Tel
+
 W3NN cells [108] was grown overnight in 5 ml LB + Ap (100 
µg/ml) under repressed conditions at 30° C. Overnight cultures were grown at 1:100 dilution 
with 100 ml LB + Ap (100 µg/ml) at 30° C until late log phase A600 = 0.8. Cells were 
collected, centrifuged and re-suspended in 500 ml of LB + Ap (100 µg/ml) for induced 
protelomerase expression at 42° C until A600 = 1.0. This was followed by a gradual 
temperature downshift and overnight incubation at 30° C. Cells were harvested and plasmid 
extracted with E.Z.N.A. Plasmid Maxi-Prep Kit (Omega, VWR).  
3.2.2 DNA Separation by Anion Exchange Membrane Chromatography 
3.2.2.1 Buffers 
The loading and washing buffers were 50 mM Tris-HCl (pH = 8.1) and the elution buffers 
were composed of loading and washing buffers with the addition of various concentrations of 
NaCl (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 2.0 M). All buffers were prepared in 18MΩ 
sterile MilliQ water. 
3.2.2.2 Membrane material, pre-treatment, loading and elution 
The hydrogel-based strong anion exchange (Q) membrane syringe columns were provided by 
Natrix Separations Inc. (Burlington, Canada). The membrane column was connected to 
MPT-2 Autotitrator (Malvern, UK) for membrane soaking, pDNA loading and elution. The 
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membrane was pre-treated by soaking in loading buffer for 16 h at room temperature prior to 
pDNA loading. Plasmid DNA feeds for membrane chromatography experiments were 
prepared by diluting the extracted pDNA to ~50 µg/ml with loading buffer. For each 
experiment, 10 ml of the diluted pDNA sample was fed into the membrane column. After 
loading pDNA, the membrane column was incubated at room temperature for 10-15 min 
prior to flushing with 40 ml of washing buffer at 4 ml/min. Different experiments were 
conducted with elution buffer of varying salt gradient, by changing salt concentration, buffer 
volumes, and flow rates (2.5-4 ml/min). Individual fractions of 0.5-2 ml were collected from 
the start of elution until complete elution as confirmed by elution with 2 M NaCl elution 
buffer. 
3.2.3 DNA Analysis 
A NanoDrop spectrophotometer (Thermo Scientific, USA) was used to measure DNA 
concentration at 260 nm. Eluted pDNA concentrations (ng/µl) in each fraction were 
calculated from absorbance values using the Beer-Lambert equation, A = E x b x c; A is the 
absorbance; E is the extinction coefficient (50 ng-cm/µl); b is the path length; and c is the 
concentration. Eluted fractions with detected DNA concentrations were analyzed by AGE. 
Plasmid isoform compositions were assessed by AGE and densitometry (AlphaImager, 
Alpha Innotech).  
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3.3 Results and Discussion 
Following the generation of LCC DNA products through our in vivo processing system, 
anion exchange membrane chromatography was applied to effectively separate successfully 
converted LCC DNA products from residual supercoiled CCC precursor parent plasmid. The 
experimental conditions for LCC DNA product purification were examined according to 
manufacturer recommendations and findings from Zhong et al. [177] to purify our DNA 
species of varying isoforms and sizes (2.7-5.6 kb). DNA was initially detected in eluted 
fractions at 0.7 M NaCl. Prolonged elution at this threshold salt concentration resulted in 
effective DNA recovery as DNA was not detected after elutions with 0.8 M and 2 M NaCl. 
From the total 357 fractions collected, those with detectable DNA fell between 189 and 329, 
all of which were collected and fractions 189-300 were further analyzed, using densitometry, 
by dividing individual fractions into 11 distinct sets of fractions (Figure 3.1). Visual 
inspection of selected fractions from each of the 11 sets indicated the initial elution of 
parental supercoiled CCC pDNA (~4.0 kb) in absence of LCC DNA. Subsequent fractions 
denoted increasing elution of supercoiled CCC pDNA accompanied by the initial elution of 
three LCC DNA species: parental LCC pDNA (5.6 kb), LCC backbone DNA (3.2 kb), and 
LCC DNA ministrings (2.4 kb) (Figure 3.1 A). The elution of LCC DNA corresponded with 
a decrease in the elution of CCC pDNA and the eventual separation of nearly all LCC DNA 
from CCC pDNA (Figure 3.1 B). Investigation of the yielded LCC DNA products showed a 
trend of increasing contribution of parental LCC pDNA at later elutions from 11.2% (set 6) 
to 52.8% (set 11) (Figure 3.1 C). Further analysis of the late elutions by AGE indicated a 
pattern of increasing elution of parental LCC pDNA over the two smaller LCC DNA 
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products, although with limited resolution (Figure 3.2). This suggested a partial separation 
between LCC DNA species according to size. However, complete separation of the different 
species by charge density, as a function of chain length, was unattainable as the different 
species were relatively similar in size. Subsequent studies were conducted to assess the effect 
of flow rate and salt gradient on the observed elution pattern. Manipulations to the flow rate 
(2.5-4 ml/min) were confirmed to have negligible effect on the observed elution pattern. 
However, the observed separation between LCC DNA and CCC pDNA was lost upon the 
application of a rapidly changing salt gradient. 
Zhong et al. [177], found that plasmid size does not affect the adsorption rate but 
influences the degree of irreversible adsorption and the recovery fraction at pH of 8.0. They 
observed recovery rates of 75%, 89%, and 65% for plasmids of 6.4, 3.7, and 2.7 kb, 
respectively. The noted differences in elution efficiency were attributed to irreversible 
adsorption for the 6.4 (22.5%), 3.7 (2.5%), and 2.7 (32.6%) kb plasmids, respectively. As the 
size of the different CCC plasmids roughly matched the sizes of the LCC DNA species, it 
was suspected that similar trends for DNA recovery amongst the three species would be 
observed. Based on the composition of LCC DNA species recovered, greater yields of LCC 
backbone DNA (3.2 kb) were observed compared to LCC minivector DNA (2.4 kb) despite 
the expected 1:1 ratio in the feed (Figure 3.1 C). This finding can likely be attributed to the 
differences in irreversible adsorption rates since the adsorption fraction was nearly constant 
for all plasmid sizes at pH of 8.0. To improve LCC DNA ministring recovery, a pH of 9.0 
may prove ideal as it promotes recovery of smaller sized DNA in conjunction with a minimal 
level of irreversible adsorption [177].    
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Figure 3.1 Separation of DNA isoforms by anion exchange membrane chromatography. 
Agarose gel electrophoresis and densitometry analysis of DNA isoforms attained from sequential sets 
of eluted fractions using anion exchange membrane chromatography. Eluted fractions (fractions 189-
300) were categorized into 11 distinct sets according to their elution order. A) Analysis of DNA 
isoforms of eluted fractions by 0.8% gel electrophoresis: DNA Ladder (lane 1); pDNA feed solution 
(lane 2); a selected fraction from each of the 11 distinct sets - fraction 191 (lane 3); fraction 199 (lane 
4); fraction 205 (lane 5); fraction 211 (lane 6); fraction 216 (lane 7); fraction 226 (lane 8); fraction 
238 (lane 9); fraction 254 (lane 10); fraction 266 (lane 11); fraction 276 (lane 12); fraction 292 (lane 
13). Visual inspection confirmed early elution of parental supercoiled CCC pDNA (~4.0 kb) followed 
by increasing elution of the LCC DNA: parental LCC pDNA (5.6 kb), LCC backbone DNA (3.2 kb), 
and LCC DNA ministring (2.4 kb) (see Figure 2.1). Separation of DNA isoforms was denoted by the 
disappearance of the ~4.0 kb band, conferring the absence of parental supercoiled pDNA in later 
fractions. B) Analysis of the average composition of LCC DNA and parental supercoiled CCC pDNA 
within the 11 distinct sets highlighting the separation of LCC DNA from parental supercoiled CCC 
pDNA. C) Complete breakdown of all three LCC DNA species within each of the 11 sets of fractions.  
 
 
In agreement with Haber et al. [184], the application of strong, positively charged 
membranes was successful in resolving different DNA isoforms and our findings, denoting 
early elution of  parental supercoiled CCC pDNA followed by LCC DNA, matched well with 
the previous findings. According to Haber et al. [184], the elution order was due to 
convective flow-induced structural behavior of the different DNA isoforms. Compact 
supercoiled CCC DNA was able to reach the membrane first and gain early access to binding 
sites. The structural nature of OC DNA constituted a lower overall surface charge density 
resulting in loose binding interactions and earlier elution [177]. On the other hand, linear 
DNA was capable of undergoing strong cooperative interactions due to high elasticity and 
their ability to form loops and trains, thereby promoting strong binding and retention, 
contributing to later elution of linear DNA after supercoiled CCC DNA.     
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Figure 3.2 Analysis of LCC pDNA species in late elutions from anion exchange membrane 
chromatography. Gel analysis of LCC DNA species attained in late elutions using 0.8% gel 
electrophoresis:  molecular mass markers (lane 1); pDNA feed solution (lane 2); sequential fractions 
attained at late elutions - fraction 284 (lane 3); fraction 288 (lane 4); fraction 292 (lane 5); fraction 
296 (lane 6); fraction 300 (lane 7). A relatively greater recovery of parental LCC pDNA was observed 
in comparison to the other two LCC DNA species. 
 
 
Purification of LCC DNA ministrings by affinity chromatography, a form of separation 
based on molecular recognition and sequence specific interactions, effectively enhances 
selectivity suitable for one step purification [190, 191]. Plasmid purification using triple-
helix [192], amino acid-DNA [193], and protein-DNA [112] affinity chromatography had 
been previously demonstrated. Triple-helix affinity chromatography involved interactions 
between pyrimidine oligonucleotides, covalently linked to the chromatographic matrix, and 
corresponding polypurine sequences at the major groove of DNA via Hoogsteen hydrogen 
bonds. Such interactions resulted in the formation of TA-T and CG-C
+
 triplexes that were 
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stable under acidic conditions [190-192]. Subsequent elution at alkaline pH prompted the 
dissociation of the triple-helix for DNA recovery. Such purification required genetic 
modifications for the inclusion of the polypurine sequences into the pDNA construct and 
were limited by low DNA recovery and slow kinetics of triple helix formation [190]. 
Similarly, protein-DNA affinity chromatography employed a protein for the recognition of 
specific sequences within the pDNA construct. Mayrhofer et al. [112] previously 
demonstrated recombination based plasmid separation (RBPS) for purification of minicircle-
DNA at purities greater than 98.5%. Such separation involved highly efficient ParA resolvase 
recombination for production of minicircle-DNA followed by affinity chromatography, using 
immobilized LacI repressors, for minicircle-DNA purification. A tandem repeat of modified 
lactose operator sites (lacOs sites) was included into the pDNA construct and served as the 
recognition sequence for LacI repressors. Elution of the LacI-bound minicircle-DNA was 
achieved through the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) and NaCl. 
Further investigation into purification of LCC DNA ministrings by affinity chromatography 
will be warranted upon addressing limitations of low binding capacity and durability of 
natural ligands, production costs of chromatographic matrix for large scale purifications, and 
potentially reduced capacities upon repeat administrations.    
Large scale production of pharmaceutical grade pDNA requires a rapid and economical 
means of generating purified pDNA free of animal-derived enzymes and toxic reagents 
[180]. Laboratory scale pDNA vector production generally involves extraction kits 
employing solvents, toxic chemicals (cesium chloride & ethidium bromide), or animal-
derived enzymes (RNase A), which poses significant issues relating to cost, scalability, and 
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safety [176, 178, 180]. Previously, several groups had attempted large-scale pDNA 
purification using a combination of tangential flow filtration and various chromatography 
techniques including HIC, SEC, and AEC [176, 178-180]. Anion exchange membrane 
chromatography had been applied for such purification processes resulting in high 
concentration of pDNA and RNA removal [176, 178]. Reductions to endotoxin levels as high 
as four orders of magnitude had been previously demonstrated in large scale purifications 
using anion exchange membrane chromatography [189]. Subsequent application of HIC may 
further enhance pDNA purity as HIC was demonstrated to successfully remove proteins, 
endotoxins, chromosomal DNA, and residual RNA [178-180, 194]. In particular, application 
of HIC was reported to eliminate over 99% of impurities while increasing pDNA purity by 
30.5 fold [178]. Improved transfection efficiency was also observed after purification by HIC 
[194]. Large scale production previously demonstrated an overall yield of 48% as 800 mg of 
pharmaceutical grade pDNA (protein <2 µg/mg plasmid; endotoxin <10 EU/mg plasmid; 
chromosomal DNA <1 µg/mg plasmid) was generated from 2 kg of bacterial cell paste [180]. 
As AEC had been utilized for large scale pDNA purification, its application for separating 
DNA isoforms should not impose additional costs or significant production delays in the 
generation of pharmaceutical grade DNA vectors. Hence, further exploration into optimal 
conditions for effective separation by anion exchange membrane chromatography will be 
warranted for downstream large scale production of LCC DNA ministrings.  
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3.4 Conclusions 
Results from this study served as a proof-of-concept highlighting the advantages of anion 
exchange membrane chromatography in pDNA purification as well as demonstrating its 
potential in the separation of different DNA isoforms. Application of a hydrogel-based strong 
Q-anion exchange membrane and manipulations of the salt gradient constituted effective 
separation of parental supercoiled CCC pDNA from LCC DNA. Further exploration of the 
optimal conditions and additional modifications will be warranted as AEC serves to be an 
integral component in downstream purification processes for the large-scale production of 
clinical grade DNA ministrings.   
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Chapter 4 
Transfection and Physical Characterization of DNA/16-3-16/DOPE Gemini 
Surfactant Based Vectors for the Delivery of LCC DNA Ministrings 
 
4.1 Introduction 
Gemini surfactants are amphiphilic molecules composed of two surfactant monomers 
chemically linked by a spacer. Gemini surfactants confer advantages of reduced cytotoxicity 
and cost effectiveness as they possess a critical micelle concentration (CMC) that is one to 
two orders of magnitude lower than their monomer counterparts [15, 85]. Gemini surfactant 
derived synthetic vectors offer numerous advantages including: 1) high positive charge for 
effective DNA complexation at low concentrations; 2) efficient DNA compaction generating 
smaller complexes than their monomeric counterparts; 3) effective endosomal escape alone 
or in combination with DOPE; and 4) suitability for long term storage, over two months at 
ambient temperatures, in lyophilized formulations without losing functionality [88, 89].  
Among the different m-s-m or N,N-bis(dimethylalkyl)-α,ω-alkanediammonium 
surfactants (where m and s represent the number of carbon atoms in the alkyl tails and in the 
polymethylene spacer group), the 16-3-16 derivative has been extensively studied due to 
their structural nature, promoting effective DNA complexation, and their capacity to adopt 
structural polymorphisms critical to endosomal escape and successful gene delivery. 16-3-16 
gemini surfactants possess a trimethylene spacer (s = 3) that constitutes compatible head 
group distances (~0.49 nm) with the spacing of phosphate groups (0.34 nm) in DNA [91]. 
Their high positive charge (relative to monomeric surfactants and lipids) promotes efficient 
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DNA binding and compaction, generating particles suitable for gene delivery. Numerous 
reports have previously indicated the ability of 16-3-16 gemini-based lipoplexes, in 
combination with DOPE, to form higher ordered phase structures including inverted 
hexagonal and cubic phase structures [15, 97, 98, 195]. Such structures are highly dependent 
on the lipoplex composition with hexagonal structures predominantly present at high mol 
ratios of DOPE and cubic phase structures at high mol ratios of gemini surfactant [98].  
Owing to the inherent properties of 16-3-16 gemini-based lipoplexes, such synthetic 
vectors had been successfully applied for in vivo cutaneous interferon-γ gene delivery as part 
of a topical treatment for localized scleroderma [91, 196, 197]. Scleroderma is a chronic 
autoimmune disorder characterized by the excessive collagen synthesis and deposition in 
skin/connective tissue, contributing to fibrosis. Induced expression of interferon-γ (IFN-γ) 
acts to suppress collagen synthesis and this serves as the basis for treatment of localized 
scleroderma using a topical formulation comprised of IFN-γ encoding, 16-3-16 gemini-based 
synthetic vectors [91, 196, 197]. The pDNA/16-3-16/DOPE synthetic vector was shown to 
successfully transfect PAM212 keratinocytes in vitro as well as normal (CD1) and IFN-γ-
deficient knockout mice in vivo. Topical application of gemini-liposomal formulation 
significantly improved IFN-γ expression in the skin of CD1 mice in conjunction with a 12 
fold increase of IFN-γ in lymph nodes [91]. With respect to IFN-γ-deficient mice, higher 
IFN-γ expression was observed over pDNA only and untreated controls in absence of skin 
damage and irritation [197]. Using a Tsk/+ scleroderma mouse model, a 20-day treatment 
regimen with the topical formulation constituted uniform IFN-γ expression that resulted in 
  109 
70-72% collagen reduction [196], thus demonstrating efficacy in treating localized 
scleroderma. 
As seen in the abovementioned studies, synthetic vectors for gene delivery typically 
consists of CCC pDNA. However, the linear topology of LCC DNA ministrings may present 
differences to DNA interaction and physicochemical properties of the resulting vector. In this 
study, 16-3-16 gemini-based synthetic vectors, derived from CCC pDNA (CCC/16-3-
16/DOPE) and LCC DNA ministrings (LCC/16-3-16/DOPE), were characterized and 
assessed for gene delivery into ovarian cancer cells (OVCAR-3). Comparative analysis of the 
physical properties for CCC/16-3-16/DOPE and LCC/16-3-16/DOPE lipoplexes, with 
respect to particle size, zeta potential, DNA encapsulation, and DNase sensitivity, was 
completed. Preliminary assessment of transfection efficiencies was conducted between the 
two vectors.              
4.2 Materials and Methods 
4.2.1 Production of CCC pDNA, LCC DNA products and LCC DNA ministrings 
The pNN9 vector [108] was used as the parental pDNA substrate for the production of LCC 
DNA ministrings and for the generation of CCC/16-3-16/DOPE lipoplexes. Tel
+
 W3NN 
[pNN9] was used for the production of egfp LCC DNA ministrings and JM109 was 
employed as hosts for plasmid amplification. LCC DNA ministrings were generated 
according to procedures outline in section 2.2.2, with the 2.4 kb DNA ministring being 
subsequently purified using AGE and gel extraction with E.Z.N.A. Gel Extraction Kit 
(Omega, VWR). The purified DNA ministrings were used for the generation of LCC/16-3-16 
and LCC/16-3-16/DOPE lipoplexes. 
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4.2.2 Generation of CCC/16-3-16/DOPE and LCC/16-3-16/DOPE Transfection 
Lipoplexes. 
16-3-16 gemini surfactants were previously synthesized according to procedures outlined by 
Wettig and Verrall [92]. 1.5 mM 16-3-16 gemini surfactant stock solutions were prepared in 
molecular water (HyClone, Thermo Scientific) with sonication (50° C) and purification 
through a 0.2 μm sterile filter (Fisher Scientific, Canada). Different aliquots of the 16-3-16 
stock solution (1.2 μl, 3 μl and 6 μl per 0.4 μg DNA) were used to generate gemini/DNA 




 charge ratios. 1 mM DOPE vesicles were prepared in 
phosphate buffer saline (PBS) according to procedures outlined by Wettig et al. [93]. The 
vesicles were filtered through a 0.45 μm sterile filter and different aliquots (3 μl, 7.4 μl and 
15 μl) were used to generate lipoplexes, of varying charge ratios, with a constant gemini to 
DOPE ratio of 1:2.5.  
The two respective lipoplexes were prepared as follows: 0.4 μg of DNA, pNN9 or egfp 
LCC DNA ministring, was mixed with different aliquots of 1.5 mM 16-3-16 gemini 




 charge ratios of 2:1, 5:1, and 10:1. After 15 minute 
incubation at room temperature, different aliquots of 1 mM DOPE were added and the 
subsequent mixture was further incubated for 30 minutes at room temperature. All other 




 charge ratios were generated in the same 
manner using different aliquots/dilutions of 16-3-16 gemini and DOPE. 
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4.2.3 Characterization of 16-3-16 Gemini Based Lipoplexes 
4.2.3.1 Particle Size and Zeta Potential 
Particle sizes for DNA, 16-3-16, DOPE, and resulting DNA/16-3-16 & DNA/16-3-16/DOPE 
lipoplexes were measured by dynamic light scattering using Malvern Zetasizer Nano ZS 
instrument (Malvern instruments, UK). Particle size distributions were obtained from light 
scattering (θ = 173°) in water at 25° C and the measured sizes were reported using a % 
volume distribution. Samples were measured in triplicates of triplicate and the resulting 
averages were reported. 
Zeta potential (ζ) for the abovementioned samples was measured by Laser Doppler 
Electrophoresis using zeta potential capillary cells and Malvern Zetasizer Nano ZS 
instrument (Malvern instruments, UK). All measurements were made at 25° C and samples 
were measured in triplicates of quintuplicate with averages being reported. 
4.2.3.2 DNase Sensitivity Assay 
The DNase sensitivity assay involved the incubation of lipoplexes with DNase I (1 unit per 1 
μg DNA) (Promega) and the DNase reaction buffer (Tris-HCl, MgSO4, CaCl2) for 30 minutes 
at 37° C. Subsequently, DNase I was inactivated by the addition of DNase stop solution 
(ethylene glycol tetraacetic acid (EGTA)) and denatured upon 10 minute incubation at 60° C. 
Lipoplexes were disrupted with the addition of phenol:chloroform:isoamyl alcohol (25:24:1, 
v/v) (Invitrogen) for the recovery of non-degraded DNA upon centrifugation. The extent of 
DNaseI induced degradation was assessed by AGE upon equal loading across all samples. 
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4.2.3.3 Transfection of OVCAR-3 Cells 
OVCAR-3 (ATCC HTB161) ovarian cancer cells were cultured in RPMI-1640 (HyClone, 
Thermo Scientific) supplemented with 20% fetal bovine serum (FBS) (HyClone, Thermo 
Scientific) and 1% penicillin-streptomycin (Fisher Scientific). OVCAR-3 cells were grown at 
37° C with 5% CO2 and maintained at 70-80% confluency prior to transfection. OVCAR-3 
cells were seeded, 50,000 cells/well, into a 24-well plate and incubated at 37° C for ~24 
hours. Cells were washed with PBS and fresh RPMI-1640, without FBS or antibiotics, was 
added. Transfection lipoplexes were prepared in Opti-Mem (Gibco, Invitrogen) and the 
resulting lipoplexes were added drop-wise at amounts corresponding to 0.4 μg of DNA per 
well. Transfection with 1.2 μl LipofectamineTM 2000 (1 mg/ml) (Invitrogen), per 0.4 μg of 
DNA, were completed according to manufacturer's protocol and served as a positive control 
in the study. Cells were subsequently incubated at 37° C for 5 hours before the transfection 
medium was replaced by fresh RPMI-1640 with 20% FBS. Cells were further incubated at 
37° C until 24 hours post-transfection at which point the cells were collected, washed, and re-
suspended in PBS. Samples were stained with propidium iodide and analyzed by 
fluorescence activated cell sorting (FACS) (BD FACSVantage SE) for the assessment of 
transfection efficiency, as determined by EGFP expression, and cell viability post-
transfection.  
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4.3 Results 
4.3.1 Particle Size and Zeta Potential (ζ) 
With regards to 5.6 kb pNN9 (CCC) and 2.4 kb DNA ministring (LCC), particle sizes of the 
two DNA vectors were surprisingly similar despite their inherent differences in DNA 
composition (Table 4-1). The differences were accounted by the supercoiled nature of CCC 
pDNA contributing to more compact conformations than their linear counterparts. Such 
notions were supported by the differences in observed zeta potentials (ζ) as DNA 
supercoiling in pNN9 (CCC) masked a fraction of the negative charges attained from the 
phosphate groups of DNA. In contrast, the structural nature of the linear isoforms contributed 
to more prominent surface charges as indicated by a greater (-) zeta potential. By itself, 16-3-
16 gemini surfactants were able to rapidly self assemble into micelles due to high 
concentrations of the stock solution and due to conditions at which lipoplexes were 
generated. The 1.5 mM 16-3-16 stock solution was generated at concentrations well above 
the CMC of the gemini surfactant (0.0255 mM) and as lipoplexes were generated below the 
Krafft temperature (Tk = 42° C), referred to as the minimum temperature at which surfactant 
forms micelles, 16-3-16 micelles were rapidly self-assembled [91, 198]. The propensity for 
16-3-16 gemini surfactant to form micelles/vesicles of varying sizes resulted in the observed 
high polydispersities as indicated by a PDI value of 0.752.    
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Table 4-1 Particle size & zeta potential of CCC pNN9, LCC DNA ministring, 16-3-16, 
and DOPE. 
 Size (d.nm) Polydispersity Index (PDI) ζ-Potential (mV) 
pNN9 (CCC) 371   90 0.466 -25   9 
DNA ministring (LCC) 363   74 0.494 -35   2 
16-3-16 50   17 0.752 55   5 
DOPE 131   18 0.257 -19   5 
16-3-16/DOPE 204   67 0.657  
 
With respect to DNA/16-3-16 and DNA/16-3-16/DOPE lipoplexes, the two vectors 
generated lipoplexes of comparable particle sizes and zeta potentials across the three tested 
charge ratios (Table 4-2). For DNA/16-3-16 lipoplexes, both CCC/16-3-16 and LCC/16-3-16 
lipoplexes exhibited the progressive formation of uniformly sized particles, as indicated by 
decreasing PDI values, at increasing charge ratios. With respect to DNA/16-3-16/DOPE 
lipoplexes, substantially larger particle sizes were observed for lipoplexes at charge ratios of 
2:1. The large particles exhibited at lower charge ratios were likely the result of aggregation 
upon charge neutralization and subsequent addition of more gemini surfactants, at 5:1 and 
10:1 charge ratios, resulted in a dramatic decrease in particle sizes with lower 
polydispersities. In closer inspection of particle size fluctuations across the spectrum of 
progressively increasing charge ratios (Figure 4.1), charge neutralization and aggregation for 
LCC/16-3-16/DOPE lipoplexes was observed to occur at the lower charge ratio of 1:1 
whereas significant aggregation of CCC/16-3-16/DOPE lipoplexes occurred at a charge ratio 
of 2:1. Aggregation of the resulting lipoplexes and interference with light scattering 
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measurements, upon charge neutralization, contributed to large standard deviations and 
populations of highly variable particle sizes [199, 200].  
 
Table 4-2 Particle size and zeta potential of DNA/16-3-16 and DNA/16-3-16/DOPE 
lipoplexes. 
 pNN9 (CCC) DNA ministring (LCC) 
 Size (d.nm) PDI ζ-Potential (mV) Size (d.nm) PDI ζ-Potential (mV) 
DNA/16-3-16 
2:1 141   24 0.402 38   1 143   40 0.351 41   9 
5:1 127   31 0.359 39   3 114   37 0.241 48   7 
10:1 100   38 0.267 48   9 132   43 0.185 43   3 
DNA/16-3-16/DOPE 
2:1 2343   1390 0.592 10   18 1634   655 0.561 22   3 
5:1 195   95 0.346 24   7 168   65 0.243 29   7 
10:1 218   119 0.372 36   6 247   144 0.409 29   6 
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charge ratios. As lipoplexes approach charge neutralization, a significant increase in 
particle size led to highly variable particles conferring large aggregate formation. Large 
aggregates for LCC/16-3-16/DOPE and CCC/16-3-16/DOPE lipoplexes appeared most 
prominent at charge ratios of 1:1 and 2:1 respectively. Progressive decreases to particle sizes 
at higher charge ratios led to stable and uniform particle formation.    
 
4.3.2 DNase Sensitivity 
Results from the DNase sensitivity assay suggested better DNA protection in DNA 
ministring (LCC) derived lipoplexes (Figure 4.2). Lipoplexes formed in absence of DOPE 





 charge ratios, DNA ministring (LCC) derived lipoplexes (lanes 15-17) exhibited 
improved stabilities over pNN9 (CCC) derived lipoplexes (lanes 5-7) as evidenced by greater 
DNA recovery upon DNase exposure. With respect to LCC/16-3-16 and LCC/16-3-16/DOPE 
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of DNA were recovered for LCC/16-3-16/DOPE lipoplexes at 2:1 charge ratio (lane 18); 
however, greater stabilities and improved DNA recovery were observed at higher charge 
ratios for DOPE containing lipoplexes (lanes 19 & 20). Comparative analysis between CCC 
and LCC derived transfection complexes, at 2:1, 5:1, and 10:1 charge ratios, confirmed 
improved DNA protection for LCC/16-3-16/DOPE lipoplexes (Figure 4.3). As a majority of 
the complexed DNA was protected from DNaseI degradation, LCC/16-3-16/DOPE 




Figure 4.2 DNase sensitivity assay for DNA/16-3-16 and DNA/16-3-16/DOPE lipoplexes. DNA 
ladder (lane 1); pNN9 (CCC) (lane 2); DNaseI exposed pNN9 (CCC) (lanes 3 & 4); CCC/16-3-16 
lipoplexes at 2:1, 5:1 and 10:1 charge ratios (lanes 5-7); CCC/16-3-16/DOPE lipoplexes at 2:1, 5:1, 
and 10:1 charge ratios (lanes 8-10); 16-3-16/DOPE (lane 11); DNA ministring (LCC) (lane 12); 
DNaseI exposed DNA ministring (LCC) (lanes 13 & 14); LCC/16-3-16 lipoplexes at 2:1, 5:1, and 
10:1 charge ratios (lanes 15-17); LCC/16-3-16/DOPE lipoplexes at 2:1, 5:1, and 10:1 charge ratios 
(lanes 18-20). Equal loading of the recovered DNA solution after DNaseI exposure indicated 
improved DNA recovery for ministring (LCC) derived lipoplexes. DNA/16-3-16 lipoplexes conferred 
better DNA recovery after DNaseI degradation over DNA/16-3-16/DOPE lipoplexes across all of the 
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Figure 4.3 DNase sensitivity assay for A) CCC/16-3-16/DOPE lipoplexes and B) LCC/16-3-
16/DOPE lipoplexes. DNA ladder (lane 1); DNA (lane 2); DNaseI exposed DNA (lane 3); DNA/16-
3-16/DOPE lipoplexes at 2:1 charge ratio (lanes 4 & 5); DNA/16-3-16/DOPE lipoplexes at 5:1 charge 
ratio (lanes 6 & 7); DNA/16-3-/16/DOPE lipoplexes at 10:1 charge ratio (lanes 8 & 9). Equal loading 
confirmed improved DNA recovery after DNaseI exposure at higher charge ratios. A majority of the 
complexed DNA ministrings (LCC) was recovered in lipoplexes at 5:1 and 10:1 charge ratios.   
 
4.3.3 Preliminary Investigation of the Transfection Efficiency of pNN9 (CCC) and DNA 
ministring (LCC) Derived Lipoplexes. 
EGFP expression was assessed and quantified through FACS for the determination of 
transfection efficiencies across the different transfection lipoplexes (Figure 4.4).  
Lipofectamine served as the positive control and demonstrated a transfection efficiency of 
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12%. In contrast, untreated control and cells treated with uncomplexed DNA did not elicit 
any EGFP expression. For CCC/16-3-16/DOPE lipoplexes, increasing transfection 
efficiencies were observed with increasing charge ratios, however, such increases were not 
statistically significant. In conjunction with slight improvements to transfection efficiency, 
higher charge ratios constituted greater cytotoxicity with cell viabilities of 60% attained with 
CCC/16-3-16/DOPE lipoplexes. Of the three LCC/16-3-16/DOPE lipoplexes, lipoplexes with 
a 5:1 charge ratio demonstrated the highest transfection efficiency (8.2%). 
 
 
Figure 4.4 Preliminary analysis of transfection efficiencies for CCC/16-3-16/DOPE and 
LCC/16-3-16/DOPE lipoplexes in OVCAR-3 cells (N=2). Both pNN9 (CCC) and DNA ministring 
(LCC) derived lipoplexes exhibited comparable transfection efficiencies at 2:1, 5:1, and 10:1 charge 
ratios. Increasing charge ratios constituted increases to both transfection efficiencies and cytotoxicity. 
LCC/16-3-16/DOPE lipoplexes at 5:1 charge ratio demonstrated higher transfection efficiency with 
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4.4 Discussion 
With regards to the influences of DNA topology, direct comparisons between pNN9 (CCC) 
and DNA ministrings (LCC) cannot be made due to the inherent differences in the size of the 
two respective vectors. More apparent differences may have arise had the parental 
supercoiled CCC pNN9 been compared with its parental LCC counterpart, however, results 
from this study denoted certain differences arising from the influences of DNA topological 
conformations. The supercoiling effect contributed to a lower effective negative charge for 
CCC pNN9 [201, 202] which led to lower surface charges (ζ = -25   9 mV) when compared 
to LCC DNA ministrings (ζ = -35   2 mV). In addition, DNA supercoiling reduced the 
overall size of the circular plasmid, which contributed to comparable particle sizes between 
pNN9 and DNA ministrings despite the fact that pNN9 was the larger sized plasmid. Such 
differences had significant effects on the interactions between DNA and 16-3-16 gemini 
surfactant in terms of counterion release during lipoplex formation. Previously, DNA/16-3-
16/DOPE lipoplexes, comprised of linear calf thymus DNA (ctDNA), demonstrated complete 
release of Na
+
 counterions during lipoplex formation; in contrast, a significant fraction of 
counterions remained bound during complex formation of CCC pDNA-derived lipoplexes 
[201, 202]. Counterion displacement was suggested to be inhibited due to the compact 
conformation of supercoiled CCC pDNA inducing geometric constraints on gemini/DNA 
interactions.    
Resulting particle sizes and zeta potentials for DNA/16-3-16 and DNA/16-3-16/DOPE 
lipoplexes were in agreement with literature [97, 197] as all lipoplexes possessed positive 
zeta potentials critical to in vitro transfection. Upon inspection of particle size variations for 
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lipoplexes across different charge ratios, both CCC/16-3-16/DOPE and LCC/16-3-16/DOPE 
exhibited significant increases in particle sizes at charge ratios corresponding to charge 
neutralization and large aggregate formation. For CCC/16-3-16/DOPE lipoplexes, substantial 
large aggregation formation was observed at a higher charge ratio of 2:1 in contrast to 1:1 for 
LCC/16-3-16/DOPE lipoplexes. Differences may be attributed to the antagonistic 
interactions between 16-3-16 gemini and DOPE [99] in combination with incomplete 
counterion release for CCC/16-3-16 lipoplexes, prompting more prominent DOPE induced 
instabilities that prevented the generation of stable, discrete lipoplex particles. Lipoplex 
instabilities were exemplified by the lower and highly variable (+) zeta potentials (ζ = 10   
18 mV) for CCC/16-3-16/DOPE lipoplexes at a charge ratio of 2:1. Such zeta potentials were 
indicative of charge neutrality that contributed to aggregation and the observed large particle 
sizes.  
DNA ministring (LCC) derived lipoplexes exhibited improved DNA encapsulation and 
protection properties as evidenced by improved DNA recovery upon DNaseI exposure. For 
both CCC/16-3-16/DOPE and LCC/16-3-16/DOPE lipoplexes, the higher charge ratios of 5:1 
and 10:1 elicited better DNA encapsulation, protecting the DNA cargo from degradation. 
However, such protection was more prominent in LCC/16-3-16/DOPE lipoplexes and this 
was attributed to the higher (-) zeta potential of DNA ministrings and the complete release of 
counterions during complexation. The highly negative zeta potentials exhibited in DNA 
ministrings denoted significant surface charges for extensive electrostatic interaction with the 
positively charged 16-3-16 gemini surfactant, leading to complete counterion release and 
reduced head group repulsions. Reduced head group repulsion between individual gemini 
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surfactants conferred better encapsulation, effectively protecting the residing DNA from 
exposure to DNaseI. With regards to LCC/16-3-16 and LCC/16-3-16/DOPE lipoplexes, 
improved DNA encapsulation and protection for LCC/16-3-16 lipoplexes were attributed to 
tight associations between DNA ministring and gemini surfactant as supported by high (+) 
zeta potentials. Despite offering smaller particle sizes and better protection from degradation, 
LCC/16-3-16 lipoplexes were shown to consistently exhibit low transfection efficiencies 
most likely due to their inability to undergo structural polymorphisms, for endosomal escape 
and DNA release, in absence of DOPE [98]. 
Across the three charge ratios, CCC/16-3-16/DOPE lipoplexes exhibited similar 
transfection efficiencies with increasing transfection efficiency and cytotoxicity being 
observed at increasing charge ratios. This was in contrast to previous reports by Wang at el. 
[96] where transfection efficiency decreased with increasing charge ratios. Nevertheless, 
transfection efficiencies attained in this study were comparable to those reported by Wang et 
al. [96] across the three tested charge ratios. With respect to LCC/16-3-16/DOPE lipoplexes, 
a charge ratio of 5:1 corresponded to the highest transfection efficiency. However, 
preliminary results did not suggest substantial improvements in transfection efficiency for 
DNA ministring derived lipoplexes. Transfection efficiency of the Lipofectamine positive 
control was drastically lower than previous reports (12% vs 32.2%) [85, 96]. The lower 
transfection efficiencies may be attributed to high passage number (18-20), contributing to 
cellular senescence, during which transfections took place. Further studies, using OVCAR-3 
as well as other cell lines, will be required for complete analysis of the differences in 
transfection efficiency attained from lipoplexes derived from CCC and LCC DNA vectors.  
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4.5 Conclusion 
Despite the size disparities between pNN9 (CCC) and DNA ministrings (LCC), differences 
in DNA topology led to the generation of lipoplexes of comparable particle sizes between the 
two DNA vectors. The capacity for DNA ministring (LCC) derived lipoplexes to undergo 
complete counterion release during lipoplex formation contributed to improved DNA 
encapsulation and protection from DNase degradation. Preliminary analysis indicated 
comparable transfection efficiencies attained from both pNN9 and DNA ministring derived 
lipoplexes. Further investigation will be required to fully ascertain the influence of DNA 
topology on transfection capacities, in gemini-based synthetic vectors, across various cell 
types.  
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Chapter 5 




The one-step in vivo LCC DNA minivector production system confers versatility as the 
eukaryotic expression cassette can be interchanged to suit numerous downstream 
applications. As shown previously, the optimized production and delivery of DNA 
ministrings, with lipid-based synthetic vectors, imparted transgene expression in ovarian 
cancer (OVCAR-3) cells. Thus, expression of the gene of interest was not deterred upon 
vector manipulations from protelomerase-mediated processing. To demonstrate the numerous 
potential applications of LCC DNA ministrings, the aforementioned system was 
implemented for downstream development of an HIV (Human Immunodeficiency Virus) 
DNA-VLP vaccine. This vaccine strategy endeavours to target delivery of DNA ministrings 
to dendritic cells and confer the generation of HIV virus-like particles (VLP) for potent 
antigen presentation and subsequent activation of humoral and cellular immunity. 
HIV and AIDS: Acquired immunodeficiency syndrome (AIDS) stems from HIV infections 
through sexual contact, infected blood products, and mother-to-child transmissions. The 
disease is characterized by a progressive depletion of CD4
+
 helper T-cells through different 
stages of infection: 1) rapid acute infection resulting in high viral loads and viremia; 2) 
asymptomatic viral latency upon viral integration; and 3) symptomatic AIDS rendering the 
host immunocompromised and susceptible to opportunistic infections. The HIV lentivirus 
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(retrovirus) is divided into two major types, HIV-1 and HIV-2. HIV-1 is the highly virulent 
form responsible for the AIDS pandemic while HIV-2 is the less virulent variation 
geographically confined to persist within West Africa [203]. HIV-1 is further divided into 
different groups (M, N, O, P) with the pandemic group M being subdivided into different 
subtypes or clades designated by letters A to K [203]. The HIV genome consists of two 
copies of a 9.5 kb ssRNA encoding polyproteins Gag (matrix, capsid, and nucleocapsid 
proteins), Pol (protease, reverse transcriptase, and integrase), and Env (surface envelope 
gp120 and transmembrane gp41); in addition, the genome also encodes regulatory proteins 
Tat and Rev and virulence accessory proteins Nef, Vif, Vpr, Vpu [203].      
Despite our extensive understanding of the biological nature of HIV and HIV 
pathogenesis, a therapeutic cure against HIV/AIDS has yet to be discovered. Currently, the 
administration of highly active antiretroviral therapy (HAART) consisting of a cocktail of 
antiretroviral agents including reverse transcriptase-, protease-, integrase-, and fusion/entry-
inhibitors can effectively suppress viral replication and disease progression. While HAART 
can significantly reduce morbidity and mortality of infected individuals, the treatment 
regimen cannot eradicate HIV infections due to latent HIV infections that persist as an 
integrated provirus, and due to low level viral replication permitting cell to cell infection 
[204]. The associated high costs of HAART, approximately $15000-20000 USD per 
individual annually, also limits the availability of this treatment regimen in developing 
countries [205]. Lifelong adherence to treatment and potential risks of HIV-resistance to anti-
retrovirals pose additional roadblocks indicating the need for alternative solutions to 
combating HIV/AIDS.  
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HIV infections pose serious immune complications due to the absence of natural 
mammalian protective immunity against the virus; contributed by infection of CD4
+
 immune 
cells, viral integration, and high genetic diversity of the virus [203, 206]. The capacity for 
genome integration into infected CD4
+
 T-cells offers a limited time frame prior to the 
establishment of latently infected T-cells and lifelong persistent infection. This is 
compounded by the lack of natural immune responses against HIV, as the virus actively 
targets immune cells while possessing mechanisms to highjack and subvert immune 
responses. In early HIV pathogenesis, HIV infects or becomes internalized by CD4
+
 
monocytes/macrophages and immature dendritic cells. Dendritic cells are elite antigen 
presenting cells (APCs) with the capacity to present antigens two orders of magnitude more 
effectively than other APCs [207]. They serve as the primary cross-presenting cells in vivo, 
promoting effective (major histocompatibility complex) MHC class I antigen presentation 
critical to CD8
+
 cytotoxic T lymphocyte (CTL) response and cellular immunity [208, 209]. 
HIV entry into immature dendritic cells is mediated by the CD4 receptor, CCR5 and CXCR4 
co-receptors, and various C- type lectin receptors including mannose receptor/CD206, DEC-
205/CD205, Langerin/CD207, DC immunoreceptor, and dendritic cell specific intercellular 
adhesion molecule-3-grabbing non-integrin or DC-SIGN/CD209 [210-212]. In particular, 
DC-SIGN serves to efficiently transmit intact virus to CD4
+ 
T-cells [211, 212]. Activation of 
these dendritic cells, via Toll-like receptors (TLRs) and proinflammatory cytokines, triggers 
their maturation and migration to lymph nodes where subsequent interactions with CD4
+
 T-
cells contribute to rapid viral transfer and infection [213, 214]. Although the abovementioned 
processes parallel those typically seen in innate and adaptive immune activation, the rapid 
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onset of HIV infection supersedes appropriate antiviral responses against the virus. HIV 
infection subsequently contributes to the dysregulation of dendritic cells that leads to 
increased apoptosis and diminished CTL responses through disruptions of cross-talk with 
natural killer cells [215]. The expression of regulatory Tat and Nef proteins induces 
additional effects that subvert immune responses and promote viral propagation. Tat 
possesses multiple functions of: 1) increasing viral mRNA production; 2) inducing 
proinflammatory cytokine and chemokine release for recruitment and infection of 
macrophages/T-cells; and 3) triggering apoptosis of uninfected CD4
+
 T-cells [203, 214, 216]. 
Nef, a major virulence factor, also induces proinflammatory cytokine and chemokine release 




 T-cells. In addition, Nef 
downregulates MHC I antigen presentation, thereby severely hampering the activation of 
CTL responses [203]. The absence of natural immunity and the inability of the host to 
intervene during early stages of infection contribute to successful viral integration and the 
generation of latently infected T-cells resulting in lifelong persistence of infection.  
In addition to CTL responses and cellular immunity, the activation of humoral immunity, 
through the production of neutralizing and non-neutralizing antibodies, promotes an effective 
response against HIV infection. Neutralizing antibodies recognize and bind to HIV surface 
antigens (gp120 and gp41) thereby neutralizing the infectivity of the virus. In contrast, non-
neutralizing antibodies bind to surface HIV antigens, stimulating the recruitment of immune 
cells to activate antibody-dependent cell-mediated cytotoxicity (ADCC) and virus inhibition 
(ADCVI). A neutralizing antibody response typically arises several weeks following HIV 
infection where the generated antibodies are strain specific, targeting idiotypic hypervariable 
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regions that are highly susceptible to mutations and sequence variations—such mutability 
corresponds to as high as 35% sequence variation in Env glycoproteins between viruses of 
different subtypes [217]. Broadly neutralizing antibodies capable of acting on cross-clade 
variants may be generated but often require chronic antigen exposure to impart affinity 
maturation [203]. Selective pressures from host immune responses and the error prone nature 
of reverse transcriptase, in combination with high viral loads, both contribute to significant 
genetic diversity that prompts viral escape and sustained viral replication [204, 206, 218]. 
Rapid viral escape and the gradual decline in humoral responses renders the acquired 
neutralizing antibodies ineffective in halting disease progression. As such, the activation of 
CD8
+
 CTL responses and the generation of broadly neutralizing antibodies play critical roles 
during HIV infections; however, the inherent properties of HIV and the limited window prior 
to persistent infection greatly complicates the search of a therapeutic cure for HIV/AIDS. 
Hence, the development of a prophylactic/therapeutic vaccine, alone or in combination with 
antiretroviral therapy, may be a viable solution in curbing viral spread. 
Various types of vaccines including whole inactivated, subunit, live recombinant viral, 
virus-like particles (VLP), DNA, and dendritic cell-based strategies have been previously 
explored as potential HIV therapeutics. Clinical trials for Remune, a whole inactivated 
vaccine free of envelope proteins, did not elicit immunological control over viral replication 
and offered no significant effect to CD4 counts or HIV progression [204]. Numerous clinical 
trials involving native and recombinant Env (gp160, gp120, gp41) subunit vaccines (eg. 
AIDSVAX) have been previously explored, but none have yet to demonstrate substantial 
clinical benefit [206]. Live recombinant vaccines are viral vectors genetically engineered to 
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carry genes encoding HIV antigens and serve to induce MHC I antigen presentation for 
activation of CTL responses. Clinical assessment of ALVAC-HIV-1, a canary pox vector 
expressing env, gag, nef, and pol gene products, enhanced HIV-1-specific cellular immunity 
for subjects receiving antiretroviral therapy during acute HIV infection but did not reduce 
viral loads upon discontinuation of antiretroviral therapy [204, 219, 220]. Detriments of 
using live recombinant vaccines are exemplified in the adenovirus serotype 5 (Ad5)-HIV 
vaccine where subjects with pre-existing immunity against Ad5 were found to be at greater 
risk of HIV infection [203, 206, 218, 221]. Results from the RV144/Thai trial, involving a 
ALVAC-HIV-1/AIDSVAX B/E prime-boost vaccine, showed very promising results as the 
Phase III vaccine study indicated a statistically significant (31.2%) reduction in HIV-1 
acquisition over placebo, amongst heterosexual volunteers; however, the vaccine failed to 
impact early post-infection viral loads and CD4 counts [218, 222]. Findings from the 
RV144/Thai trial are promising and further investigations are underway investigating the 
mechanistic nature of the prime-boost vaccine. 
Virus-like particles (VLP) are self-assembling, non-replicating, non-infectious, DNA-free 
particles of similar size to their wild type counterparts and display conformational epitopes 
that closely mimic the native virion [223-226]. Although HIV VLPs only require Gag 
polyprotein for efficient particle assembly, budding, and release, chimeric enveloped VLPs 
may be generated using Gag polyprotein in combination with recombinant Env 
glycoproteins. VLP-based vaccines possesses numerous advantages as VLPs possess 
multiple viral epitopes for the stimulation of both cellular and humoral immunity without the 
deleterious effects of live attenuated viruses. VLPs are able to induce dendritic cell 
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maturation and migration while possessing the capacity for promoting antigen presentation 
and cross-presentation in absence of infection. In vitro and in vivo studies previously 
confirmed MDDC-mediated natural killer cell activation in the presence of HIV-VLPs, 
suggesting the capacity for VLP-activated cross-talk [226] in combination with generating 
neutralizing antibodies as antigens are expressed in their native form. 
Extensive efforts by Kang et al. [227-229] have culminated into the successful 
development of chimeric gene constructs corresponding to the generation of different VLPs 
with neutralizing (gag-V3 and gag-C3) and T cell (gag-TCE) epitopes. The gag-V3 construct 
confers the expression of a HIV-2 Gag polyprotein fused with neutralizing epitopes found 
within the variable 3 (V3) region of gp120. The HIV-2 Gag precursor protein was selected to 
carry the different HIV-1 V3 domains because: 1) HIV-2 Gag precursors secrete highly 
immunogenic VLPs, 2) HIV-2 Gag contains cross reactive CTL epitopes that confer 
protection from HIV-1, and 3) HIV-2 Gag forms chimeric VLPs with up to 198 additional 
amino acids [227].  
Neutralizing epitopes within V3 are vital to the generation of neutralizing antibodies and 
the incorporation of V3 domains from different HIV clades (B, C, & E) corresponds to the 
induction of broadly neutralizing antibodies. The in vivo immunization of BALB/c mice with 
Gag-V3 chimeric VLPs induced CTL activity against V3-stimulated cells [229], denoting the 
capacity for activating both humoral and cellular immunity. And, as expected, the Gag-V3 
VLPs conferred neutralizing antibodies and CTL responses against a broad spectrum of HIV-
1 isolates [227]. Currently, the chimeric gene constructs are employed as part of a HIV-1 
prime-boost prophylactic vaccine (SAV001-H) comprised of: 1) whole inactivated HIV virus 
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modified with a targeted deletion of nef gene and the replacement of the Env protein natural 
signal sequence (EnvNSS) with that of honeybee melittin; and 2) replication deficient 
adenoviral vectors, carrying the chimeric constructs, for VLP formation and release [228]. 
The success of this vaccine was highlighted by its recent completion of phase I clinical trials 
and future plans of phase II clinical trials in 2014.   
Building on the advantages of VLP-based vaccines, the application of DNA-VLP vaccines 
targeting dendritic cells offers additional benefits. Dendritic cells are the most potent APCs 
offering the unique ability to undergo cross-presentation, for MHC I antigen presentation, 




T-cells [204, 221]. Direct 
delivery of DNA vectors encoding antigen to dendritic cells provides an internal source of 
immunogenic peptides for MHC I loading and presentation, while avoiding the inherent risks 
associated with the use of viral vectors [230]. In addition, simultaneous presentation of 
multiple epitopes derived from the same antigen can be achieved. Subsequent VLP formation 
and release serves to promote activation of nearby dendritic cells, prompting MHC II antigen 
presentation and the generation of neutralizing antibodies. In this study, DNA ministrings 
were generated towards the expression and production of Gag-V3 VLPs to be utilized in the 
downstream development of a HIV DNA-VLP prophylactic/therapeutic vaccine. Culturing 
and transfection conditions were optimized for gene delivery, via lipid-based synthetic 
vectors, into K562-αvβ3 cells for later assessment of targeted delivery using RGD peptides.    
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5.2 Materials and Methods 
5.2.1 Construction of pGagV3(BCE) Vector 
The 6.56 kb pGagV3(BCE) vector was designed using the pNN9 vector [108] as the 
template. The egfp gene, residing as the gene of interest in pNN9, was replaced with the 
chimeric gene construct gagV3(BCE) (gift from Dr. Chil-Yong Kang, UWO) to generate the 
pGagV3(BCE) vector. The chimeric gene construct gagV3(BCE) expresses a HIV-2 Gag 
polyprotein with three V3 neutralizing epitopes (from HIV-1 clades B, C, and E) near the C-
terminus [227-229]. 
 
Figure 5.1 Schematic of pGagV3(BCE) Vector. Adapted from [228]. 
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5.2.2  Production of gagV3(BCE) LCC DNA Ministrings 
The pGagV3(BCE) vector was transferred into Tel
+
 W3NN cells using standard 
transformation techniques described in [154]. The production of gagV3(BCE) DNA 
ministrings was accomplished by batch cultivation as described in section 2.2.2. Briefly, a 
single colony of Tel+ W3NN [pGagV3(BCE)] was grown overnight in 5 ml LB + Ap (100 
μg/ml) under repressed conditions at 30° C with aeration. Fresh cells were grown from the 
overnight culture (50 ml; 1:100 dilution) at 30° C with aeration to late log phase A600 = 0.8. 
Protelomerase expression was induced upon temperature upshift and incubation at 42° C for 
60 min. The cultures were subjected to post-induction incubation at 37° C for 30 min prior to 
overnight incubation at 30° C. Cells were harvested and plasmid extracted with E.Z.N.A. 
Plasmid Mini/Maxi-Prep Kit (Omega, VWR). The production of gagV3(BCE) DNA 
ministrings was confirmed by AGE. 
5.2.3  Transfection of K562 Cells 
Immortalized myelogenous leukemia K562 cells, with induced surface expression of 
CD51/CD61 (αvβ3) integrin (K562-αvβ3) were generously provided by Dr. Scott Blystone 
(SUNY Upstate Medical University, Syracuse, NY, USA). K562-αvβ3 cells were cultured in 
Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% FBS and Geneticin 
(G418) (1.2 mg/ml of IMDM) for sustained receptor expression. K562-αvβ3 cells were grown 




 cells/ml prior to 
transfection. 500 μl of K562-αvβ3, corresponding to 100,000 or 500,000 cells/well, were 
seeded into 24-well plates and incubated at 37° C for 60 min prior to transfection. 
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Transfection was carried out using Lipofectamine
TM 
2000 and 16-3-16 gemini/DOPE 
synthetic vectors comprised of pNN9 or egfp expressing DNA ministring. 
For transfection with Lipofectamine, CCC pNN9 and egfp-expressing LCC DNA 
ministrings were complexed with varying amounts (2-5 μl/ 0.5 μg DNA) of 1 mg/ml 
Lipofectamine
TM
 2000 (Invitrogen) according the manufacturer's protocol. Resulting 
lipoplexes were added drop-wise at amounts corresponding to 0.5 μg of DNA per well. Cells 
were subsequently incubated at 37° C for 5 h prior to the addition 500 μl of fresh IMDM 
(10% FBS; G418) and further incubation until 24 or 48 h post-transfection. At each 
respective time point, cells were collected, washed, and re-suspended in PBS. Samples were 
stained with propidium iodide and analyzed by fluorescence activated cell sorting (FACS) 
(Guava easyCyte
TM
, Millipore) for the assessment of transfection efficiency, as determined 
by EGFP expression, and cell viability post-transfection. Duplicate samples were assessed, 
by FACS, with respect to samples measured at 24 hours post-transfection.   
For 16-3-16/DOPE synthetic vectors, the transfection complexes were prepared as 
follows: 0.5 μg of pNN9 vector or egfp DNA ministrings was mixed with different aliquots 




 charge ratios of 2:1, 5:1, and 
10:1. After 15 minute incubation at room temperature, different aliquots of 1 mM DOPE was 
added to ascertain a constant gemini to DOPE ratio of 1:2.5 and the subsequent mixture was 
further incubated for 30 min at room temperature. The resulting lipoplexes were added drop-
wise corresponding to 0.5 μg of DNA per well. Cells were subsequently incubated at 37° C 
for five hours prior to the addition 500 μl of fresh IMDM (10% FBS; G418) and further 
incubation until 24 h post-transfection. After 24 h, cells were collected, washed, and re-
  135 
suspended in PBS. The samples were stained with propidium iodide (PI) and analyzed by 
fluorescence activated cell sorting (FACS) for the assessment of transfection efficiency, as 
determined by EGFP expression, and cell viability post-transfection.          
 
5.3 Results 
5.3.1 Production of gagV3(BCE) LCC DNA Ministrings 
The 6.56 kb pGagV3(BCE) vector consisted of the same genetic components as the 5.6 kb 
pNN9 plasmid with the exception of the replacement of the 717 bp egfp gene with the 1,647 
bp gagV3(BCE) chimeric gene construct. As such, the resulting eukaryotic expression 
cassette was flanked by two SuperSequence sites, enabling the generation of LCC DNA 
ministrings. Functionality of the pal site was preserved as heat-induced expression of tel
 
conferred the generation of LCC DNA products upon protelomerase processing of 
pGagV3(BCE) (Figure 5.2). Tel processing of pGagV3(BCE) constituted the production of 
parental LCC DNA (6.56 kb), LCC backbone DNA (3.2 kb), and gagV3(BCE) LCC DNA 
ministrings (3.36 kb), all of which were also present upon protelomerase processing of 
pNN9. The similar sizes of LCC backbone DNA and gagV3(BCE) LCC DNA ministrings 
contributed to the observed overlap in gel bands.      
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Figure 5.2 Tel-mediated processing of precursor plasmids into egfp and gagV3(BCE) LCC DNA 
ministrings. Representative gel image of LCC DNA ministring production for respective ministrings 
bearing egfp and gagV3(BCE) as the gene of interest: ladder (lane 1); W3NN [pNN9] (lane 2); 
W3NN [pGagV3(BCE)] (lane 3); JM109 [pNN9] (lane 4); JM109 [pGagV3(BCE)] (lane 5). Tel 
protelomerase processing of pGagV3(BCE) resulted in the generation of three LCC DNA products: 
parental LCC DNA (6.56 kb), LCC backbone DNA (3.2 kb), and gagV3(BCE) LCC DNA ministrings 
(3.36 kb). Differences in the gel profiles for W3NN [pNN9] and W3NN [pGagV3(BCE)] were due to 
differences in the sizes of egfp and gagV3(BCE) with overlap in the gel bands corresponding to LCC 
backbone DNA and gagV3(BCE) LCC DNA ministrings.    
 
5.3.2 Preliminary Investigation into Optimal K562 Transfections with Lipofectamine 
Variations to cell seeding and quantity of transfection reagent were assessed to ascertain 
optimal conditions for attaining high transfection efficiencies in K562 cells (Figure 5.3). 
Initial assessment of transfection efficiency with varying amounts (2-5 μl/0.5 μg DNA) of 
Lipofectamine denoted increasing transfection efficiencies with increasing amounts of 
Lipofectamine. Transfection complexes with 5 μl of Lipofectamine elicited the highest 
transfection efficiencies, 7.0% for CCC pNN9 and 4.6% LCC DNA ministring, in samples 
seeded with 100,000 cells. In comparison between transfection efficiencies of 100,000 and 
500,000 seeded cells, higher transfection efficiencies were attained when seeding 500,000 
cells for transfections involving CCC pNN9 (9.3%) and DNA ministrings (7.1%). Further 
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improvements were observed with increasing post-transfection incubation as transfection 
efficiencies of 13.9% and 11.1% were achieved for CCC pNN9 and LCC DNA ministring 
upon FACS analysis at 48 h post-transfection. Hence, transfection of 500,000 cells using 
diluted transfection complexes with 5 μl of Lipofectamine constituted conditions for the 
highest observed transfection efficiencies upon FACS analysis at 48 h post-transfection. 
 
 
Figure 5.3 Preliminary analysis of transfection efficiencies attained from variations to cell 
seeding and post transfection incubation using Lipofectamine (N=1). Progressive improvements 
in transfection efficiencies were observed with changes to cell seeding, from 100,000 to 500,000 
K562 cells, and extended post-transfection incubation, from 24 h (A) to 48 h (B), prior to FACS 
analysis. High cell viabilities were observed for all tested conditions. Minimal variations to 
transfection efficiencies were observed in duplicate samples. *Duplicate samples not available. 
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Transfection efficiencies were subsequently assessed using 16-3-16/DOPE synthetic 
vectors under the aforementioned optimal conditions. Initial analysis denoted a progressive 




) charge ratios; 
however, higher transfection efficiencies came at a cost of greater cytotoxicity (Figure 5.4). 
Increases to transfection efficiency and cytotoxicity for DNA ministrings, were more 




) charge ratios. In particular, the high transfection 
efficiencies (19.4%) attained with LCC/16-3-16/DOPE lipoplexes, at 10:1 charge ratios, 
corresponded to the lowest observed cell viabilities (68.7%). LCC/16-3-16/DOPE lipoplexes 
at 5:1 charge ratios resulted in a cell viability of 82.1% while attaining comparable 
transfection efficiencies to CCC pNN9/16-3-16/DOPE at 5:1 and 10:1 charge ratios.  
 
5.4 Discussion 
The LCC DNA minivector production system demonstrated high versatility as different LCC 
DNA ministrings may be produced to suit numerous applications. The growing AIDS 
pandemic and the significant prospects of the SAV001-H prophylactic vaccine prompted 
exploration into LCC DNA ministrings conferring the downstream development of a HIV 
DNA-VLP vaccine. Successes in VLP formation upon the delivery of gagV3(BCE) LCC 
DNA ministrings will demonstrate a proof of concept, highlighting the use of DNA 
ministrings in diverse applications. 
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Figure 5.4 Preliminary analysis of transfection efficiencies using DNA/16-3-16/DOPE lipoplexes 
(N=1). Increasing charge ratios (2:1, 5:1, and 10:1) constituted increases to both transfection 
efficiencies and cytotoxicity. For lipoplexes at 10:1 charge ratio, LCC DNA ministrings elicited 
higher transfection efficiencies than pNN9, but at a cost of greater cytotoxicity. 
 
 
As confirmed, the insertion of the gagV3(BCE) chimeric gene construct, in place of the 
egfp gene, did not alter protelomerase mediated processing of the corresponding parental 
pGagV3(BCE) vector into DNA ministrings. Tel processing of pGagV3(BCE) resulted in the 
production of the same LCC DNA products as observed in pNN9. The similar sizes of the 
LCC backbone DNA and gagV3(BCE) LCC DNA ministring may potentially interfere with 
complete separation and purification of the DNA ministring. However, as the DNA 
ministring will be utilized in the downstream development of a HIV DNA-VLP vaccine, the 
residual LCC backbone DNA, possessing CpG motifs, may serve as an adjuvant for 
immunostimmulation upon successful gene delivery. As the LCC backbone DNA is co-
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administered as a separate entity, transgene silencing from backbone sequence induced, 
heterochromatin-associated histone modifications [115] will be avoided; thus preserving 
effective transgene expression and VLP formation.  
The proposed HIV DNA-VLP vaccine involves targeted delivery of gagV3(BCE) DNA 
ministrings to dendritic cells. The αvβ3 integrin, also referred to as CD51/CD61 or 
vitronectin receptor, was selected to demonstrate targeted delivery of Arg-Gly-Asp (RGD) 
peptides. RGD peptides most prominently interact with the CD51 family of receptors and 
previous studies have demonstrated improved binding and internalization of cationic 
liposomes through RGD-dependent receptor mediated endocytosis [231]. In addition, αvβ3 is 
a receptor of dendritic cells involved in efficient and selective phagocytosis of apoptotic 
bodies [232]. Dendritic cells expressing high levels of CD51 were shown to express higher 
levels of MHC I, denoting higher cross presentation and activation of cellular immunity 
[233]. Selective targeting of αvβ3 contributed to improved Adenoviral serotype 5 (Ad5) 
transduction that initiated dendritic cell maturation and CD8
+
 T cell responses against Ad-
encoded antigens [233, 234]. The delivery of Ad5 vectors improved with greater CD51 
surface expression and was impeded by competitive binding of RGD peptides; both of which 
demonstrate the critical role of αvβ3 in the observed improvements to Ad5 transduction. 
Lastly, the RGD domain of HIV Tat was shown to inhibit dendritic cell-mediated 
phagocytosis of apoptotic bodies. This inhibition was suspected to involve αvβ3 [235] and 
was speculated to contribute to HIV induced dysregulation of dendritic cells, limiting their 
capacity to undergo antigen presentation.  
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K562-αvβ3 was considered to be an appropriate model demonstrating targeted delivery of 
RGD-functionalized synthetic vectors. GFP-encoding  phage, displaying high affinity αvβ3 
binding protein (3JCLI4), was shown to elicit improved internalization and transgene 
expression in K562-αvβ3 cells when compared to the undecorated control phage [236]. 
Hence, K562-αvβ3 was used as a convenient, cost-effective means of assessing the efficacy 
of targeted delivery and the associated improvements on transfection efficiencies for RGD-
functionalized lipoplexes. Actively dividing leukemia cells, grown in suspension, typically 
exhibit low transfection capacities. Among them, K562 cells are considered to be relatively 
transfection competent [237]. Using SucPG complex, composed of pH-sensitive fusogenic 
liposomes and DNA-bound lipoplexes, K562 cells were shown to elicit the lowest 
transfection efficiency (5%) among the tested cancer-derived cell lines, and transfection 
using Lipofectamine was less efficient than that achieved with SucPG complexes [238]. The 
low transfection efficiencies may be attributed to cytotoxicity as transfected K562 cells, 
grown in suspension, were reported to exhibit 35.1  7.8 % cell death—a stark difference 
compared to the 2.8  0.17 % cell death observed for non-transfected cells [237].  
The observed transfection efficiencies with Lipofectamine, for both CCC pNN9 and LCC 
DNA ministrings, were comparable to previous literature results. In contrast to adherent 
cultures, a greater number of K562 cells must be seeded in order to elicit higher transfection 
efficiencies. In addition, extended post-transfection incubation, from 24 to 48 h, led to higher 
transfection efficiencies. Using similar transfection conditions to this study, Amini et al. 
[239] reached 25% transfection efficiency in K562 cells with Lipofectamine upon FACS 
analysis 72 h post-transfection. This was comparatively higher than the transfection 
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efficiencies attained in this study. Hence, further improvements to transfection efficiency 
may arise using their outlined transfection protocols, which involve modifications to the 
current protocol in terms of fresh medium supplementation and incubation pre/post 
transfection. With respect to transfection using DNA/16-3-16/DOPE lipoplexes, preliminary 
analysis indicated improved transfection efficiencies for LCC DNA ministring over CCC 
pNN9 DNA. Improvements in transfection efficiency for LCC/16-3-16/DOPE lipoplexes 
over their CCC pDNA counterparts were more apparent than previous transfections 
involving OVCAR-3 cells (see Figure 4.4). This was suspected to be the result of 
transfection with K562 cells of lower passage number (6) in contrast to the cells with high 
passage number (18-20) used in OVCAR-3 transfections. Further investigation will be 
warranted to confirm such findings. 
As αvβ3 integrin is not uniquely expressed by dendritic cells, the use of ligands targeting 
conserved receptors of dendritic cells is proposed to further improve targeted delivery and 
vector endocytosis in dendritic cells. Ligands targeting CD205, a receptor highly expressed 
by dendritic cells, may suit such purpose as CD205 is involved in the presentation of 




 T-cells [240]. 
Immunolipoplexes functionalized with anti-CD205 antibodies was shown to improve 
transfection efficiency (~10%) in immature and mature dendritic cells over non-
functionalized lipoplexes [241], prompting the use of such antibodies as ligands for targeted 
delivery.   
Prospects of DNA-VLPs as a viable HIV vaccine was strengthened by DermaVir, a 
topical formulation consisting of a pDNA encapsulated within a shell of mannobiosylated 
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polyethylenimine (PEIm) for delivery into Langerhans cells [205, 242]. Advantages 
associated with DNA vaccines were exemplified by DermaVir as the delivered pDNA 
encodes a VLP, comprising 15 antigens (13 native and 2 genetically modified HIV-1 





 T-cells respectively [242]. DermaVir increased HIV specific memory T-cells in 
individuals receiving HAART while inducing a gradual suppression of viral loads in 
antiretroviral-naive, HIV infected individuals [205]. Similarly, the targeted delivery of 
gagV3(BCE) DNA ministrings into dendritic cells is speculated to induce neutralizing 
antibodies and CTL responses, both of which are critical factors to an effective HIV vaccine. 
Processing of internally expressed antigens in dendritic cells will prompt MHC I 
presentation, inducing CTL responses. Subsequent budding of unprocessed Gag-V3 VLPs 
will activate exogenous uptake of antigens for MHC II presentation and the generation of 
neutralizing antibodies. 
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Figure 5.5 Schematic for targeted delivery of gagV3(BCE) DNA ministring into dendritic cells. 
A) Targeted delivery of gagV3(BCE) DNA ministring derived synthetic vectors into dendritic cells; 
B) Successful endosomal escape enabling the release of DNA cargo for nuclear entry; C) Expression 
of gagV3(BCE) results the expression of gag-V3; D) Formation of VLPs; E) Antigen processing; F) 
VLP budding and release leading to internalization by other antigen presenting cells (APC); G) MHC 
I antigen presentation to CD8
+
 T cells for CTL response and cellular immunity; H) MHC II antigen 
presentation to CD4
+
 helper T cells for neutralizing antibody production by B cells. 
 
5.5 Conclusion 
HIV DNA-VLPs may be excellent vaccine candidates as they possess the capacity to induce 
CTL responses and neutralizing antibodies, both of which are necessary for effective 
vaccination against HIV. Targeted delivery of gagV3(BCE) DNA ministrings to dendritic 
cells may serve to directly stimulate HIV-specific immune responses, thereby prompting 
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prevention and suppression of subsequent HIV challenge. Results from this study marked the 
early stages in the development of a HIV DNA-VLP vaccine. Synthesis of pGagV3(BCE) 
led to successful production of gagV3(BCE) LCC DNA ministrings through the LCC DNA 
minivector production system. Optimal transfection in K562-αvβ3 cells served as the initial 
step for evaluating targeted delivery using RGD peptides and this model will act as the basis 
for comparison in future studies involving dendritic cells.  
  





As genes are the inherent blueprint to all living organisms, gene therapy offers limitless 
potential for the future treatment of various diseases and genetic defects.  While sound and 
powerful in theory, the delivery of gene therapeutics may and has induced unforeseen 
adverse reactions that can result in morbidity or even death. While viral vectors continue to 
comprise the majority of gene therapeutics, and demonstrating high efficacy with positive 
clinical outcomes, such safety concerns persist, thwarting the future generation of 
translational technologies. Non-viral delivery GT systems serve as an alternative that 
addresses the abovementioned safety limitations, but suffer from low transfection efficiencies 
that limit their efficacy and continue to pose substantial roadblocks in the promotion of  such 
systems into clinical relevance. With respect to lipid-based synthetic vectors, extensive 
research has been focused on the structural composition of cationic lipids and the molecular 
mechanisms associated with improved delivery. In addition (though often overlooked), 
careful consideration must also be put into the design of the DNA cargo such that optimal 
transgene expression, and corresponding therapeutic effect, can take place. LCC DNA 
ministrings offer heightened effectiveness, while conferring an exceptional safety profile. 
LCC DNA ministrings are designed to offer high versatility with use toward many 
applications, and the implementation of the one step in vivo DNA minivector production 
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system allows rapid, simple and scalable production of both CCC and LCC DNA 
minivectors.  
In the present study, numerous aspects pertaining to the generation of gene therapeutics 
with LCC DNA ministrings had been explored with relevance to both industry and clinical 
settings. Upon systematic assessment of induction duration, cultivation strategy, and 
genetic/chemical modifications for optimal production of LCC DNA ministrings in the in 
vivo system, high yields conferring ~90% production efficiency were observed. 
Improvements in production efficiency and ministring yields, over the current system, were 
observed with: a two-step continuous cultivation strategy, a ΔhflX host mutation background, 
the application of ciprofloxacin, and the introduction of slow stop dnaB[Ts] mutation.  
Purification of LCC DNA ministrings using anion exchange membrane chromatography 
demonstrated rapid, scalable purification of DNA vectors as well as its potential in the 
separation of different DNA isoforms. The application of a hydrogel-based strong Q-anion 
exchange membrane, with manipulations to salt gradient, constituted effective separation of 
parental supercoiled CCC precursor pDNA and LCC DNA. Upon comparative analysis 
between synthetic vectors derived from LCC DNA ministrings and CCC pDNA, differences 
in DNA topology contributed to differences in particle size and protection from DNase 
degradation. Lastly, gagV3(BCE) LCC DNA ministrings were successfully produced. This 
paves the way for their targeted delivery into dendritic cells, conferring subsequent VLP 
formation and antigen presentation which serve as the basis of the HIV DNA-VLP vaccine.    
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6.2 Future Directions 
6.2.1 Further Optimization of LCC DNA Minivector Production System for Complete 
pDNA Processing 
Findings from the present study showed improvements to production efficiency upon 
individual modifications using two step continuous cultivation and through genetic 
modifications in the introduction of ΔhflX deletion and dnaB[Ts] slow stop mutation. Hence,   
two step continuous cultivation in a genetically modified ΔhflX strain may potentially serve 
to attain complete pDNA processing with dramatically higher yields of LCC DNA 
ministrings and is currently being investigated. While potentially additive, the addition of the 
dnaB[Ts] slow stop mutation would further compromise cell health and limit plasmid yields 
due to the replication deficiency, even at permissive temperatures. Such modifications can be 
simultaneously applied with temperature oscillations, as highlighted by Caspeta et al. [161], 
allowing cells to better accommodate to heat stress for improved protelomerase expression, 
reduced by-product accumulation, and higher DNA ministring yields. 
6.2.2 Targeted Delivery into K562-αvβ3 with RGD-Functionalized Synthetic Vectors 
K562-αvβ3 cells serve as an appropriate model to demonstrate targeted delivery of RGD-
functionalized synthetic vectors. As such, we anticipate that transfection of K562-αvβ3 cells 
by LCC/16-3-16/DOPE lipoplexes functionalized with RGD peptides, via electrostatic 
interactions, should confer higher transfection efficiencies than that imparted by non-
functionalized lipoplexes. Transfection of non-functionalized and RGD-functionalized 
lipoplexes into K562-αvβ5 cells would serve as controls, confirming enhanced transfection 
efficiencies in K562-αvβ3 as result of targeted delivery. 
  149 
6.2.3 Targeted Delivery into Dendritic Cells and VLP Formation 
The abovementioned non-functionalized and RGD-functionalized LCC/16-3-16/DOPE 
lipoplexes will be assessed for transfection into dendritic cells. Transfection efficiencies will 
be assessed by FACS for the successful delivery of egfp LCC DNA ministrings. 
Subsequently, gagV3(BCE) LCC DNA ministrings will be delivered into dendritic cells to 
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